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Lack of pediatric clinical data has led to a large gap in knowledge concerning drug efficacy, safety and 
dosing guidelines within the pediatric population. Many pediatric off-label doses are based largely on 
adult studies with little or no pediatric experience; this has the potential to lead to treatment failures, 
toxicities, and various other drug-related adverse events. Given that recruitment to pediatric trials is 
difficult, researchers have recently used physiologically-based pharmacokinetic (PBPK) models as a 
means to efficiently plan pediatric clinical studies. PBPK models are mechanistic in nature and 
mathematically describe the disposition of drugs in an organism.  This in silico technique predicts 
pharmacokinetic (PK) profiles based on compound physicochemical properties and multiple physiological 
input parameters of the individual, such as organ volumes, tissue composition, blood flow, and clearance 
(CL). Pediatric PK parameters are typically predicted using a pediatric PBPK model that has been 
developed using an adult PBPK model and clinical PK data. Within this workflow for pediatric PBPK 
model development, adult intravenous (IV) data is typically used; however, there are many instances 
where there may not be an IV formulation available for certain compounds. As a result, the question 
remains if the workflow for pediatric PBPK modeling produces accurate pediatric PK predictions in the 
absence of adult IV data. In this case, IV data from pre-clinical species (i.e. rat) may be an alternative to 
human IV data. The objective of this study was to assess the ability of pediatric PBPK models to predict 
observed pediatric PK parameters using a model development workflow that uses rat IV PK data, as 
opposed to adult human IV PK data. The implications of both workflows were assessed by comparing the 
precision and bias of the predicted vs. observed PK exposure metrics in children. This study demonstrated 
that rat IV data is a viable alternative to using adult IV PK data within the pediatric PBPK model 
development workflow and the majority of exposure metrics were within 2 fold from the observed 
pediatric data, regardless of workflow or Biopharmaceutics Classification System (BCS) class of the 
compound.  Ultimately, the model was not hindered in its prediction accuracy, despite a lack of 
distribution and clearance data that would otherwise have been derived from human IV data. Overall, the 
application of rat IV data as a substitute for human IV data in PBPK modeling is a novel approach that 
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An alarmingly large number of drugs prescribed to children lack dosing information specific to pediatric 
populations, leading to off-label dosing of many drugs in children [1]. This has the potential to lead to 
treatment failures, toxicities, and various other drug-related adverse events[2]. Unfortunately, conducting 
clinical trials in pediatric participants has many challenges both ethical and logistical [3, 4]. A recent 
study indicates only 46% of drug products listed in the 2009 Physician’s Desk Reference for pediatric use, 
are appropriately labeled and tested for this demographic [4], and as high as 60-90% of prescribed drug 
products are used off-label [5, 6]. Many of these doses are based largely on adult studies with little or no 
pediatric experience. Lack of pediatric clinical data has led to a large gap in knowledge concerning drug 
efficacy, safety and dosing guidelines within the pediatric population [6].  
In recognition of the lack of substantial pediatric clinical data, the Food and Drug Administration (FDA) 
has implemented multiple initiatives and regulations to try and close this knowledge gap. In the late 90s, 
the FDA Modernization Act (FDAMA) was created with the purpose of offering a monetary incentive to 
drug companies for performing pediatric research [7]. Companies would be offered an additional six 
months of patent exclusivity of their drug product as encouragement to conduct pediatric research [7]. 
Other significant regulations implemented include the Pediatric Rule Regulation in 1998, the Pediatric 
Research Equity Act in December 2003, and the Best Pharmaceuticals for Children Act (BPCA) in 
January 2002 which was renewed in the FDA Safety and Innovation Act (2012) [7]. The purpose of each 
mandate was to encourage and guide pediatric research in the USA using a combination of industry 
incentives and requirements.  
Given that recruitment to pediatric trials is difficult, researchers have recently used physiologically-based 
pharmacokinetic (PBPK) models as a means to replicate pediatric clinical studies to show the potential 
applications of PBPK models in clinical investigation [8]. PBPK modeling and simulation is a novel in 
silico technique that may potentially aid in the prediction and estimation of pharmacokinetic (PK) 
parameters [2]. Fundamental PK parameters examined within clinical studies are area under the curve 
(AUC), maximum concentration (Cmax) and time at which Cmax has occurred (Tmax). AUC is the 
measure of systemic exposure of a drug over a given time interval and is a function of dose administered. 
Cmax and Tmax help to quantify absorption of a compound administered by non-intravenous routes. 
PBPK models are mechanistic in nature and mathematically describe the disposition of drugs in an 
organism.  This in silico technique predicts PK profiles based on compound physicochemical properties 
and multiple physiological input parameters of the individual, such as organ volumes, tissue composition, 
blood flow, and clearance (CL) [9]. PBPK models have been previously used for prediction of human 
bioavailability, and extrapolation across species and within human age groups to predict human PK 
parameters [10]. This method has been widely adopted for toxicological risk assessment as well as in 
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pharmaceutical research and development [9]. Provided sufficient data, a PBPK model has the ability to 
generate predictions of pharmacokinetic behaviour in virtual individuals and populations, and is 
beneficial in aiding clinical trial planning [9]. Figure 1 illustrates an example of a whole body PBPK 
model, whereby each organ is represented by a compartment that is interconnected through systemic 
circulation. Oxygenated arterial blood is circulated throughout the organs, and subsequently ends up as 
venous blood which  returns to the lungs for subsequent oxygenation and re-circulation [10]. Each 
compartment representing individual organs is defined by a tissue blood flow rate and tissue volume 












Each compartment within the model has a respective tissue to plasma partition coefficient which depends 
on a compound’s physicochemical properties such as lipophilicity (LogP), ionization constant (pKa), and 
fraction unbound (fu) of drug in plasma [10, 12]. The partition coefficient (Kp) more specifically 
represents the concentration of drug in tissue (Csstissue) relative to plasma (Cssplasma) at steady state, and is 




   (1)  
Kps are important input parameters for a PBPK model and they are usually derived using prediction 
algorithms that link drug physico-chemistry with tissue specific parameters [13]. Not only do Kp 
estimates aid in determining the extent of tissue specific drug exposure relative to plasma concentrations, 
but they can also estimate the extent of total distribution. Two of the most commonly used methods for 
predicting Kp in humans are the correlation-based and the tissue composition based techniques. The 


































correlation-based method provides a means of estimating human Kps based on empirically derived 
regression equations using drug physicochemical properties relative  to Kps for muscle and adipose tissues 
derived experimentally in preclinical animal species [14]. The tissue composition based method for 
predicting Kps is mechanistic in nature, as it relies on drug specific parameters such as protein binding, 
lipophilicity, and pKa as well as tissue specific parameters such as relative fractions of water, neutral 
lipids, phospholipids, and proteins in organs [15]. 
The uptake of compound into a tissue can be identified as either permeability rate limited or perfusion 
rate limited. Permeability rate limited conditions occur under conditions in which the permeability-
surface area product (P·SA) for large polar molecules across membranes is less than blood flow, thereby 
creating resistance towards drug transport across membranes, irrespective of drug delivery to the tissue 
via perfusion. Alternatively, perfusion rate limited conditions occur typically under conditions in which 
the permeability-surface area product (P·SA) for small lipophilic molecules across membranes exceeds 
blood flow, thus organ uptake is limited primarily by blood flow. The rate of change of a total drug 






(𝑄𝑎𝑟𝑡𝐶𝑎𝑟𝑡 − 𝑄𝑣𝑒𝑛 ·
𝐶𝑇
𝑓𝑢·𝐾𝑝
) − 𝐸(𝑡)   (2) 
 
Where 𝑉𝑇 is the volume of the tissue, 𝑄𝑎𝑟𝑡  and 𝑄𝑣𝑒𝑛 are the rate of arterial and venous blood flow, 
respectively, through the tissue, Cart refers to the drug concentrations found in systemic plasma 
concentration entering via the arterial route, the overall term 
𝐶𝑇
𝑓𝑢·𝐾𝑝
 represents venous plasma concentration 
where Kp is the tissue-blood partition coefficient in that tissue, fu is fraction unbound in blood, and lastly 
E(t) is the rate of organ specific drug elimination; in non-eliminating organs E(t) = 0 [13, 16]. 
Permeability rate limited kinetics are often represented by equations (3) and (4) [17]: 
𝑑(𝑓𝑢·𝐶𝑐𝑒𝑙𝑙)
𝑑𝑡
· 𝑉𝑐𝑒𝑙𝑙 = 𝑃 · 𝑆𝐴 · (𝑓𝑢 · 𝐶𝑒𝑥−𝑐𝑒𝑙𝑙) − 𝑃 · 𝑆𝐴 · (𝑓𝑢 ·  𝐶𝑐𝑒𝑙𝑙) (3) 
𝑑(𝑓𝑢·𝐶𝑒𝑥−𝑐𝑒𝑙𝑙)
𝑑𝑡
· 𝑉𝑒𝑥−𝑐𝑒𝑙𝑙 = 𝑄 · (𝑓𝑢 · 𝐶𝑎𝑟𝑡) − 𝑃 · 𝑆𝐴 · (𝑓𝑢 · 𝐶𝑒𝑥−𝑐𝑒𝑙𝑙) + 𝑃 · 𝑆𝐴 · (𝑓𝑢 · 𝐶𝑐𝑒𝑙𝑙) − 𝑄 · (𝑓𝑢 · 𝐶𝑣𝑒𝑛)    (4) 
In equation (3), 
𝑑𝐶𝑐𝑒𝑙𝑙
𝑑𝑡
 is the rate of change of concentration of a drug found in the cellular space, where  
𝑉𝑐𝑒𝑙𝑙 is volume of the cellular space,  P represents compound specific membrane permeability, SA is the 
organ specific membrane surface area, (𝑓𝑢 · 𝐶𝑒𝑥−𝑐𝑒𝑙𝑙) and (𝑓𝑢 · 𝐶𝑐𝑒𝑙𝑙) refer to unbound drug 
concentration entering and leaving the cells respectively, thus incorporating both drug and organ specific 
components [10, 17]. Generic PBPK models often operate under the assumption of perfusion rate limited 
kinetics although organ structure can be altered to account for permeability rate limitations.  
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Pediatric PBPK models are developed to help predict age-related changes of exposure to drugs from 
adults to children, when there is a lack of observed pediatric PK data [18]. These predictions can be 
extended to help design clinical trials that will generate relevant pediatric data for the purpose of drug 
labeling, and also reduce the number of children required for clinical trials [19]. The development of a 
pediatric PBPK model requires the model structure and inputs as described in the above paragraphs 
however, to be relevant in the pediatric population, the scaling of factors such as age-dependant CL, and 
age related body composition must be appropriately defined to effectively predict pharmacokinetic 
parameters [20]. Typically the creation of a pediatric PBPK model begins with the development of an 
adult PBPK model, as shown in Figure 2:  
Figure 2. Standard workflow employed in the development of a PBPK model for pediatrics based on an adult IV model 
 
Since PBPK model outcomes are only as good as the accuracy of their inputs and the underlying 
understanding of mechanism, inputs can be optimized and mechanisms more greatly understood with in 
vivo data, of which there exists much in the case of adults. The understanding that emerges from the 
development process of an adult PBPK model is carried over to the pediatric models of which there 
exists, usually, no in vivo PK information, especially in the early phases of the drug development process. 
The simulation process begins by gathering compound specific physicochemical data, physiological 
information, as well as drug CL information to develop a naïve adult PBPK model for the prediction of 
concentration time profiles in adults. The input of CL as well as the input of distribution, generally 
dominated by Kp, can be optimized by comparing the naïve prediction to the in vivo plasma concentration 
time data following intravenous (IV) administration. Once CL inputs and inputs related to the rate and 
extent of distribution are optimized and the simulation of IV data represents observed data, an oral profile 
is simulated using the optimized CL and distribution inputs.  The method holds the assumption that the 
optimized CL and distribution parameters do not vary between routes of administration [10]. The 
generated adult oral PBPK model is then evaluated using observed PK data from studies conducted in 
adults. Optimization of absorption inputs, mainly dissolution profile and intestinal permeability (Pint), may 
be required at this stage. Once parameters have been optimized to minimize error between the 
experimental and simulated concentration time points, an adult population model must be created to 
incorporate inter-individual variability with regards to anthropometric parameters [21]. Creating a virtual 
adult population, will assist in the understanding of PK estimate variability within individuals of a 

















confidence is gained that the adult PBPK and population models accurately represent various in vivo adult 
PK data, the model can be scaled to children. Any systematic deviations of simulated and observed data 
in adults is very likely to also manifest in the same misspecification in the pediatric model as was 
demonstrated by Maharaj et al using lorazepam [22]. The scaling of the model to children involves the 
scaling of physiological and anatomical input parameters such as organ volumes, blood flows, and 
ontogeny factors relating to transporters (i.e. efflux and influx), glomerular filtration rate (GFR) as well as 
hepatic enzymatic activity related to CL. Drug specific inputs are assumed the same between adults and 
children. Once all relevant inputs are scaled,  pediatric IV or oral plasma concentration time profiles are 
generated [20].  
Typically it is very important to have clinically derived adult IV data for a drug, as it is the only way to 
accurately derive CL and volume of distribution, given the assumption of complete absorption into 
systemic circulation. Volume of distribution at steady state (Vss) can often be estimated from Kp values, 
which help identify the extent of drug distribution in each organ. The relationship between Kp and Vss is 
denoted in equation (5) as: 
𝑉𝑠𝑠 = 𝑉𝑝𝑙𝑎𝑠𝑚𝑎 + ∑ 𝐾𝑝𝑖 × 𝑉𝑡𝑖𝑠𝑠𝑢𝑒,𝑖 × (1 − 𝐸𝑖)
𝑛
𝑖=1
  (5) 
Where Vplasma and Vtissue are physiologic volumes of plasma and tissue, and E is the extraction ratio of the 
eliminating tissue [23]. Vss is more specifically a metric that describes the extent of drug distribution in an 
individual. As a primary pharmacokinetic parameter, Vss acts as foundational building block to aid in the 
prediction of estimating loading dose, and deriving half-life when applied in conjunction with observed 
CL values [24]. In the absence of adult human IV data, the optimization of distribution parameters must 
be completed using in vivo PK data from a pre-clinical species, e.g. rat.  Since curve shape following IV 
administration is greatly affected by distribution parameters (as well as CL), and humans and rats are both 
mammals with assumed similar organ compositions, an assumption is made that the Kp for unbound drug 
distribution, the ratio of unbound drug concentration in the tissue vs. plasma, is the same between all 
mammalian species. In the study conducted by Jones et al., Vss in humans was predicted by assuming 
that the unbound Kp in human was equivalent to that in preclinical species [25]. Although the assumption 
holds for many tissue types of several mammals, recent literature would suggest an exception for lipid-
rich tissue, wherein there exists a manifold difference of inter-species Kp measure [26]. In the absence of 
adult IV data, which would allow for a more confident prediction of Kp measures, an alternate workflow 
must rely on human Kp measures derived directly from the optimization of Kps from IV data in preclinical 
(i.e. rat) species to derive an operational estimate of V using equation (5).   
CL estimates are extremely important PBPK model inputs as they are the backbone for establishing 
dosing rates. CL is the volume of reference fluid (i.e. plasma) within a system that is completely cleared 
of drug over a given time interval. Multiple organs and enzymes are responsible for drug elimination such 
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as the gastrointestinal wall, liver, lungs, and kidneys, however total plasma CL can be derived via the 
addition of each unique plasma  CL [27]. The two main organs responsible for CL of a drug are the 
kidneys and liver, a factor that must be considered when designing a PBPK model simulation. In vivo 
drug CL is typically derived from plasma concentration time profiles using equations (6) and (7) 




  (6) 
 
𝐶𝐿𝑜𝑟𝑎𝑙 =
𝐷𝑜𝑠𝑒 · 𝐹𝑎 · 𝐹ℎ
𝐴𝑈𝐶(0→∞)
   (7) 
Where Dose, in equation (6) is the IV dose administered and AUC is the area under the plasma 
concentration curve from 0 to infinity. Within equation (7), Fa and Fh are the fraction of drug absorbed 
into the portal vein, and the fraction of drug making it to the portal vein that is not subject to elimination 
by the liver, respectively [27]. 
Within a PBPK model framework, intrinsic CL (CLint) is the CL input. For active processes where 
perfusion rate limits organ uptake, plasma CL and CLint are correlated as described by the well-stirred 
model using equation (8): 
CLH= 
𝑄ℎ · 𝑓𝑢𝑏 · 𝐶𝐿𝑖𝑛𝑡
𝑄ℎ+𝑓𝑢𝑏·𝐶𝐿𝑖𝑛𝑡
  (8) 
Using the liver as an example, the well stirred model is an approach that integrates total hepatic plasma 
CL (CLH) with hepatic blood flow (Qh), intrinsic CL (CLint), as well as fraction of unbound drug in blood 
(fub). 
 
Derivation of the input parameter estimates that define both plasma CL, (CLint), and Vss, (Kp), is impeded 
by noise when oral absorption profiles are used to understand these parameters. Prediction of CL and V 
when IV data is unavailable is limited to CL/F and V/F where F is oral bioavailability [10]. F is the 
fraction of orally administered dose that is available to the systemic circulation, therefore considering the 
effects of both absorption and elimination via first pass metabolism [10]. As a result, the amount of drug 
available to systemic circulation is limited to the product of drugs escaping the intestines, liver, and lung 
[10]; CL and Vss are not directly knowable following an oral administration.  This adds emphasis to the 
value clinical adult IV data contributes to the prediction accuracy of these inputs. IV data also provides a 
means of assessing curve shape which is a function of the rate of distribution. For instance, assumption of 
a perfusion limited uptake into organs may not be reasonable for larger drug molecules and this would be 
evident if an observed IV profile were overlaid onto a predicted profile that assumed instantaneous 
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mixing of organs. These modifications are integral components of the development of an adult PBPK 
model and, if poorly executed, will result in poor pediatric PBPK models.  
The mechanistic nature of PBPK modeling allows for extrapolation of an adult PBPK model to children, 
based on age related differences in physiology, anatomy, as well as drug- and organism-specific 
properties such as CL and protein binding [18]. Once the adult IV and oral profiles have been simulated, 
and the PBPK model optimized and subsequently evaluated for accuracy,  data must be collected from 
literature with respect to pediatric anatomical values for organ volumes and blood-flows [18, 28].  
Parameters such as pediatric organ blood flows are generally derived from adult values while operating 
under the assumption that the proportion of cardiac output to the organs is similar to that in adults [18, 
28]. Other input parameters such as maturation functions for hepatic and renal CL processes and age 
dependant protein binding would also be required [12, 18].  
Scaling CL in children is largely based upon organ size and flow, fu and ontogeny of relevant processes. 
Fraction unbound has successfully been scaled in children by McNamara et al. and has been explained in 
further details within the method section of this study [29]. CL process maturation specific to hepatic and 
renal processes were adapted from successful methods presented by McNamara et al [30] and Rodin et 
al.[31] respectively,  as well as Edginton et al [32]. The next step in the workflow requires the simulation 
of a virtual pediatric population, as described in Edginton 2010 and Maharaj et al., 2013, to allow for 
evaluation of   variability [20-22]. The appeal of PBPK modeling is strongly based on the ability to 
integrate models that define the age dependence of ADME in a single platform [20]. This approach 
provides the means to generate an age dependant dosing regimen that may support a translational 
approach to pediatric trial design, as well as the potential to simulate pediatric dosing scenarios for a 
defined target exposure [20].  
Assessing pathways of CL for a drug in the absence of IV data poses a large source of uncertainty. 
Having IV data and conducting a mass balance elimination study allows one to assess how much of a 
substance is eliminated through each route relative to an absolute administered dose. Renal CL is 
dependent on various physiological parameters such as renal blood flow, renal vascular resistance, as well 
as drug specific physicochemical factors [33]. The net balance of renal CL is a function of the 
physiological processes of tubular secretion (TS), tubular reabsorption (TR), and glomerular filtration rate 
(GFR). Total renal CL is usually derived following an IV study whereby the amount of drug excreted 
unchanged in urine can be quantified and divided by dose to generate the fraction excreted unchanged in 
urine (fe). Total plasma CL times fe is total renal CL in the case of the use of IV data and renal CL/F in 
the case of using data following oral administration. As a result, the oral absorption model that is used to 
generate F within the PBPK model is relied upon with CL being optimized based on matching AUC or 
terminal slope to observed data following oral administration. As such, if F is wrongly predicted, renal 
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CL inputs are inaccurate. The maximum renal CL due to GFR is GFRmax and can be calculated as defined 
in equation (9) below: 
𝐺𝐹𝑅𝑚𝑎𝑥 = 𝐺𝐹𝑅 ∙ 𝑓𝑢  (9) 
The mean GFR value used in this study was assumed to be 120 mL/min per 70kg [31]. TS cannot be 
measured directly, however if renal plasma CL of a substance is greater than the GFRmax, it is assumed 
that TS has occurred. Similarly, if renal plasma CL is less than GFRmax, it is assumed that TR has 
occurred and, within a PBPK model, is represented as an appropriately reduced GFR fraction input.  
Defining renal CL using human IV data is relatively straightforward whereas defining renal CL following 
oral administration is less certain. Like renal CL, hepatic CL may be quantifiable when only oral data is 
available, as a function of F (i.e. CL/F), but its quantification will be less certain in the absence of IV 
data. Hepatic plasma CL is dependent upon many factors such as liver blood flow, fu, enzymatic and 
various transport processes [32]. Data from a combination of published human liver microsomal (HLM), 
recombinant enzyme, and hepatocyte assays can be obtained to determine the extent of phase I and/or 
phase II metabolism on the metabolic fate of compounds [34]. Human liver microsomal assays determine 
the major pathway of metabolism responsible for the fate of a compound between phase I oxidative, 
primarily cytochrome P450 enzymes, or phase II conjugation, primarily glucuronosyltransferase (UGT) 
enzymes [34]. Subsequently, the application of recombinant cytochrome P450 (CYP) and UGT enzyme 
assays determine which specific enzyme(s), within the individual phases, are responsible for the 
metabolism of the parent compound. Hepatocyte assays aim to closely mimic in vivo conditions, as they 
contain all drug metabolising enzymes as well as influx/efflux transporters [34]. As a result, in vitro 
hepatocyte assays are valuable in their utility to closely approximate CLint of various enzymes in vivo. 
Although the workflow for development of the pediatric PBPK model typically follows Figure 2 [22], 
there are instances where an integral component is missing and may affect the predictive accuracy of the 
pediatric PBPK model outcome. This may be the case when an IV formulation for humans has not been 
developed and therefore no IV PK information is available in adults. Absence of IV adult data would 
result in an alternate workflow (Figure 3) where obtained CL and V inputs may be less certain.  In this 
case, another means of assessing these inputs would be required and we suggest IV data from preclinical 
species, for example the rat. In a recent study, published in 2011 by Parrot et al., a group aimed to assess 
whether human adult and pediatric data for the prodrug oseltamivir, and its metabolite, can be scaled from 
marmoset monkey data [35]. This study focused on pre-clinical rat IV data due to the abundance of 
published rat IV data for various compounds. Pre-clinical rat IV data has been shown to effectively derive 
predictions in adult humans, using a PBPK modeling approach, for hepatic metabolism, renal excretion, 
as well as prediction of absorption and volume of distribution using tissue composition equations within 
1-3 fold error for observed and predicted data [25]. If V was predicted with accuracy and only adult oral 
PK data were available, CLint could be optimized with confidence by optimizing CLint to match the 
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terminal phase of the in vivo data; a phase that is reliant only on the ratio of CL to V once absorption has 
been completed.  
 
Figure 3. Alternate workflow for creating a whole-body PBPK model in pediatrics based on rat IV data as a substitute for human 
IV data 
The biopharmaceutics classification system (BCS) is a framework for cataloguing orally administered 
drugs into four classes based on their magnitudes of permeability and solubility (Figure 4). The rate and 
extent of absorption for orally administered drug products is governed primarily by a combination of their 
gastrointestinal permeability, aqueous solubility, and in vitro dissolution profile [26].  According to the 
FDA, a drug product is considered “highly permeable” when the extent of absorption in an adult is ≥ 90% 
of the administered dose in comparison to an IV reference dose or as quantified by a mass balance study 
[36]. FDA guidelines also state that a drug is considered highly soluble when it is soluble in 250 mL of 
aqueous media between a pH range of 1-7.5 at 37 ± 1.8°C [26, 36].  BCS Class I drugs are characterized 
by high permeability and high solubility, thus resulting in a high rate and extent of absorption, or 
bioavailability. BCS Class II drugs are characterized by high permeability and low solubility. As a result, 
it is assumed that the oral absorption of a Class II drug product is limited by its ability to dissolve. Inverse 
to Class II drugs, BCS Class III drugs are highly soluble and are permeability limited throughout the 
gastrointestinal tract [24]. In the prediction of pediatric PK, the BCS of the target drug may influence the 
predictive accuracy of the pediatric PBPK model. Solubility and permeability can alter in vivo 
bioavailability or F and, since CL and V estimates in the absence of human IV data are dependent on F, 
the alternate workflow (Figure 3) may or may not be accurate for any BCS class other than BCS I where 
is F is close to 1.    
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Figure 4. Biopharmaceutics Classification System (BCS) based on degree of compound permeability and solubility 
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2. Objectives & Hypotheses  
 
Objectives 
The objective of this study was to assess the ability of pediatric PBPK models, developed under 
Workflow 1 (Figure 3) and Workflow 2 (Figure 2), to predict observed PK parameters and to assess the 
implications to model accuracy when there is a lack of adult IV data.  
Aim 1: To assess the ability of Workflow 1 and Workflow 2 to predict observed pediatric PK parameters.  
Null hypothesis 1 (H1): Workflow 1 and Workflow 2 derived predictions of pediatric PK data will not be 
significantly different from observed data.  
Aim 2: To determine if predictions from Workflow 1, where human IV data is not available, are 
equivalent to predictions from Workflow 2, where human IV data is available. 
Null hypothesis 2 (H2): PK predictions from Workflow 1 will not be significantly different from 
Workflow 2. 
Based on H1 and H2, the question of the need for human IV data will be answered using the following 
logic:  
In the event that H1, for both workflows, and H2 are accepted, the conclusion is that human IV data is not 
a necessary component of the workflow for model development and models were accurate.  
In the event that H1 for both workflows is accepted and H2 is rejected, the conclusion is that human IV 
data is not a necessary component of the workflow for model development and models were accurate.  
In the even that H1 for Workflow 1 is accepted, H1 for Workflow 2 is rejected and H2 is also rejected, 
then we must conclude that human IV data is not a necessary component of model development. 
In the event that H1 for Workflow 1 is rejected, H1 for Workflow 2 is accepted and H2 is rejected, the 
conclusion is that human IV data is a necessary component of the workflow for model development. 
 In the event that H1 for either workflow is rejected and H2 is accepted, the conclusion is that human IV 
data is not a necessary component of the workflow for model development and models were not accurate. 
If H1 is rejected for both workflows and H2 is also rejected, then it is unknown if human IV data is a 
necessary component for model development.  
Aim 3 To compare pediatric PK prediction accuracy using Workflow 1 vs. Workflow 2. 
Null hypothesis 3 (H3): Pediatric predictions of observed data using Workflow 1 will be more accurate 
and less bias as compared to Workflow 2. 




3.1 Data collection 
 
Each of nine drugs examined within this study were selected from literature and FDA summary databases 
for drugs that have passed the approval process in adult and pediatric populations [37, 38]. 
Experimentally derived in vivo pre-clinical and clinical study data requirements for each of the nine drugs 
consisted of:  
1. Plasma concentration time profiles obtained from rat and adult IV studies 
2. Plasma concentration time profiles obtained from adult oral studies 
3. Plasma concentration time profiles obtained from pediatric IV or oral studies or PK parameters 
obtained from pediatric IV or oral studies including AUC, Cmax, and Tmax.  
The following additional parameters were also required: 
1. Molecular weight and chemical structure to evaluate presence of halogens 
2. Acid dissociation constants (i.e. pKa)  
3. Solubility and dissolution profile, ideally in a buffer medium representative of physiological 
conditions 
4. Fraction unbound in plasma and binding partner (e.g. Albumin or Alpha 1-acid glycoprotein)  
5. A measure of experimentally derived lipophilicity (e.g. LogP) 
6. An understanding of the CL pathways and proportions of each pathway to total CL in adults.  
Of the nine compounds, three are from each of BCS I, II, and III; BCS IV compounds were not 
considered due to their poor predictability of drug disposition in humans. Drugs pertaining to BCS I 
include: 
1. lorazepam  
2. acetaminophen 
3. levofloxacin  




Lastly, BCS class III drugs examined in this study include: 
1. acyclovir  
2. cimetidine  




3.2 Software for PBPK model development 
 
Key model development software programs utilized in this study were PK-Sim® (ver. 5.2, Bayer 
Technology Services GmbH, Leverkusen, Germany) and MoBi® (ver. 3.2, Bayer Technology Services 
GmbH, Leverkusen, Germany). PK-Sim® is a tool that allows the user to create whole-body 
physiologically based pharmacokinetic models based on anatomical and physiological parameters for 
humans and many common pre-clinical animal species. It consists primarily of 17 organs and tissues that 
further consist of sub-compartments such as red blood cells, plasma, interstitial space, and cellular space. 
The gastrointestinal compartment within the whole-body PBPK model is further divided using the 
advanced compartmental absorption and transit model (ACAT), which incorporates first pass metabolism 
and colonic absorption [39]. The ACAT model is employed as a method to predict the bioavailability of 
compounds and can include liver and gut metabolism, efflux and influx transport within the gut [39]. The 
versatility of the ACAT model stems from the intricate dissection of linear and non-linear metabolism 
kinetics, various states of compound release/uptake, and the transit flow of a drug compound throughout 
the several sub-divisions of the stomach, small intestine and colon [39]. Input parameters in the whole 
body PBPK model, ACAT inclusive, encompass physicochemical properties that are used to predict Kp, 
cellular permeability and intestinal permeability. CLint information is a user defined input. All Kp 
algorithms incorporated into the PBPK models within this study  follow mechanistic equations proposed 
by Rodgers and Rowland, 2006 [40]. MoBi® was used for parameter optimization using a 1/y weighted 
least squares regression function. MoBi was also implemented for population modeling which 
incorporates PK-Sim® models and MATLAB (version 7.0, Mathworks, MI, USA) functions for this 
purpose [9].  
3.3 Project workflow overview 
 
Two workflows were implemented throughout the study to assess the prediction accuracy of pediatric PK 
estimates derived via the standard workflow and the alternate workflow. As presented previously, 
Workflow 2 (Figure 2) follows the standard format [22] while Workflow 1 follows the alternate 
workflow, where adult IV data are missing and substituted with preclinical rat in vivo IV data (Figure 3). 
Workflow 1 was consistently simulated before Workflow 2, so as to eliminate any knowledge bias of a 




3.4 Pediatric PK predictions for BCS class 1 compounds 
3.4.1 Acetaminophen 
Workflow 1 of acetaminophen  
 
Development of the Rat PBPK model following IV administration 
A rat PBPK model was created for the drug acetaminophen, based on a rat IV study conducted by Watari 
et al. 1983 [41]. Organism specific anatomy and physiology parameters incorporated into PK-Sim, 
pertaining to a generic rat, were applied. Physicochemical properties such as fu in rat, pKa, molecular 
weight, and observed total plasma CL [41] were obtained from literature (Table 1). Three experimental 
plasma concentration data sets were obtained from Watari et al. 1983, each of which was dose normalized 
to plasma concentrations following a 1 mg/kg dose [41]. Following simulation of the rat PBPK model, 
experimentally derived in vivo data was superimposed upon the simulated plasma concentration profile 
[41].  Given that the simulated data points did not reflect the curve shape of the observed data, model 
parameters influencing distribution (e.g. LogP) and CL were numerically optimized using a Monte Carlo 
algorithm. The Monte Carlo algorithm randomly samples multiple iterations of designated model 
parameters until a global minimum is located within defined boundaries; Figure 5 presents the results of 
this optimization. Overall curve shape was not sensitive to LogP within a ten percent range, therefore the 
observed value of 0.49 was used [41] (Table 1). Total hepatic plasma CL was optimized to 52 mL/min/kg 
from an observed CL of 51 mL/min/kg [41]. Although CL within the rat model was not scaled to humans 
in subsequent models, rat plasma CL was optimized for overall goodness of fit assessment and 
comparison based on observed data obtained from literature. 
Table 1. Acetaminophen physicochemical input parameters for the rat and adult models within 
Workflow 1 
 Initial input Initial Value Reference Value in final model 
Fu (rat) 0.82 [41] 0.82 
Fu (human) 0.95 [42] 0.95 
LogP (log units) 0.49 [42] 0.49 
pKa 9.5 (acid) [42] 9.5 (acid) 
Solubility at ref pH 14.5 mg/mL (pH=7.0) [42] 14.5 mg/mL 





Figure 5. Simulated (line) and observed (symbols) plasma concentration data following a 1 mg/kg IV bolus administration of 
acetaminophen to rats. Dose normalized observed data is taken from Watari et al[41].  
 
Development of the acetaminophen adult PBPK model following oral administration  
Using the rat model as a base, all species specific inputs were changed to reflect an average 30 year old 
European human male. This included anatomical and physiological inputs. All drug-specific inputs were 
maintained as in the rat PBPK model (Table 1) with the addition of compound specific solubility and 
dissolution data. Three adult PBPK models were simulated, and were based upon three oral studies 
following a 325 mg [43], 500 mg [44] and 1000 mg [45] oral administration. A 10 minute dissolution 
time for each oral formulation [43-45] was also included. Observed data was superimposed upon the 
simulated plasma concentration time profiles for an initial visual goodness of fit assessment.  
 Given that the simulated data points did not fall within the range of observed data, model parameters 
influencing absorption (i.e. Pint) and total plasma CL (Table 2) were numerically optimized respective to 
each simulation (Figure 6a-c). An oral PK profile is regarded as 2 phases, an initial phase of drug 
absorption and a terminal phase dominated by elimination. The absorption phase is highly sensitive to 
intestinal permeability. This value is calculated by PK-Sim as a function of the input physicochemical 
parameters (i.e. Molecular weight, LogP) and therefore is the most uncertain parameter in the absorption 
component of the model. Other absorption parameters are physiological in nature (e.g. small intestinal 
transit time, gastric emptying time) and are less likely to be incorrect. As a result, intestinal permeability 
is the first parameter that is optimized. Only if this parameter is incapable of explaining observed 
absorption will physiological inputs be considered for optimization.  In the case of the terminal phase, if 
Vss is accurately predicted (confidence gained from rat IV data) and absorption is over, the terminal 
phase of the observed data can be used to estimate CL. Due to the absence of CL information from a 
human IV application, matching the terminal phase of the simulated profile to observed data provides us 
with the greatest certainty towards estimating CL. Intestinal permeability and CL parameters were 
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optimized for each study (Table 2, Figure 6a-c) where, ideally, the AUC0-inf of the simulation is optimized 
to within ±10% of the corresponding observed AUC. Within the PBPK model, CL optimizations are 
expressed through specific CL (CLspec) which is the intrinsic CL divided by the volume in which the 
process occurs, expressed in units of L/min/Lintracellular volume, or 1/min. For the final adult oral model, the 
arithmetic mean of each optimized parameter was used (Table 2) in all subsequent models.  
Table 2. Optimized total hepatic CLspec, and intestinal permeability (Pint) for three simulated adult oral 
profiles. The arithmetic mean of the three studies is presented. 
Oral dose administration 
simulation  
Pint (cm/min) 
Specific hepatic CL (CLspec) 
optimized (1/min) 
325 mg dose [43] 1.01 E-05 0.273 
500 mg dose[44] 3.49 E-04 0.389 
1000 mg dose [45] 7.67 E-05 0.225 
Arithmetic mean  1.45 E-04 0.296 
 
CL pathway partitioning 
Within the adult PBPK model, CL was input as a hepatic process only, as hepatic CL is the greatest 
proportion of overall CL. The next step was to proportion this CL into individual pathways that are 
responsible for acetaminophen metabolism, as determined from literature sources. The CL pathways were 
determined through literature searches which incorporated in vitro and in vivo data, as was done in 
Edginton 2006 [18]. Types of data that were sourced included mass balance data following oral 
administration to adults and in vitro studies that incorporated microsomes, recombinant microsomes and 
human hepatocytes. Since this section of the project workflow must operate under the assumption of an 
alternate workflow, any data derived from an adult human IV study could not be used to assess CL 
proportions.   
In a mass balance study following an oral acetaminophen administration conducted by Prescott et al,  
55% of total administered dose was recovered in urine as glucuronide metabolites [46]. Court et al [47] 
assessed in vitro UGT metabolism and determined that UGT 1A9 (61% of total intrinsic CL), UGT1A1 
(29%) and UGT1A6 (10%) were responsible for acetaminophen glucuronidation. For the PBPK model, 
UGT1A9 and UGT1A1 were weighted to account for 100% of total intrinsic CL related to 
glucuronidation; 68% and 32% respectively [47]. In the study conducted by Prescott et al, 32% of total 
administered dose was recovered as a sulfonation product [46]. Adjei et al [48] determined in vitro that 
the responsible enzyme was primarily SULT1A1. Prescott et al. determined 5% of total administered dose 
was renally cleared [46], and 8% of total administered dose was a metabolite [46] produced primarily by 
CYP2E1 [49]. Prescott et al had a total recovery of acetaminophen of 93% with only 7% unchanged in 
feces [46].  As a result of this high bioavailability, of approximately 93%, the proportions of CL can be 
directly used without correction for the fraction not absorbed to systemic circulation.  
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Table 3 presents the CL proportions used in the adult PBPK model. Since the optimized CL was 100% 
hepatic, 5% of the total plasma CL was removed in order to account for fe. To achieve a 5% fe, GFR 
fraction was numerically optimized, due to the occurrence of TR, for each study as was total hepatic 
CLspec (Table 4). The arithmetic mean of the three total hepatic CLspec was further subdivided into one of 
four hepatic enzymes and their importance to overall hepatic CL is presented in Table 3. In the final 
model, the simulated AUC matched the observed AUC within a ±10% boundary (Figure 6). A final mean 
adult oral PBPK model was created and ready for population modeling and pediatric scaling. 




Notes and reference 
Glucuronide (UGT) 55% (0.55) 
CL proportions determined by Prescott et al [46] following 
an oral acetaminophen administration, mass-balance study. 
55% of total administered dose was glucuronide metabolites 
[46].   
UGT 1A9 68% Court et al [47] assessed in vitro UGT metabolism. UGT 1A9 
(61% of total intrinsic CL), UGT1A1 (29%) and UGT1A6 
(10%) were isoforms responsible for acetaminophen 
glucuronidation. UGT1A9 and UGT1A1 were weighted to 
accounted for 100% of total intrinsic CL.  
UGT 1A1 32% 
Sulfonation (SULT1A1) 32% (0.32) 
32% of total administered dose was sulfonation products 
[46].  Adjei et al [48] determined in vitro that the responsible 
enzyme was primarily SULT1A1. 
Renal 5% (0.05) 
5% of total administered dose was renally cleared unchanged 
[46].   
CYP 2E1 (toxic metabolite) 8% (0.08) 
8% of total administered dose was a metabolite [46] 
produced primarily by CYP2E1 [49]. 
 
Table 4. Optimized CLspec and GFR fraction for each of three simulated profiles following oral 
dose administration in adults 
Study group by oral dose Hepatic CLspec (1/min) GFR fraction 
325 mg dose [43] 0.172 0.19 
500 mg dose[44] 0.24360 0.27 
1000 mg dose [45] 0.1418 0.16 
Arithmetic mean 0.186 0.21 
 
Table 5. Relative proportions of individual pathways of CL within the adult oral model 
Enzyme 
Percent contribution to 
overall hepatic CL (%) 
Proportion of CLspec = 0.186 
1/min 
UGT1A9 39.4 0.0733 
UGT1A1 18.5 0.0345 
SULT1A1 33.7 0.0627 












Figure 6. Simulated (line) and observed (symbols) plasma concentration data following a A) 325 mg [43] B) 500 mg [44] and C) 
1000 mg [45]  oral dose of acetaminophen in adults. Simulated profiles are optimized for Pint and CL. 
 
Development of an adult oral population PBPK model  
Inter-individual variability in drug disposition due to differences in physiology (e.g. organ volumes, organ 
blood flows, and CL) between study participants is important to consider. Predictive population modeling 
permits an a priori or “bottom up,” speculation of the pharmacokinetic variability of a drug without 
conducting clinical studies beforehand. Application of a virtual population of individuals in this study 
serves as a surrogate to assess the correctness of inter-individual variability parameterization. This 
application lends itself to ensure a greater probability of deriving biologically sound PK variability 
estimates in children, assuming similar input variability between adults and children [21]. Virtual 
population generation followed the method of Willmann et al 2007 [21]. A range of body weights and 
heights are set by the user or constrained by realistic populations values using databases such as the 
National Health and Nutrition Examination Survey (NHANES) database  [21]. For each virtual individual 
with a specific weight and height, organ weights and blood flows are assigned [21]. In order to ensure that 
individuals of the same weight and height are not identical, inter-individual variability of anatomical and 
physiological parameters is incorporated using a stochastic Monte Carlo method. The Monte Carlo 
algorithm randomly samples from designated model parameters with defined means, limits, and 
variability, based on user-defined distributions (i.e. normal, log normal, uniform). Inter-individual 
variability of all organ volumes and blood flows is already incorporated into PK-Sim using variability 
(e.g. coefficients of variation (CV) and distributions derived from literature [21]. Other inputs not varied 
in PK-Sim but requiring variability include those associated with the gastrointestinal tract (e.g. gastric 
emptying time, small intestinal transit time, small intestinal surface area) as well as CL-related variability 
in GFR and to account for the differences in, primarily, enzymatic protein concentration differences per 
gram of liver amongst different people.  
For the population model of acetaminophen, 100 virtual individuals were generated within an age range 
of 18-55 years. In order to reflect the observed study, in which all participants were male, all virtual 
individuals were male. Additional variability, over and above organ volumes and blood flows, was also 
A C B 
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included (Table 6) and followed variability estimates and distributions from literature. Once the 
population had been generated, the population was administered a 500 mg oral dose to reflect the study 
conducted by Rawlins et al [43]. The observed data obtained from Rawlins et al was superimposed onto 
the model predictions (Figure 7). Progression of the workflow depends on a visual check of whether or 
not the population model is able to encompass a significant portion of observed data (Figure 7). The 
standard deviation of the observed data was smaller than simulated in the terminal phase although this 
comparison is difficult to make as there were only 6 individuals within the observed study. Only if the 
number of individuals within the study is deemed high enough to accurately represent the population 
would the variability metrics be substantially changed. The risk of changing variability in the PBPK 
model based on a very small sample size is that it may or may not represent variability in another, much 
larger or much different, population. Methods for dealing with this are an emerging area of research. 
Observed data fell towards the lower limit of the population curve. This may be largely due to a 
potentially larger mean weight within the study population (n = 6); weights were not presented in the 
study. The mean weight of the simulated population was approximately 70 kg, which could be lower than 
the sample mean weight. Since this could not be confirmed and because the mean oral profiles for which 
the pediatric predictions are based were very well simulated, the model was deemed reasonable enough to 















Table 6. Population variability of acetaminophen incorporated into population model simulations of acetaminophen 
Pathway Value Distribution Notes and reference 
Gastric emptying 
time (GET) 
CV = 24% Log normal 
Gastric emptying time was obtained from Willmann 
2007 [50]. GET was derived statistically in the 





CV = 22.5% Log normal 
Small intestinal transit time was obtained from 
Willmann et al. [50]. SITT was derived statistically 
in the population module of PK-Sim following log 
normal distribution. 
Small intestinal 
surface area  
9 fold variation in a uniform 
distribution (mean*3 – 
mean/3). Each individual had 
the same surface 
enhancement factor applied. 
Uniform As taken from Willmann et al [50] 
GFR (specific) CV = 25% Normal Determined from Van Biesen et al [51] 
CYP2E1 
(specific) 
CV = 16 %  Log normal 
CV of CYP2E1 protein activity Vmax was obtained 
from Bourrie et al., using human liver microsomal 
assays to assess protein activity and metabolite 
production for Aniline [52]. 
SULT1A1 
(specific) 
CV = 29%  Log normal 
CV of sulfonation Vmax was obtained from 
Alhusainy et al. using human liver microsomal assays 




CV = 20% Log normal 
CV of glucuronidation by UGT1A1 Vmax was 
obtained from Borlak et al. using human liver 
microsomal assays to assess protein activity and 
glucuronide metabolite production [54] 
UGT1A9 
(specific) 
CV = 50% Log normal 
CV of glucuronidation by UGT1A9 Vmax was 
obtained from Borlak et al. using human liver 
microsomal assays to assess protein activity and 




































Figure 7. Simulated mean (solid line) and standard deviation (dotted lines) plasma concentration data in 100 individuals as 
compared to observed (symbols) mean and standard deviation plasma concentration data following a 500 mg oral dose of 
acetaminophen in adults Rawlins et al [43]. Observed SD has been calculated from standard error mean (SEM) reported by 















Workflow 2 of acetaminophen 
 
Development of the human PBPK model following IV administration 
In contrast to the substituted nature of Workflow 1, Workflow 2 was constructed based on adult IV in 
vivo data as the base model. Similar to the development of the rat IV PBPK model in Workflow 1, the 
adult IV PBPK model incorporated relevant physicochemical drug data, observed mean drug CL, and 
dose. Since this workflow incorporates data from in-human studies, patient demographic data was also 
incorporated into this model. An IV PBPK model was simulated for the drug acetaminophen based on the 
dosing protocol from an adult IV study conducted by Rawlins et al [43]. Organism specific anatomy and 
physiology parameters incorporated into PK-Sim, pertaining to an average 30 year old European male 
were used. Physicochemical properties such as fu, lipophilicity (LogP), pKa, molecular weight, and 
observed total plasma CL were obtained from literature (Table 1). Once the PBPK adult IV base model 
had been simulated, following a 1000 mg IV dose administration, observed data was superimposed upon 
the simulated plasma concentration profile. Given that the simulated data points did not accurately reflect 
the curve shape of the observed data, model parameters influencing distribution (LogP) and CL (hepatic 
CL) were numerically optimized. LogP was optimized to 0.66 and the total hepatic plasma CL was 
optimized to 259 mL/h/kg, which resulted in a CLspec of 0.316 1/min (Figure 8).  
A mass balance study following IV administration was conducted by Clements et al [55]. From this study, 
it was determined that 4.3% of the dose was renally excreted unchanged. As a result, a renal component 
was added into the adult IV model. Both renal (GFR fraction) and hepatic specific CL were numerically 
optimized to fit observed data (Table 7; 0.194 1/min hepatic CLspec and GFR fraction of 0.14). The 
hepatic component was further divided into the four enzymes responsible for hepatic CL (Table 7), as 
described in Workflow 1. Once all CL pathways had been quantified, the individual CLspec values would 
serve as the final CL input for each subsequent model within Workflow 2.  
 
Figure 8. Simulated (line) and observed (symbols) plasma concentration data following an IV dose of acetaminophen in adults, 
including simulated fe (dotted line). IV profile was optimized for CL and distribution (i.e. LogP) based on data from Rawlins et 
al [43].  
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Table 7. Relative proportions of individual pathways of CL within the adult IV 
model in Workflow 2 
Enzyme 
Percent contribution of 




UGT1A9 39.4 0.0703 
n/a 
UGT1A1 18.5 0.0299 
SULT1A1 33.7 0.0699 
CYP2E1 8.4 0.0242 
Total 100.0 0.194 0.14 
 
 
Development of the acetaminophen adult PBPK model following oral administration  
Three adult oral models were simulated following a 325 mg, 500 mg, and 1000 mg oral administration of 
acetaminophen respectively, similar to building the adult oral model in Workflow 1. Physicochemical 
input parameters such as pKa, molecular weight, optimized LogP, and optimized CL remained unchanged 
from the optimized adult IV model, with the addition of compound specific solubility at reference pH 
(Table 1). Organism specific anatomy and physiology parameters incorporated into PK-Sim, pertaining to 
an average 30 year old European male, were used. Once each PBPK adult oral model had been simulated, 
observed data [43-45] was superimposed upon the simulated plasma concentration profile.  Given that the 
simulated data points did not fall within the range of observed data, the most uncertain model parameter 
influencing absorption, Pint, was numerically optimized respective to each simulation (Table 8, Figure 9 a-
c). The arithmetic mean of the Pint value would serve as the final input within the adult oral model scaled 
to pediatrics. 
Table 8.Numerically optimized Pint for each of three simulated profiles following 
oral dose administration in adults within Workflow 2 
Study group by oral dose  Pint (cm/min)  
325 mg dose [43] 1.08 E-05 
500 mg dose[44] 1.20 E-05 
1000 mg dose [45] 1.13 E-05 








Figure 9. Simulated (line) and observed (symbols) plasma concentration data following a A) 325 mg B) 500 mg and C) 1000 mg 
oral dose of acetaminophen in adults, as well as simulated fe (dotted line). Simulated profiles are optimized for Pint and hepatic 
CL. 
C B A 
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Development of an adult oral population PBPK model 
Similar to Workflow 1, an adult population of 100 individuals was created within PK-Sim consisting of 
18-55 year old males to reflect the demographics of the reference observed study participants [43]. The 
same nine aspects of population variability were factored into the adult oral model (Table 6); 
physicochemical and mean CL parameters remained consistent from the previous model. Once the 
population model had been simulated, accounting for the added variability, observed data obtained from 
Rawlins et al following a 500 mg oral dose was superimposed onto the model. Figure 10 presents the 
observed and simulated data. Observed data points fell towards the lower limit of the population curve. 
For similar reasons as discussed in Workflow 1, the model was deemed reasonable.  
Time [h]
































Figure 10. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following a 500 mg oral dose of 
acetaminophen in adults Rawlins et al [43]. Observed SD have been calculated from standard error mean (SEM) reported by 
Rawlins et al. 
 
 
Building the acetaminophen pediatric population model for Workflow 1 and 2 
Scaling the adult oral model to children 
The mean adult oral model created using either the rat IV or adult IV base models must be scaled down to 
pediatric populations to successfully create the pediatric PBPK model. The methods used for scaling are 
not dependent on the workflows used to derive the final adult oral model. As a result, scaling an adult 
model to a pediatric model is identical for Workflow 1 and Workflow 2. Many scaling factors from adults 
to children were considered.  
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Scaling anatomy and physiology 
Age dependencies of relevant anatomical and physiological parameters (i.e. organ specific volumes, 
blood flows and tissue composition) were set as incorporated into PK-Sim. The values used in PK-Sim 
are presented in Edginton et al [18]. 
Scaling unbound fraction (fu) 
Albumin is a highly abundant protein in plasma and interstitial fluid and it binds to a number of 
compounds at two distinct sites [12]. Alpha 1-acid glycoprotein is another plasma protein that binds 
drugs, such as lipophilic cations, and has considerable inter- and intra-patient variability in its 
concentration found in plasma [12]. The fraction of free drug concentration to total drug concentration is 
referred to as fraction unbound [12]. Predictions of fu relative to that in adults were estimated using 
equations presented by McNamara and Alcorn [12, 49]. Using knowledge of plasma protein binding 
characteristics in adults, and known age related differences in binding protein concentrations in plasma, 
the authors were able to successfully scale fu from adults to infant pediatric patients. The ratio of protein 
concentration in a child relative to adult serum albumin concentration [12],  to a maximum of 100%, is: 
𝑙𝑒𝑣𝑒𝑙 (% 𝑜𝑓 𝑎𝑑𝑢𝑙𝑡) = 0.005627 ∗ 𝐷𝑎𝑦𝑠 + 76.7 (10) 
The ratio of protein concentration in a child relative to adult glycoprotein concentration is:  
𝑙𝑒𝑣𝑒𝑙 (% 𝑜𝑓 𝑎𝑑𝑢𝑙𝑡) = 0.01137 ∗ 𝐷𝑎𝑦𝑠 + 53.4   (11) 
 
This equation is represented by the variable 
𝑃𝑖𝑛𝑓
𝑃 𝑎𝑑𝑢𝑙𝑡
 in the following equation for fraction unbound in 








   (12) 
Equation (12) is used to scale unbound fraction in adults to children of different ages during pediatric 
PBPK model development [12]. As plasma protein levels in infants begin to stabilize to adult levels, 
equation (10) and (11) begin to approach a ratio of 1; a maximum value of 1 was incorporated into the 
model. Knowledge of the binding partner and binding capacity in adults (fup, adult) was determined from 
literature.  
Scaling CL  
Physiology-based CL scaling significantly relied upon methods from Edginton et al, 2006 [32].  For the 
purposes of scaling CL, it must be known how the drug is cleared in adults and the relative proportion of 
total plasma CL that is attributed to each pathway. This is because each pathway is scaled individually as 
each pathway has a unique maturation function. CL scaling operates under the assumption that CL 
pathways are the same in children as they are in adults, enzyme kinetics operates within the linear range, 




Scaling Renal CL  
Glomerular filtration rate is a measure of renal function in adults. Mature adult GFR values are well 
understood to be approximately 100-120mL/min. In children, Rhodin et al [31] quantified GFR 
maturation taking into account changes in both size and age. The model generated by Rhodin et al, 
defines GFR, in equation (13), as: 
𝐺𝐹𝑅 = 𝐹(𝑝𝑚𝑎) × 𝐹(𝑠𝑖𝑧𝑒) × 𝐺𝐹𝑅(𝑚𝑎𝑡)  (13) 
GFR (mat) is the mature value for GFR (mL/min).  F(size) refers to allometric scaling for body size while 
incorporating weight of the ith individual (Wi), weight of a standard individual (Wstd = 70kg), and an 






    (14) 
F(pma) in equation (13) denotes a sigmoid hyperbolic model that takes into account maturation half time 






   (15) 
In the pediatric PBPK model, adult GFR was scaled towards the estimated GFR of pediatric patients 








× 𝐶𝐿𝐺𝐹𝑅,𝑎𝑑𝑢𝑙𝑡   (16) 
TS in adults was scaled to pediatric patients by incorporating the effects of age and body weight on 
maturation and growth using the following equation (17) as proposed by Hayton, 2000[33]:  
𝑇𝑆𝑎𝑔𝑒,𝑤𝑒𝑖𝑔ℎ𝑡 = 𝑎 ∗ 𝑊
𝑏𝑒−𝑘𝑚𝑎𝑡∗𝑎𝑔𝑒 + 𝑐𝑊𝑏(1 − 𝑒−𝑘𝑚𝑎𝑡∗𝑎𝑔𝑒)   (17) 
Where W is body weight, b is body weight exponent, kmat is the maturation rate constant, a and c refer to 
immature values of TS from birth, and mature values of TS based on influences of allometry and age as 
discussed in Hayton, 2000 [33]. 
Scaling Hepatic CL 
The scaling of hepatic plasma CL from adults to children takes into account physiological factors such as 
organ size and blood flow, fu and ontogeny factors for hepatic enzymes that modify CLint, and follows a 
perfusion rate limited model. Within the PBPK model framework, organ size, organ blood flow and fu are 
already considered. The perfusion rate limited model assumes instantaneous, well-stirred, drug 
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distribution across membranes into single compartment organs, whereas an added permeability rate 
limitation would introduce a far more complex multi-compartmental organ structure into the model [56].  
Ontogeny factors for enzymes requires input if pediatric predictions of CL are to be made. An example 
will be demonstrated with UGT2B7, one of the most extensively studied glucuronidation enzymes in 
humans and a pathway of CL for acetaminophen. It is estimated that UGT2B7 enzyme activity reaches 
adult activity by 1 year of age in infants [57]. Intrinsic CL in adults (e.g. L/min/gram liver tissue) can be 
scaled to pediatric subjects using the equation [57]: 
𝐶𝐿𝑖𝑛𝑡 𝑈𝐺𝑇2𝐵7(𝑐ℎ𝑖𝑙𝑑) = 𝑂𝑆𝐹𝑈𝐺𝑇2𝐵7 × 𝐶𝐿𝑖𝑛𝑡 𝑈𝐺𝑇2𝐵7(𝑎𝑑𝑢𝑙𝑡) (18) 
where 𝐶𝐿𝑖𝑛𝑡 𝑈𝐺𝑇2𝐵7(𝑐ℎ𝑖𝑙𝑑)  is the intrinsic CL due to UGT2B7 scaled to children, 𝐶𝐿𝑖𝑛𝑡 𝑈𝐺𝑇2𝐵7(𝑎𝑑𝑢𝑙𝑡) is 
intrinsic CL due to UGT2B7 in adults, and  OSFUGT2B7 is the Ontogeny Scaling Factor specific to age 
[57]. Intrinsic CL values specific to pediatric populations are directly incorporated into the PBPK model 
for each child while model parameters accounting for physiological and anatomical changes are already 
incorporated.  
 
 Population Derivation 
Creation of pediatric populations was closely based on the algorithm and methods of Willmann et al, 
2007 [21] as discussed previously. A reference pediatric population of 5000 individuals between the ages 
of 0-17 years, inclusive, was produced under a uniform distribution with a uniform distribution in each 
month of age within that range. Each child within the virtual population had parameter values scaled for 
age, with the starting point being the final mean adult male previously created from either Workflow 1 or 
Workflow 2. Virtual populations consisted of up to a maximum of 1000 kids isolated from the reference 
population to reflect patients within the age range established in the in vivo study being replicated. Age 
groups were uniformly distributed among a maximum of 1000 children depending on the lowest age 
denomination of the youngest patient defined in the study. For example, if a study is conducted among 20 
children from 2 months to 17 years of age (204 months), the virtual population of up to a maximum of 
1000 children in the virtual population were uniformly distributed from 2 months to 204 months of age, 
so as to allow a unbiased platform (e.g. equal year distribution would create a population of 0-1 year olds 
that have fewer children than all other years). Although we delineate a uniform distribution of age within 
the virtual population, this may not necessarily equate identically to the distribution of ages within the 
observed in vivo study. Due to ethical and logistical constraints and limitations of clinical studies, it is not 
always possible to have a uniform distribution of age groups within the sample population, which may 
make sample resolutions for statistical inferences difficult. The output from the pediatric population 





Development of the pediatric population model for Workflow 1 and 2 of acetaminophen  
A pediatric population of up to a maximum of 1000 individuals between the ages of 0.9-13 years, 
inclusive, was isolated from the reference pediatric population for acetaminophen. Drug-specific 
parameters were equal to those of the final adult oral acetaminophen simulation. Similar to methods 
discussed in section 1.4, nine aspects of population variability specific to pediatrics were factored into the 
pediatric population model, as obtained from literature (Table 9). Contrary to variability parameters 
incorporated into the adult population model, Table 9 includes gastric emptying time (GET), and small 
intestinal transit time (SITT) variability specific to pediatrics as obtained from Willmann et al [58], and 
was applied as such to each subsequent pediatric population simulation within this study. Once variability 
had been successfully incorporated into the pediatric population PK parameters of AUC0-inf, Cmax, and 
Tmax following the observed study protocol dosing regimen were obtained for comparison to observed 
values for prediction accuracy assessment.   
Table 9. Pediatric  inter-individual variability factors applied to the pediatric population of acetaminophen 
Pathway Value Distribution Notes and reference 
GET CV % = 60% Log normal 
Gastric emptying time (GET) in the fasted state was 
obtained from Willmann et al [58], as derived from in 
vitro experiments.  
SITT  CV = 60% Log normal 
Small intestinal transit time (SITT) was obtained from 
Willmann et al. [58], as derived from in vitro 
experiments.  
Small intestinal 
surface area  
9 fold variation in a 
uniform distribution 
(mean*3 – mean/3). 




Uniform As taken from Willmann et al [50] 
GFR (specific) CV = 25% Normal Determined from Van Biesen et al [51] 
CYP2E1 (specific) CV = 16 %  Log normal 
CV of CYP2E1 protein activity Vmax was obtained from 
Bourrie et al., using human liver microsomal assays to 




CV = 29%  Log normal 
CV of sulfonation Vmax was obtained from Alhusainy et 
al. using human liver microsomal assays to assess protein 
activity and sulfonated metabolite production [53]. 
UGT1A1 (specific) CV = 20% Log normal 
CV of glucuronidation by ugt1A1 Vmax was obtained 
from Borlak et al. using human liver microsomal assays 
to assess protein activity and glucuronide metabolite 
production [54]. 
UGT1A9 (specific) CV = 50% Log normal 
CV of glucuronidation by ugt1A9 Vmax was obtained 
from Borlak et al. using human liver microsomal assays 






3.4.2 Levofloxacin  
Workflow 1 of levofloxacin 
 
Development of the rat PBPK model following IV administration 
A rat PBPK model was created for the drug levofloxacin, based on a rat IV study (20 mg/kg) conducted 
by Fujieda et al [59]. Organism specific anatomy and physiology parameters, of a generic rat, were used. 
Physicochemical properties such as fu in rat, LogP, pKa, and molecular weight were obtained from 
various sources within literature (Table 10). Following simulation of the rat PBPK model, experimentally 
derived in vivo data was superimposed upon the simulated plasma concentration profile. Given that the 
simulated data points did not reflect the curve shape of the observed data, model parameters influencing 
distribution and CL were numerically optimized (Figure 11). The optimal LogP was 1.8, and plasma CL 
was optimized to a CLspec value of 5.95 1/min (Table 10).  
Table 10. Levofloxacin initial input, and optimized final model parameterization for Workflow 1 and Workflow 2 
  Initial input Initial Value Reference Value in final model 
fu (rat) 0.84 [60] 0.84 
Fu (human) 0.7 [60] 0.7 
LogP (experimental) 1.49 [61] 1.8 







Solubility 300 mg/ml at 6.5pH [62] 300 mg/ml at 6.5pH 
Dissolution  50% dissolved in 10 min [61] 50% dissolved in 10 min 
 
 
Figure 11. Simulated (line) and observed (symbols) plasma concentration data following 20 mg/kg levofloxacin to rats. 







Development of the levofloxacin adult PBPK model following oral administration 
Using the rat PBPK model as a base, all drug specific physicochemical input parameters such as pKa, 
molecular weight, and solubility at reference pH, and optimized LogP were maintained as in the 
optimized rat PBPK model (Table 10). Species specific inputs such as fu of levofloxacin in humans, 
anatomy, physiology as well as formulation solubility and dissolution parameters were applied to the 
model [60, 61]. Three experimental studies were obtained from literature, in which a sample group of 
participants were administered oral doses of 500, 750, and 1000 mg of levofloxacin [63, 64]. Since 
levofloxacin displays dose independent linear kinetics, plasma concentration data obtained from each 
study was dose-normalized to 500 mg [65]. Observed data was superimposed upon the simulated plasma 
concentration time profiles following 500 mg of levofloxacin, for an initial visual goodness of fit 
assessment. Given that the simulated data points did not fall within the range of observed data, model 
parameters influencing absorption (Pint) (Table 11) and total plasma CL  were numerically optimized 
respective to each simulation (Figure 12a-c). 
 
CL pathway partitioning  
Within the initial adult PBPK model, CL input was compartmentalized as a superficial hepatic and renal 
component. The next step was to proportion this CL into individual pathways that are responsible for 
levofloxacin metabolism, as determined from mass balance studies [65]. Literature suggests 80% of oral 
levofloxacin is excreted via the urine unchanged, whereas >5% of the dose is recovered in urine as 
glucuronidated metabolite [65]. Experimentally, total renal CL was found to be greater than GFRmax, 
thereby indicating that a significant portion of levofloxacin is eliminated via active TS by renal 
transporters. GFR fraction was set to a maximum ratio of 1, and an additional TS component was added 
to the adult PBPK model in place of an overall renal plasma CL. The isoforms primarily responsible for 
the glucuronidation of levofloxacin are UGT1A1, UGT1A3, and UGT1A9; however in vitro studies show 
that in vivo glucuronidation of levofloxacin is mainly due to UGT1A1 [66]. As a result, UGT1A1 was 
considered the only glucuronidation enzyme responsible for levofloxacin metabolism. Once CL pathways 
had been defined within the model, UGT1A1 activity and TS were numerically optimized so that fe 
approximately reflected observed values (0.80) (Table 11, Figure 12 a-c).  The final mean adult model 








Table 11. Numerically optimized Pint, TS and UGT1A1 parameters for the oral model of levofloxacin 
Study group dosing before 
dose normalization (mg) 
Pint (cm/min) TS CLspec (1/h) UGT1A1  CLspec (1/min) 
500 [63] 3.23 E-05 0.247 0.00377 
750 [64] 1.17 E-05 0.251 0.00383 
1000 [64] 0.93 E-05   0.265 0.0038 











Figure 12.  Simulated (line) and observed (symbols) plasma concentration profiles, and fe (dotted line) for a 500 mg oral 
levofloxacin administration. B) and C) have been dose normalized from 750 mg and 1000 mg respectively. All graphs were 
optimized for CL and Pint. 
 
Development of the adult oral population PBPK model for levofloxacin 
For the population model for levofloxacin, 100 virtual individuals were generated within an age range of 
18-55 years. Additional variability was also included (Table 12) and followed variability estimates and 
distributions from literature. Six aspects of population variability were factored into the adult population 
model (Table 12), four of which were similarly incorporated within the acetaminophen model. 
Physicochemical parameters were not further modified from the optimized adult PBPK model. Once the 
population model had been simulated to generate an arithmetic standard deviation curve, observed data 
obtained from each of the experimental observed studies was superimposed onto the model [63] [64] 
(Figure 12). Given that a majority of observed data points fell within one standard deviation of the mean 
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Table 12. Population variability incorporated into the adult population model simulations in PK-Sim and MoBi for 
levofloxacin 
Pathway Value Distribution Notes and reference 
GET  CV = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a 
uniform distribution 
(mean*3 – mean/3). Each 
individual had the same 
surface enhancement 
factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30 Log normal 
Determined Willmann et al., 2014, following log 
normal distribution [15].  
UGT1A1 (specific) CV = 20% Log normal 
CV of glucuronidation by ugt1A1 Vmax was 
obtained from Borlak et al. using human liver 
microsomal assays to assess protein activity and 
glucuronide metabolite production [54] 
 
Time [h]



































Figure 13. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 










Workflow 2 of levofloxacin 
 
Development of the human PBPK model following IV administration 
An adult IV PBPK model was simulated for the drug levofloxacin based on the dosing protocol from an 
IV infusion study conducted in adults by Chien et al, in which 500 mg of levofloxacin was administered 
over a 1 hour period to 10 adults between the ages of 18-55 years [63]. Similar to the development of the 
rat PBPK model in Workflow 1, the adult IV PBPK model incorporated relevant organism, and drug 
specific physicochemical parameters (Table 10). Since the standard workflow incorporates data from 
human studies, patient demographic data was also incorporated into this model. Model parameters 
influencing distribution (LogP) and CL were numerically optimized. 
Clearance pathways were derived based on a mass balance study, conducted by Fish et al, following an 
IV dose of levofloxacin to healthy volunteers [67].  Within the study, it was observed that  80-87% of the 
dose was recovered unchanged in urine, with approximately 5-10% of the dose recovered as 
glucuronidated metabolites of levofloxacin [67]. Within the model, renal CL was partitioned into GFR 
and TS since total renal CL of levofloxacin exceeded GFRmax. Hepatic metabolism and TS were 
optimized. As presented in Figure 14, LogP was numerically optimized to 1.78, TS and UGT1A1 were 
optimized to reflect observed fe (0.8-0.87) (Figure 14).  
 
Figure 14. Simulated (line) and observed (symbols) plasma concentration data following a 500 mg IV infusion of levofloxacin in 
adults, including simulated fe (dotted line). IV profile was optimized for CL and distribution (i.e. LogP) Based on data from 
Chien et al [64]. Adult IV model optimized for LogP and CL.  
 
Development of the levofloxacin adult PBPK model following oral administration  
Three adult oral models were simulated following an oral dose of 500 mg levofloxacin, similar to 
building the adult oral PBPK model in Workflow 1. Physicochemical input parameters such as pKa, 
molecular weight, optimized LogP, and optimized CL remained unchanged from the optimized adult IV 
model, with the addition of compound specific solubility at reference pH (Table 10). Organism specific 
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anatomy and physiology parameters incorporated into PK-Sim, pertaining to an average 30 year old 
European male, were used. Once each PBPK adult oral model had been simulated, observed data [63, 64] 
was superimposed upon the simulated plasma concentration profile.  Pint was numerically optimized 
respective to each simulation (Table 13, Figure 15 a-c). The arithmetic mean Pint value would serve as the 
final input within the adult oral model scaled to pediatrics.  
Table 13. Numerically optimized Pint, TS, UGT1A1 CLspec, LogP for the adult PBPK model of levofloxacin within the 
standard workflow 
Study group dosing before 
dose normalization (mg) 
Pint (cm/min) TS CLspec (1/min) 
UGT1A1 CLspec  
(1/min) 
LogP (log units) 
500 mg IV [63]  0.232  0.004 1.78 
500 [63] 1.4 E-05 
750 [64] 1.1 E-05 
1000 [64] 1.2 E-05 









Figure 15. Simulated (line) and observed (symbols) plasma concentration profiles of 500 mg [63] oral levofloxacin. B) and C) 
have been dose normalized from 750 mg [64] and 1000 mg [64] respectively. All graphs were optimized for CL and Pint. 
 
Development of an adult oral population PBPK model 
An adult population of 100 individuals was created within PK-Sim consisting of 18-55 year old males to 
reflect the demographics of the reference observed study participants [63, 64]. Since CL pathways were 
different between workflows, the same seven aspects of population variability from Workflow 1 were 
factored into the Workflow 2 adult population model as obtained from literature (Table 12). Once the 
population model had been simulated to generate an arithmetic standard deviation curve, observed data 
obtained from each of the experimental observed studies was superimposed onto the model (Figure 16). 
Given that the majority of data points fell within one standard deviation of the mean population model, it 
was determined sufficient to progress to pediatric development.  
 







































Figure 16. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 500 mg oral 
dose of levofloxacin in adults  
 
Development of the pediatric population model for Workflow 1 and 2 of levofloxacin 
A pediatric study investigating the pharmacokinetics of levofloxacin in infants and children between the 
ages of 0.5-16 years was obtained from literature [68]. In the study, patients received a 7mg/kg dose to a 
maximum of, of oral levofloxacin (n = 8), and were subdivided into five groups based upon age. A 
pediatric population of up to a maximum of 1000 individuals between the ages of 0.5-16 years, inclusive, 
were isolated from the reference pediatric population to reflect the demographic of the observed pediatric 
study [68].  Similar to methods discussed previously, once population variability was included in the 









3.4.3 Lorazepam  
Workflow 1 of lorazepam 
 
Development of the rat PBPK model following IV administration  
A rat PBPK model was created for the drug lorazepam, based on a rat IV study conducted by Atack et al. 
Three observed data sets were obtained from Atack et al, each of which wad dose normalized to a 0.05 
mg/kg IV dose [69]. Observed data was dose normalized to reflect a 0.05 mg/kg IV dose of lorazepam.  
Organism specific anatomy and physiology parameters, of a generic rat, were used. Physicochemical 
properties such as fu in rat, LogP, pKa, and molecular weight were obtained from various sources within 
literature (Table 14). Following simulation of the rat PBPK model, experimentally derived in vivo data 
was superimposed upon the simulated plasma concentration profile. Given that the simulated data points 
did not reflect the curve shape of the observed data, model parameters influencing distribution and CL 
were numerically optimized (Figure 17); the optimal LogP was 2.6. 
Table 14. Lorazepam initial input, and optimized final model parameterization for Workflow 1 and 
Workflow 2 
 Initial input Initial Value Reference Value in final model 
fu (rat) 0.091 [69] 0.091 
fu (human) 0.11 [70] 0.11 
LogP (experimental) 2.39 [71] 2.6 







Solubility 0.08 mg/ml [70] 0.08 mg/ml 
Dissolution  50% dissolved in 20 min [73] 50% dissolved in 20 min 
 
 
Figure 17. Simulated (line) and observed (symbols) plasma concentration data following 0.05 mg/kg mg lorazepam to rats. 




Development of the lorazepam adult PBPK model following oral administration 
Using the rat PBPK model as a base, all drug specific physicochemical input parameters such as pKa, 
molecular weight, and solubility at reference pH, and optimized LogP were maintained as in the 
optimized rat PBPK model. Species specific inputs such as fu of lorazepam in humans, anatomy, 
physiology as well as formulation solubility and dissolution parameters were applied to the model [70] 
[73]. Three experimental studies were obtained from literature, which were all dose normalized to reflect 
a 1.5 mg oral dose, due to dose dependant linear kinetics of lorazepam [74]. Observed data was 
superimposed upon the simulated plasma concentration time profiles following 1.5 mg of lorazepam, for 
an initial visual goodness of fit assessment. Given that the simulated data points did not fall within the 
range of observed data, model parameters influencing absorption (i.e. transcellular intestinal permeability) 
and total hepatic plasma CL  were numerically optimized respective to each simulation (Table 15,Figure 
18a-c). 
 
CL pathway partitioning 
Within the initial adult PBPK model, CL input was compartmentalized as superficial hepatic CL. In a 
mass balance study following oral administration of lorazepam conducted by Greenblatt et al, 
approximately 75-82% of total administered dose was excreted as a glucuronide metabolite, and less than 
0.5% was excreted as unchanged parent compound [74]. In vitro studies suggest hepatic metabolism of 
lorazepam is primarily facilitated by hepatic UGT2B7 [75]. Due to the very low fe, CL was completely 
partitioned into hepatic UGT2B7 CL within the model. Once CL pathways had been defined within the 
model, UGT2B7 activity was optimized Table 15. Figures remained unchanged.  
Table 15. Mean optimized Pint and hepatic UGT2B7 CLspec 
Study dosing before dose 




2 [74] 6.80 E-06 0.16 
3 [74] 8.20 E-06 0.23 
1.5 [74] 7.68 E-06 0.28 











Figure 18. Simulated (line) and observed (symbols) plasma concentration profiles of 1.5 mg oral lorazepam. A-C have been dose 
normalized to reflect a 1.5 mg dose. All graphs were optimized for Pint and total CL 
 
Development of the adult oral population PBPK model for lorazepam 
For the population model of lorazepam, 100 virtual individuals were generated within an age range of 18-
55 years. Additional variability was also included into the adult population model, with respect to 
UGT2B7 (Table 16). Physicochemical parameters were not further modified from the optimized adult 
PBPK model. Once the population model had been simulated to generate an arithmetic standard deviation 
curve, Observed data obtained from each observed study was superimposed on the model. Given that the 
majority of observed data points sufficiently fell within on standard deviation of the mean population 
simulation, the model was deemed adequate to more forward to pediatric predictions.  
Table 16. Population variability incorporated into the adult population model simulations in PK-Sim for lorazepam 
Pathway Value Distribution Notes and reference 
GET CV % = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform 
distribution (mean*3 – mean/3). 
Each individual had the same 
surface enhancement factor 
applied. 
Uniform Table 6 
UGTB7 
(specific) 
CV = 35% Log normal 
CV of glucuronidation by UGT2B7 Vmax was 
obtained from Upichat et al. using human liver 
microsomal assays to assess protein activity and 
































































































Figure 19. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 

















Workflow 2 of lorazepam 
 
Development of the human PBPK model following IV administration 
An adult IV PBPK model was simulated for the drug lorazepam based on the dosing protocol from an IV 
infusion study conducted in adults by Greenblatt et al, in which 2 mg of lorazepam was administered as 
an IV bolus [74]. Similar to the development of the rat PBPK model in Workflow 1, the adult IV PBPK 
model incorporated relevant organism, and drug specific physicochemical parameters (Table 10). 
Additionally, since this workflow incorporates data from in-human studies, patient demographic data was 
also incorporated into this model. Model parameters influencing distribution (LogP) and CL were 
numerically optimized (Table 17, Figure 20). 
Clearance pathways were derived based on a mass balance study conducted by Greenblatt et al, following 
an IV dose of levofloxacin to healthy volunteers [74]. Within the study, it was observed that 
approximately 85-90% of the dose was recovered as a glucuronidated metabolite in the urine, with less 
than 0.5% of the dose recovered unchanged in urine. Within the model, CL was completely partitioned 
into hepatic UGT2B7 metabolism. 
 
Figure 20. Simulated (line) and observed (symbols) plasma concentration data following a 2 mg IV bolus dose of levofloxacin 
in adults. IV profile was optimized for CL and distribution (i.e. LogP) Based on data from Greenblatt et al [74] 
 
Development of the levofloxacin adult PBPK model following oral administration  
Three adult oral models were simulated following an oral dose of 1.5 mg lorazepam, similar to building 
the adult oral PBPK model in Workflow 1. Physicochemical input parameters such as pKa, molecular 
weight, optimized LogP, and optimized CL remained unchanged from the optimized adult IV model, with 
the addition of compound specific solubility at reference pH. Organism specific anatomy and physiology 
parameters incorporated into PK-Sim, pertaining to an average 30 year old European male, were used. 
Once each PBPK adult oral model had been simulated, observed data [74] was superimposed upon the 
simulated plasma concentration profiles. Pint was numerically optimized respective to each simulation 
Time [h]





























(Table 17, Figure 21a-c). The arithmetic mean Pint value would serve as the final input within the adult 
oral model scaled to pediatrics. 
Table 17. Numerically optimized Pint, LogP, UGT2B7 CLspec for the standard workflow of lorazepam 
Study dosing before dose 
normalization (mg)  
Pint (cm/min) UGT2B7 CLspec (1/min) LogP (log units) 
2 mg IV dose [74]  0.39 2.45 
2 [74] 7.65 E-06 
3 [74] 7.71 E-06 
1.5 [74] 7.35 E-06 













Figure 21. Simulated (line) and observed (symbols) plasma concentration profiles of 1.5 mg oral lorazepam. All graphs were 
optimized for CL and Pint 
 
Development of an adult oral population PBPK model 
Similar to Workflow 1, an adult population of 100 individuals was created within PK-Sim consisting of 
18-55 year old males to reflect the demographics of the reference observed study participants [74]. The 
same aspects of variability were factored into the adult population model, as discussed in Workflow 1 
(Table 16). Once the population model had been simulated to generate an arithmetic standard deviation 
curve, observed data obtained from each of the experimental observed studies was superimposed onto the 
model (Figure 22). Given that the majority of data points fell within one standard deviation of the mean 


















































































































Figure 22. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to observed (symbols) mean and standard deviation plasma concentration data following a 1.5 mg oral dose of 
lorazepam 
 
Development of the pediatric population model for Workflow 1 and 2 of lorazepam 
Three observed studies for the investigation of lorazepam pharmacokinetics in pediatrics were obtained 
from literature. Since lorazepam is commonly administered to infants and pediatrics intravenously, each 
study follows a given IV bolus dose to each respective study group. A pediatric population of up to a 
maximum of 1000 individuals for each age group of 0.6-1 year, 2.7-7.6 years, and 3-17 years was isolated 
from the pediatric reference population for lorazepam. Drug-specific parameters were equal to dose of the 
final adult oral lorazepam simulation. Four aspects of population variability were factored into the 
pediatric population model. Once variability had been successfully incorporated into the pediatric 
population simulation of 1000 individuals following a 1 mg dose, PK parameters of AUC0-inf, Cmax, and 
half-life (T½) following the observed study protocol dosing regimen were obtained for comparison to 









3.5 Pediatric PK predictions for BCS class 2 compounds 
3.5.1 Ofloxacin 
Workflow 1 of ofloxacin 
 
Development of the rat PBPK model following IV administration 
A rat PBPK model was created to simulate a 40 mg/kg intravenous bolus dose administration of 
ofloxacin, based on the study conducted by Wang et al [77]. All rat specific physiology parameters 
incorporated within PK-Sim were applied to the PBPK model simulation. Various in vitro 
physicochemical properties required for initial input into the model, such as molecular weight, 
experimental LogP, plasma proteins binding, pKa, aqueous solubility and dissolution were obtained from 
literature and incorporated into the rat PBPK simulation (Table 18). An experimentally derived in vivo 
data set obtained from literature was superimposed upon the simulated plasma concentration profile to 
assess model prediction of distribution. Given that the simulated plasma concentration profile did not 
reflect the curve shape of the observed data, model goodness of fit was achieved via numerical 
optimization of LogP and CL (Figure 23). A numerical optimization of LogP determined 0.36 as the best 
value of input in order to achieve line shape (Table 18).  
Table 18. Physicochemical initial parameter inputs for ofloxacin within Workflow 1 
Input Parameter Initial Value Reference Final applied to model 
Molecular weight 361.37   C(18)H(20)FN0(3) [78] 361.37   C(18)H(20)FN0(3) 
LogP (log units) 0.35 [79] 0.36 
Plasma protein Albumin [80] Albumin 
fu (rat) 0.77 [81] 0.77 
fu (human) 0.75 [80] 0.75 
pKa (acidic)  6.1 [82] 6.1 
pKa (base) 8.2 [82] 8.2 
Solubility in water 
(aqueous) 
2.66 mg/mL [78] 2.66 mg/mL 





Figure 23. Simulated (line and observed (symbols) plasma concentration data following a 40 mg/kg IV bolus administration of 
ofloxacin  to rats. IV profile optimized for LogP, based on data from Wang et al [90] 
 
Development of the ofloxacin adult PBPK model following oral administration  
Using the rat model as a base, three adult oral PBPK models were simulated for the drug ofloxacin.  
Physicochemical input parameters such as pKa, molecular weight, and optimized LogP remained 
consistent between the optimized rat IV model and the adult oral model (Table 18). Organism specific 
parameters were changed to reflect an average 30 year old European human male, with the addition of 
formulation specific dissolution time, solubility data at reference pH, and fu in humans. Dosing protocol 
for each simulation was based upon three existing in vivo adult pharmacokinetic studies following an oral 
400 mg dose administration [80, 83, 84]. Each PBPK adult oral model was simulated and simulated data 
points did not fall within the range of observed data. Model parameters influencing absorption (Pint) and 
CL were numerically optimized respective to each simulation (Table 19, Figure 24a-c).  
 
CL pathway partitioning 
A mass balance study following oral dose administration of ofloxacin suggest the compound is minimally 
metabolized,  approximately  <4%, and excreted mainly unchanged by renal CL processes with an fe of 
0.7 [80]. Much of the dose was also recovered in bile fluids unchanged. Renal CL was much greater than 
GFRmax, which suggests the involvement of TS. Due to the presence of TS; GFR fraction was set to a 
value of 1 within the PBPK model. Parameters pertaining to TS and biliary CL were numerically 
optimized using corresponding observed studies (Table 19). Mean values of the optimized CL and Pint 
parameters from the three optimized adult oral simulations (Figure 24a-c) were incorporated into a final 





Table 19. Workflow 1- optimized CL parameters for adult oral model of ofloxacin 
Study Pint (cm/min) TS specific (1/min) Biliary CLspec 
Lehto [83] 5.15 E-6 0.6853 3.1  E-3 
Lode [80] 7.42 E-6 0.5744 3.1  E-3 
Yuk [84] 5.57 E-6 0.6853 3.1  E-3 









Figure 24. Simulated (line) and observed (symbols) plasma concentration data following a 400 mg oral dose administration of 
ofloxacin in humans, including fe (dotted). Data is taken from A) Lehto [87] B) Lode [84] C) Yuk [88] 
 
Development of an adult oral population PBPK model 
For the population model for ofloxacin, 100 virtual individuals were generated within an age range of 18-
55 years. Six aspects of population variability were factored into the adult population model (Table 20). 
Biliary CL inter-individual variability was introduced into the model, and was assigned a standard CV of 
30% following log normal distribution [32]. Observed data obtained from each of the experimental 
observed studies was superimposed onto the model to assess the model’s ability to encompass observed 
data within one arithmetic standard deviation of the simulated population (Figure 25). Physicochemical 
parameters were not further modified from the optimized adult PBPK model. Once the population model 
had been simulated to generate an arithmetic standard deviation curve, observed data obtained from each 
of the experimental observed studies was superimposed onto the model [85, 86]. Given that the majority 
of data points fell within one standard deviation of the mean population model, it was determined 













































Figure 25. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 400 mg oral 








Table 20. Population variability incorporated into the adult population model of ofloxacin 
Pathway Value Distribution Notes and reference 
GET CV % = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform 
distribution (mean*3 – mean/3). 
Each individual had the same 
surface enhancement factor 
applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
Biliary CV = 30% Log normal 
Standard population variability 
attributed to Biliary CL in adults and 
children based on Edginton, 2006 [32] 
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Workflow 2 of ofloxacin 
 
Development of the human PBPK model following IV administration 
An adult IV PBPK model was simulated for the drug ofloxacin based on the dosing protocol from an IV 
study conducted in adults by Lode et al, in which 100 mg of ofloxacin was administered  as an IV bolus 
to 18 healthy adult participants [80]. Organism specific input parameters pertaining to anatomy and 
physiology were incorporated within PK-Sim, reflecting an average 30 year old European male were 
applied to the model. Physicochemical primary input parameters such as fu, lipophilicity (LogP), pKa, 
molecular weight, and solubility at reference pH were obtained from literature (Table 18).  
A mass balance study conducted by Lode et al suggests fe of ofloxacin was approximately 0.7-0.8 
following an IV dose; ofloxacin metabolites accounted for <4% of recovery [80]. The remaining dose was 
recovered in bile fluids unchanged [80]. Similarly to Workflow 1, a biliary component, TS, and GFR 
were incorporated within the model.  
Once the PBPK adult IV base model had been simulated following a 100 mg IV bolus, experimentally 
derived in vivo data from Lode et al [80], was superimposed upon the simulated plasma concentration 
profile. Model parameters influencing distribution (i.e. LogP) and CL were numerically optimized, and 
the simulated AUC matched the observed AUC within ±10%. Log P was optimized to 1.6 log units. TSspec 
was optimized to reflect the observed fe of 0.7-0.8; the optimized value was 0.617 1/min (Table 21, 
Figure 26).   
 
 
Figure 26. Simulated (line) and observed (symbols) plasma concentration profile of ofloxacin following a 100 mg IV bolus. 







Development of the adult oral model for ofloxacin  
Similarly to Workflow 1, three adult oral models were simulated to reflect demographic and dosing 
regimen of three observed obtained from literature [80, 83, 84]. Subsequently, each PBPK model was 
numerically optimized against the corresponding experimental study [80, 83, 84]. All physicochemical 
input parameters such as pKa, molecular weight, solubility, optimized LogP and CL remained consistent 
between the optimized adult IV model and each adult oral model (Table 18).  
Once all three PBPK adult oral models had been simulated following a 400 mg oral dose, experimentally 
derived in vivo data was superimposed upon the simulated plasma concentration profiles [80, 83, 84]. 
Model parameters influencing absorption (Pint) were numerically optimized (Table 21, Figure 27). The 
mean Pint and CL values calculated from the optimized oral and IV PBPK models, were incorporated into 
a final mean adult simulation, which was further utilized in building the subsequent adult population 
model.  
Table 21. Optimized Pint, TS, and Hepatic CL for the standard workflow of ofloxacin 
Study Pint  (cm/min) TS CLspec (1/min) 
Hepatic CLspec 
(1/min) 
LogP (log units) 
Lehto [83] 6.37 E-06 0.617 0.038 1.6 
Lode [80] 8.37 E-06 
Yuk [84] 6.28 E-06 









Figure 27.  Simulated (line) and observed (symbols) plasma concentration data following a 400 mg oral dose administration of 
ofloxacin in humans, including fe (dotted). Data is taken from A) Lehto [87] B) Lode [84] C) Yuk [88] 
 
Development of an adult oral population PBPK model 
An adult population of 100 individuals was created within PK-Sim to assess variability of ofloxacin 
exposure in adults following a 400 mg oral dose administration to 100 adults. Observed data obtained 
from each of the experimental observed studies was superimposed onto the model to assess whether 
observed data would be successfully encompassed within one standard deviation of the population model 
A B C 
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simulation (Table 20, Figure 28). Given that the majority of data points fell within one standard deviation 
of the mean population model, it was determined sufficient to progress to pediatric model development. 
Table 22. Population variability incorporated into the adult population model simulations in MoBi for ofloxacin 
Pathway Value Distribution 
Notes and 
reference 
GET CV = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had the 
same surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
Biliary CV = 30% Log normal Table 27 
 
Time [h]


































Figure 28. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 400 mg oral 
ofloxacin in adults  
 
Development of the pediatric population model for Workflow 1 and 2 of ofloxacin 
A pediatric study investigating the pharmacokinetics of ofloxacin in infants and children between the ages 
of 0.25-2years, 2-6 years, and 6-8 year olds was obtained from literature [87]. In the study, patients 
received a 20 mg/kg dose of oral ofloxacin. This experimental study served as the comparative reference 
for the assessment of the utility of Workflow 1 in predicting the PK profile in pediatrics for CL, as 
compared to the standard workflow.  
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A population of up to a maximum of 1000 individuals were randomly selected from the reference 
pediatric population, to reflect the age demographic of each observed study for ofloxacin. Drug-specific 
inputs were equal to those of the final adult oral ofloxacin simulation. All relevant inter-individual 
population variability parameters were applied to the pediatric models (Table 23). Once variability had 
been successfully incorporated into the pediatric population simulation, population PK parameters of 
AUC0-inf, Cmax, and Tmax following the observed study protocol dosing regimen were obtained for 
comparison to corresponding observed values and further data analysis. 
Table 23. Population variability incorporated into the pediatric population model for ofloxacin 
Pathway Value Distribution Notes and reference 
GET CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform distribution (mean*3 
– mean/3). Each individual had the same surface 
enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 61% Log normal Table 13 















3.5.2 Ciprofloxacin  
Workflow 1 of ciprofloxacin 
 
Development of the rat PBPK model following IV administration 
A rat PBPK model was created for the drug ciprofloxacin, based on a rat IV study (5 mg/kg) conducted 
by Naora et al [88]. Organism specific parameters pertaining to anatomy and physiology of a generic rat 
(e.g. 275 g) were applied. Physicochemical properties such as fu in rat, LogP, pKa, and molecular weight 
were obtained from various sources within literature (Table 24); ciprofloxacin binds primarily to albumin 
within rat and humans. Following simulation of the rat PBPK model, experimentally derived in vivo data 
was superimposed upon the simulated plasma concentration profile. Given that the simulated data points 
did not reflect the curve shape of the observed data, model parameters influencing distribution and CL 
were numerically optimized (Table 25, Figure 29). Numerical optimization suggested an optimal LogP 
value of 1.99 log units.  
Table 24. Ciprofloxacin physicochemical input parameters for the rat and adult models within Workflow 1 
Initial Input Initial Value Reference Value in final model 
fu (rat) 0.70 [88] 0.70 
fu (human)  0.70 [88] 0.70 
LogP (log units) 1.32  [89] 1.99  







Solubility 0.17mg/mL at 6.8pH [89] 0.17mg/mL at 6.8pH 
Dissolution >75% at 45 min [94] >75% at 45 min 
 
 





Development of the ciprofloxacin adult PBPK model following oral administration 
Using the rat model as a base, all species specific inputs were changed to reflect an average 30 year old 
European human male. This included anatomical and physiological inputs. All drug-specific inputs were 
maintained as in the rat PBPK model (Table 24) with the addition of compound specific solubility and 
dissolution data (Table 18). Three adult PBPK models were simulated, and were based upon three oral 
studies following doses of 100 mg [86], 250 mg [85], and 750 mg [86] of ciprofloxacin. Observed data 
was superimposed upon the simulated plasma concentration time profiles for an initial visual goodness of 
fit assessment. Given that the simulated data points did not fall within the range of observed data, model 
parameters influencing absorption (Pint) (Table 25) and total plasma CL were numerically optimized 
respective to each simulation (Figure 30a-c). 
 
CL pathway partitioning 
CL was characterized in the initial adult PBPK model by generic renal and generic hepatic components. 
The next step was to proportion this CL into individual pathways that are responsible for ciprofloxacin 
clearance. Ciprofloxacin undergoes the renal CL processes of GFR, TS as well as having hepatic, and 
CYP1A2 metabolism. According to literature, approximately 40-50% of orally administered ciprofloxacin 
is excreted in the urine [86, 95, 96] with approximately 15-20% of the oral dose recovered as biologically 
active metabolites in feces and urine [97]. Additionally, total renal plasma CL had been found to exceed 
GFRmax, therefore literature suggests a significant portion of ciprofloxacin is eliminated via active TS [85, 
97]. As a result, GFR and TS were added to the adult oral model in place of an overall generic renal CL 
component, as well as CYP1A2, in place of a generic hepatic component within the naïve adult oral 
model.  
Once CL pathways had been defined within the oral model, parameters pertaining to TS, CYP1A2 CL 
activity were numerically optimized using the respective observed studies (Figure 30a-c). Although there 
are many uncertainties with respect to bioavailability estimates within an oral model when lacking IV 
data, renal CL input parameters were fixed to reflect an observed fe of 40% as closely as possible. The 
mean value of the optimized TS, hepatic CL and Pint (Table 25) from each of the three simulated PBPK 
models was incorporated into a final mean adult model, which was applied to the subsequent adult 






Table 25. Optimized total hepatic CLspec, Pint for three simulated adult oral profiles 
Study dosing before 
dose normalization  
Pint (cm/min) CYP1A2 CLspec (1/min) TS CLspec (1/min) 
100 [86] 1.04 e-04 0.127 2.86 
250 [85] 2.11e-03 0.191 2.88 
750 [86] 5.87e-05 0.184 3.43 







Figure 30. Simulated (line) and observed (symbols) plasma concentration profiles, including fe (dotted), of ciprofloxacin 
following A) 100 mg [86] B) 250 mg [85] and C)750 mg [86] or oral ciprofloxacin. 
 
Development of an adult oral population PBPK model 
For the population model for ciprofloxacin, 100 virtual individuals were generated within an age range of 
18-55 years. Six aspects of population variability were factored into the adult population model (Table 
26), each of which was similarly incorporated within the previously described models. Physicochemical 
parameters were not further modified from the optimized adult PBPK model. Once the population model 
had been simulated to generate an arithmetic standard deviation curve, observed data was superimposed 
[85, 86] (Figure 31). Given that the majority of data points fell within one standard deviation of the mean 
population model, it was determined sufficient to progress to pediatric model development.   
Table 26. Population variability incorporated into the adult population model simulations of ciprofloxacin 
Pathway Value Distribution Notes and reference 
GET CV = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform 
distribution (mean*3 – mean/3). Each 
individual had the same surface 
enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
CYP1A2 (specific) CV = 30% Log normal Table 19 






























Figure 31. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to observed (symbols) mean and standard deviation plasma concentration data following data following a 100 mg oral 

















Workflow 2 of ciprofloxacin 
 
Development of the human PBPK model following IV administration 
An adult IV PBPK model was simulated for the drug ciprofloxacin based on the dosing protocol from an 
IV study conducted in adults by Wise et al, in which a 100 mg IV bolus was administered to six healthy 
adults [98]. Similar to Workflow 1, organism specific input parameters pertaining to anatomy and 
physiology were incorporated within PK-Sim, reflecting an average 30 year old European male. 
Physicochemical parameters such as fu, LogP, pKa, and molecular weight were applied to the model, as 
obtained from literature (Table 24). Once the PBPK adult IV base model had been simulated following a 
100 mg IV bolus, experimentally derived in vivo data from Wise et al, was superimposed upon the 
simulated plasma concentration profile to allow for a goodness of fit assessment [98]. Model parameters 
influencing distribution (LogP) and CL were optimized (Figure 32). LogP was optimized to 1.85 log 
(Table 27). 
A study by Hoffken et al suggests approximately 40-60% of the IV administered dose was recovered as 
parent compound excreted unchanged in urine [86], with approximately 20-30% of the dose recovered in 
urine and feces  as metabolites [86], and the remainder was recovered in feces unchanged; this was 
characterized as both a CYP1A2 and generic biliary CL component within the model (Table 27).  
 
Figure 32. Simulated (line) and observed (symbols) plasma concentration data following a 100 mg IV bolus of ciprofloxacin in 
adults, including simulated fe (dotted line). IV profile was optimized for CL and distribution (i.e. LogP) Based on data from Wise 
et al[98]. Adult IV model optimized for LogP and CL 
 
Development of the ciprofloxacin adult PBPK model following oral administration  
Three adult oral models were simulated following 100 mg, 250 mg, and 750 mg oral doses of 
ciprofloxacin respectively.  Physicochemical input parameters such as pKa, molecular weight, optimized 
LogP, and optimized CL remained unchanged from the final adult IV model, with the addition of 
compound specific solubility at reference pH (Table 24). Organism specific anatomy and physiology 
parameters incorporated into PK-Sim, pertaining to an average 30 year old European male, were used. 
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Once each PBPK adult oral model had been simulated, observed data [85, 86] was superimposed upon the 
simulated plasma concentration profile.  Given that the simulated data points did not fall within the range 
of observed data, the most uncertain model parameter influencing absorption, Pint, was numerically 
optimized respective to each simulation (Table 27, Figure 33a-c). The arithmetic mean Pint value would 
serve as the final input within the adult oral model scaled to pediatrics. 
Table 27. Numerically optimized parameters of Pint, TS, CYP1A2 CL and LogP for the standard workflow of ciprofloxacin 









LogP (log units) 
100 mg IV bolus [98]  1.01 0.59 0.6 1.85 
100 [86] 0.0134 E-02  
250 [85] 0.0175 E-02  
750 [86] 0.0375 E-02  








Figure 33. Simulated (line) and observed (symbols) plasma concentration profiles of ciprofloxacin following A) 100 mg B)250 
mg and C)750 mg oral dose administration within Workflow 2 
 
Development of an adult oral population PBPK model 
Similar to the population model of ciprofloxacin in Workflow 1, 100 virtual individuals were generated 
within an age range of 18-55 years. Seven aspects of population variability were factored into the adult 
population model, six of which was similarly incorporated within Workflow 1 (Table 26), with the 
addition of a 30% CV of Biliary CL (Table 26), as described in previous models. Physicochemical 
parameters were not further modified from the optimized adult PBPK model. Once the population model 
had been simulated, following a 100 mg oral dose administration,  observed data obtained from each 
study was dose normalized to reflect a 100 mg dose, and superimposed onto the model  [85, 86] (Figure 
34). Observed data points successfully fell approximately within the arithmetic standard deviation limits 
of the population model.  
































Figure 34. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 100 mg oral 
dose of ciprofloxacin in adults. 
 
Development of the pediatric population model for Workflow 1 and 2 of ciprofloxacin 
A pediatric study investigating the pharmacokinetics of ciprofloxacin in infants and children between the 
ages of 5-14 weeks and 1-5 years was obtained from literature [99]. In the study, patients received a 15 
mg/kg dose or oral ciprofloxacin. This experimental study served as the comparative reference for the 
assessment of the utility of Workflow 1 in predicting the PK profile in pediatrics for CL, as compared to 
the standard workflow.  
A pediatric population of up to a maximum of 1000 individuals reflecting the observed study were 
isolated from the reference pediatric population for ciprofloxacin. Drug-specific parameters were equal to 
those of the final adult oral ciprofloxacin simulation. Six aspects of population variability were factored 
into both pediatric population models as obtained from literature (Table 28). Once variability had been 
successfully incorporated into the pediatric population simulations, PK parameters of AUC0-inf, Cmax, and 
Tmax following the observed study protocol dosing regimen were obtained for comparison to 
corresponding observed values and further data analysis. 
Table 28.  Population variability incorporated into the pediatric population model simulations for Ciprofloxacin 
Pathway Value Distribution 
Notes and 
reference 
GET CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had the 
same surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 61% Log normal Table 13 




Workflow 1 of valsartan  
 
Development of the Rat PBPK model following IV administration  
A PBPK model simulation was created to simulate a 1 mg/kg IV bolus of valsartan in rats.  Drug specific 
physicochemical were obtained from literature and incorporated into the rat PBPK simulation (Table 29). 
A study by Yamashiro et al [87] suggests that valsartan metabolism in the rat is due primarily to hepatic 
mechanisms, which was reflected in the rat PBPK model CL processes. Observed in vivo data following 1 
mg/kg valsartan IV bolus administration to rats was obtained from literature [87]. Once the initial, or 
naïve, PBPK rat model had been simulated, both experimentally derived in vivo data sets were 
superimposed upon the simulated plasma concentration profile. Given that the simulated data points did 
not reflect the curve shape of the observed data, model parameters influencing distribution (LogP) and CL 
were numerically optimized (Figure 35); LogP was optimized to 3.09. Although the terminal phase within 
the rat model in Figure 35 did not match observed line-shape, the objective of the optimized model was to 
define the distribution phase of the plasma concentration profile which is ideally captured by the initial 
time points.  
Table 29. Physicochemical initial parameter inputs for valsartan in the Rat and adult model 
 Input Parameter Initial Value Reference Final value in model 
Molecular weight 435.52 [100] 435.52 
LogP (experimental) 1.5 [100] 3.09 
Fu rat 0.05 [101] 0.05 
Fu human 0.05 [101] 0.05 
pKa (acidic) x 2 3.9 and 4.73 [100] 3.9 and 4.73 
Aqueous solubility  0.18 g/L [100] 0.18 g/L 






Figure 35. Simulated (line) and observed (symbols) valsartan Rat IV profile optimized for LogP, following 1 mg/kg IV bolus 
dose administration based on data from Yamashiro et al [87] 
 
Development of the valsartan adult PBPK model following oral administration 
Three adult oral PBPK models were simulated for the drug valsartan in which all physicochemical input 
parameters such as pKa, molecular weight, and solubility at reference pH, as well as optimized LogP 
remained consistent between the optimized rat IV model and the adult oral model (Table 29). Organism 
specific anatomy and physiology parameters such as fu in humans, as well as solubility and dissolution 
data were applied to the model. Dosing guidance for each simulation was based upon three existing in 
vivo adult pharmacokinetic studies following and 80 mg oral dose administration [100, 103, 104]. CL of 
valsartan was designated completely within generic hepatic and renal systems.  
Once each PBPK adult oral model had been simulated following an oral dose of 80 mg of valsartan, 
experimentally derived in vivo data [100, 103, 104], was superimposed upon the simulated plasma 
concentration profile. Model parameters influencing absorption (Pint) and CL were numerically optimized 
(Table 30).  
 
CL pathway partitioning 
Pharmacokinetic studies following oral dose administration suggest approximately 10% recovery of 
unchanged compound in the urine, approximately 70% of the compound was recovered in bile fluids and 
feces unchanged, and approximately 9% was released as a hepatic CYP2D6 metabolite [105]. CYP2D6 
metabolism, biliary CL, GFR, and TS CL processes were applied to the adult oral model [105]. CYP2D6 
metabolizing enzyme was localized completely within the liver. All CL parameters were numerically 
optimized (Table 31, Figure 36a-c). Arithmetic mean values of the optimized CL and Pint parameters from 
the adult PBPK models were incorporated into a final adult PBPK model. Despite poor fit of the 
simulated rat PBPK model to observe data in the terminal phase (Figure 35), the adult oral model was not 
impeded by the large deviation in line shape. 
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Table 30. Optimized distribution and CL  parameters of valsartan  
Study Pint (cm/min) 






Flesch [103] 3.70 E-06 0.315 0.194 0.457 
Criscione [100] 3.70 E-06 0.331 0.189 0.343 
Macek [104] 3.90 E-06 0.254 0.188 0.229 







Figure 36. Simulated (line) and observed (symbols) plasma concentration profiles of valsartan following 80 mg oral dose 
administration, based on data from A) Flesch et al [103] B) Criscione et al [100] C) Macek et al [104] including fe (dotted) 
 
Development of an adult oral population PBPK model  
For the population model for valsartan, 100 virtual individuals were generated within an age range of 18-
55 years. Once the population had been generated, the population was administered a 80 mg oral dose to 
reflect the observed studies [100, 103, 104]. Six aspects of population variability were factored into the 
adult population model (Table 31) as obtained from literature. CYP2D6 variability was incorporated into 
the model as obtained from Dorne  et al [106] following a log normal distribution with CV of 66% in 
adults. Physicochemical parameters were not further modified from the optimized adult PBPK model. 
Once the population model had been simulated to generate an arithmetic standard deviation curve, 
observed data obtained from each of the experimental observed studies was superimposed onto the model 
(Figure 37). Given that the majority of data points and/or  their respective observed standard deviations 
fell within one standard deviation of the mean population model, it was determined sufficient to progress 










































































Table 31. Population variability incorporated into the adult population model simulations for valsartan 
Pathway Value Distribution Notes and reference 
GET CV % = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform 
distribution (mean*3 – 
mean/3). Each individual had 
the same surface 
enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
CYP2D6 CV = 66% log normal 
Determined from Dorne et al [106] in which the 
inter-individual variability for various phase I, 
II and renal metabolic processes was assessed 
with various probe substrates.  
Biliary CV = 30% Log normal Table 27 
 
Time [h]































Figure 37. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to  observed (symbols) mean and standard deviation plasma concentration data following data following a 80 mg oral 











Workflow 2 of valsartan 
 
Development of the human PBPK model following IV administration 
An adult PBPK model was simulated for the drug valsartan based on the dosing protocol from an IV 
study conducted in adults by Flesch et al, in which 20 mg of valsartan was administered  as an IV bolus to 
12 healthy adult participants [103]. Organism specific input parameters pertaining to anatomy and 
physiology were incorporated within PK-Sim, reflecting an average 30 year old European male were 
applied to the model. Physicochemical primary input parameters such as fu, LogP, pKa, molecular 
weight, and solubility were obtained from literature (Table 29).  
A mass balance study of valsartan suggests fe was 0.30 following an IV dose. Biliary CL is an important 
route of elimination for valsartan, as a greater concentration of valsartan was found in bile fluids 
unchanged, as compared to plasma samples [103]. Similar to Workflow 1, biliary, CYP2D6, GFR, and TS 
pathways of CL were defined within the model.  
Once the PBPK adult IV base model had been simulated following a 20 mg IV bolus dose administration, 
experimentally derived in vivo data from Flesch et al [103], was superimposed upon the simulated plasma 
concentration profile (Figure 38). Given that the simulated data points did not reflect curve shape and 
exposure of the experimental data, LogP and CL were numerically optimized (Table 32).  
 
Figure 38. Simulated (line) and observed (symbols) plasma concentration data of a 20 mg IV bolus of valsartan in humans, 
including fe (dotted) optimized for distribution and CL. Observed data taken from Flesch et al [103] 
 
Development of the valsartan adult PBPK model following oral administration 
Similarly to Workflow 1, three adult oral PBPK models were simulated to reflect the dosing protocol of 
three observed obtained from literature, 80 mg oral valsartan. In addition to the physicochemical input 
parameters, optimized LogP and CL remained unchanged from the optimized adult IV model. Organism 
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specific anatomy and physiology input parameters were incorporated into PK-Sim, for a mean European 
30 year old male. Once all three PBPK adult oral models had been simulated, experimentally derived in 
vivo data was superimposed upon the simulated plasma concentration profiles [100, 103, 104]. Model 
parameters influencing absorption (Pint) were numerically optimized (Table 32, Figure 39a-c). The 
arithmetic mean of each optimized parameter was incorporated into a final mean adult simulation, which 
was further utilized in building an adult population model.  
Table 32. Optimized absorption and CL parameters of valsartan 









Flesch IV [103]  0.967 0.626 0.366 0.36 
Flesch [103] 1.30 E-6 
Criscione [100] 1.32 E-6 
Macek [104] 1.70 E-6 









Figure 39. Simulated (line) and observed (symbols) plasma concentration profiles of valsartan following 80 mg oral dose 
administration, based on data from A) Flesch et al [93] B)Criscione et al [90] C) Macek et al [94] 
 
Development of an adult oral population PBPK model 
An adult population of 100 individuals was created within PK-Sim to assess variability of valsartan 
exposure in adults following an 80 mg oral dose (Figure 40). Eight aspects of population variability were 
factored into the adult population model (Table 33) as obtained from literature. CYP2D6 variability was 
incorporated into the model as obtained from Dorne  et al [106] following a log normal distribution with 
CV of 66% in adults. Physicochemical parameters were not further modified from the optimized adult 
PBPK model. Once the population model had been simulated to generate an arithmetic standard deviation 
curve, observed data obtained from each of the experimental observed studies was superimposed onto the 
model for an assessment of the models ability to appropriately characterize population variability (Figure 
40). Given that the majority of data points fell within one standard deviation of the mean population 
model, it was determined sufficient to progress to pediatric model development. 
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Table 33. Population variability incorporated into the adult population model simulations of valsartan 
Pathway Value Distribution Notes and reference 
GET CV = 24% Log normal Table 6 
SITT  CV = 22.5% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a 
uniform distribution 
(mean*3 – mean/3). 




Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 60.7% Log normal Table 13 
CYP2D6 CV = 66%  Determined from Dorne et al [106] in which the inter-
individual variability for various phase I, II and renal 
metabolic processes was assessed with various probe 
substrates. 
Biliary CV = 30% Log normal Table 27 
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Figure 40. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 80 mg oral 
valsartan in adults 
 
Development of the pediatric population model for Workflow 1 and 2 of valsartan 
A pediatric study investigating the pharmacokinetics of valsartan in infants and children after a 2 mg/kg 
oral dose administration, with a maximum single dose of 80 mg, was obtained from literature [107]. 
Subjects were stratified into four age groups; 1-4 years, 4-6 years, 6-12 years, and 12-16 year olds. This 
experimental study served as the comparative reference for the assessment of the utility of Workflow 1 in 
predicting the PK profile in pediatrics for CL, as compared to the standard workflow.  
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A pediatric population of up to a maximum of 1000 individuals reflecting the observed study were 
isolated from the reference pediatric population for valsartan. Similar to methods discussed previously, 
seven aspects of population variability were factored into the pediatric population model, as obtained 
from literature (Table 34). Once variability had been successfully incorporated into the pediatric 
population, PK parameters of AUC0-inf, Cmax, and Tmax following the observed study protocol dosing 
regimen were obtained for comparison to corresponding observed values and further data analysis. 
Table 34. Population variability incorporated into the pediatric population model simulations in PK-Sim and MoBi for 
Workflow 1 and 2 
Pathway Value Distribution Notes and reference 
GET  CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform 
distribution (mean*3 – 
mean/3). Each individual had 
the same surface enhancement 
factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 61% Log normal Table 13 
CYP2D6 CV = 66%  
Determined from Dorne et al [106] in which the 
inter-individual variability for various phase I, II 
and renal metabolic processes was assessed with 
various probe substrates. 
















3.6 Pediatric PK predictions for BCS class 3 compounds 
3.6.1 Acyclovir  
Workflow 1 of acyclovir 
 
Development of the rat PBPK model following IV administration  
A rat  PBPK model simulation was created for the drug acyclovir, based on rat IV studies conducted by 
Ogiso et al [108], and Ye et al [109], in which rats were administered a 1 mg/kg IV bolus. All rat specific 
physiological parameters incorporated within PK-Sim were applied to the PBPK model simulation. 
Various in vitro physicochemical properties required for initial input into the model, such as fu in rat, 
LogP, pKa, and molecular weight, were obtained from literature and incorporated into the rat model 
simulation (Table 35). Once the initial, or naïve, PBPK rat model had been simulated, both 
experimentally derived in vivo data sets were superimposed upon the simulated plasma concentration 
profile (Figure 41). Given that the simulated plasma concentration profile did not reflect the curve shape 
of the observed data, model goodness of fit was achieved via numerical optimization (Figure 41). A 
numerical optimization of LogP determined -0.75 as the best value of input in order to match line shape.  
Table 35. Physicochemical initial parameter inputs for acyclovir 
Initial Input Initial Value reference  Final value in model 
Fu (rat) 0.67 [110] 0.67 
Fu (human) 0.85 [111] 0.85 
LogP (experimental) -0.95 [111, 112] -0.75 







Solubility 2.62 mg/ml [62] 2.62 mg/ml 




Figure 41. Simulated (line) and observed (symbols) plasma concentration data following a 1 mg/kg IV bolus of acyclovir in rats.  
Observed data taken from Ogiso et al [108], and YE et al [109]  
 
Development of the acyclovir adult PBPK model following oral administration  
Three adult oral PBPK models were simulated for the drug acyclovir. Three experimental studies were 
obtained from literature following a 400 mg oral dose of acyclovir [116-118]. For each adult oral PBPK 
model simulation, physicochemical input parameters and optimized LogP remained unchanged from the 
optimized rat IV model (Table 35). Organism specific anatomy and physiology parameters incorporated 
into PK-Sim, pertaining to an average 30 year old European male, free fraction of acyclovir in humans, 
solubility and dissolution data were applied to the human oral model. CL of acyclovir was designated 
completely as a renal process, as there was not any literature reference found to identify metabolite 
excreted via urine or feces following an oral dose administration. For this workflow, it was therefore 
assumed there was no significant contribution of hepatic CL pathways towards the metabolism of 
acyclovir. Once each PBPK adult oral model had been simulated, in vivo data from the three observed 
studies were superimposed upon the simulated plasma concentration profile (Figure 42a-c) [116-118].  
Model parameters influencing absorption (i.e. Pint) (Table 36), and total renal plasma CL were 
numerically optimized respective to each simulation, to match observed AUC within ±10%. 
 
CL pathway partitioning  
Within the adult PBPK model, CL was input as a renal process only, as there was not any literature 
available to support hepatic metabolism of acyclovir following an oral dose. Subsequently, renal CL was 
proportioned into individual pathways responsible for acyclovir CL as understood from literature. In a 
mass balance study conducted by Vergin et al, 24 patients received a 400 mg oral dose of acyclovir. 
Approximately 15.4% ± 4.7 of the total acyclovir dose administered was recovered as unchanged in urine 
[118]. There were no significant data found to support metabolites of acyclovir recovered following an 
oral dose administration only. In the study, total renal CL was greater than GFR, thereby indicating that a 
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significant portion of acyclovir is eliminated via active TS by renal transporters; as a result, GFR and TS 
CL compartments were incorporated into the PBPK model. Although there are many uncertainties with 
respect to bioavailability estimates within an oral model when lacking IV data, renal CL input parameters 
were fixed to reflect an observed fe of 15.4% ± 4.7 as closely as possible. The optimization of Pint, and CL 
to match observed AUC, may alter the final fe value based on the model’s ability to predict 
bioavailability. The arithmetic mean of optimized CL and absorption parameters were incorporated into a 
final adult model.  
Table 36. Numerically optimized Pint, TS CLspec for each of three simulated profiles 
following oral dose administration in adults 
Oral dose administration 
simulation  
Pint  (cm/min) TS CLspec (1/min) 
Bangaru et al. [116] 3.50 E-07 0.659 
Vergin et al. [118] 3.04 E-07 0.527 
Yuen et al. [117] 2.76 E-07 0.654 







Figure 42. Simulated (line) and observed (symbols) plasma concentration data following a 400 mg oral dose of acyclovir, 
including fe (dotted). Observed data taken from A) Bangaru et al [116] B) Vergin et al [118] C) Yuen et al [117] 
 
Development of an adult oral population PBPK model  
For the population model of acyclovir, 100 virtual individuals were generated within an age range of 18-
55 years. Once the population model had been generated, the population was administered a 400 mg oral 
dose to reflect the dosing protocol in observed studies [116] [117] [118].  Five aspects of population 
variability were factored into the adult population model as obtained from literature (Table 37). 
Physicochemical parameters were not further modified from the optimized adult PBPK model. Once the 
population model had been simulated to generate an arithmetic standard deviation curve, observed data 
obtained from each of the experimental observed studies was superimposed onto the model (Figure 43). 
Given that the majority of data points fell within one standard deviation of the mean population model, it 
was determined sufficient to progress to pediatric development. 
 
A B C 
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Table 37. Population variability incorporated into the adult population model simulations of acyclovir 
Pathway Value Distribution Notes and reference 
GET CV % = 24% Log normal Table 6 
SITT CV = 22.5% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform 
distribution (mean*3 – mean/3). 
Each individual had the same 
surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
 
Time [h]


























Figure 43. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 400 mg 












Workflow 2 of acyclovir 
 
Development of the human PBPK model following IV administration  
An adult IV PBPK model was simulated for acyclovir based on the dosing protocol from an IV infusion 
study conducted in adults by Soul-Lawton et al, in which 350 mg of acyclovir was administered over a 1 
hour period to 12 healthy participants [119]. Similar to the rat IV PBPK model, organism specific and 
drug specific physicochemical parameters (Table 35) were applied to the model.  
Study findings by Soul-Lawton et al suggest acyclovir has an fe of 0.87 ± 0.19 following an IV dose, with 
an additional 13.78% ± 4.2% of the dose recovered as 9-(carboxymethoxymethyl)guanine (CMMG), as 
well as <2% of the dose recovered as 8-hydroxy-9-[(2-hydroxyethoxy)methyl]guanine (8-OHACV) 
acyclovir metabolites [119]. Since the recovery of 8-OHACV was <2%, it was not included within the 
model, as it will not provide a significant contribution towards clearance. Due to the recovery of acyclovir 
metabolite CMMG, a hepatic component was incorporated into the IV model. Due to a lack of knowledge 
regarding the exact enzyme responsible for acyclovir metabolism into CMMG, the specific ontogeny of 
said enzyme was not incorporated into the model. This may affect the models ability to accurately 
quantify the variability of CL in adults and pediatrics as the model progresses. Since renal CL far 
exceeded creatinine CL within the observed IV study, it is apparent much of the compound undergoes TS 
[118].  Due to multiple tandem processes of renal CLs, GFR fraction was set to a fixed value of 1 within 
the simulation, whereas TS was subject to further optimization to reach a fe value close to 0.87. Once the 
PBPK adult IV base model had been simulated following a 350 mg IV infusion, experimentally derived in 
vivo data from Soul-Lawton et al [119] was superimposed upon the simulated plasma concentration 
profile (Figure 44). Given that the simulated data points did not reflect curve shape and exposure of the 
experimental data, model parameters influencing distribution (LogP) and CL were numerically optimized 
(Table 37).  
 
Figure 44. Simulated (line) and observed (symbols) plasma concentration data in adults following a 350 mg IV infusion of 




Development of the acyclovir adult PBPK model following oral administration 
Similarly to Workflow 1, three adult oral PBPK models were simulated to reflect the dosing protocol of 
three observed obtained from literature. All physicochemical input parameters, optimized LogP and CL 
remained unchanged from the optimized adult IV model. Organism specific anatomy and physiology 
input parameters were incorporated into PK-Sim, for a mean European 30 year old male. CL parameters 
were not changed from the adult IV model. Each PBPK model was numerically optimized for absorption 
(Pint) against the corresponding experimental study (Table 38, Figure 45 a-c) [116-118]. The mean Pint, 
TSspec, and hepatic CLspec values obtained from the IV and oral models were incorporated into a final 
mean adult simulation, which was further utilized in building an adult population model.  
Table 38. Numerically optimized Pint, TS, and hepatic CL parameters for acyclovir within the 
standard workflow 
Simulation specific 








Soul-Lawton et al [119]  0.779 0.0397 -0.68 
Bangaru et al. [116] 1.73 E-04 
Vergin et al. [118] 1.70 E-04 
Yuen et al. [117] 1.67 E-04 








Figure 45. Simulated (line) and observed (symbols) plasma concentration data following a 400 mg oral dose of acyclovir. 
Observed data taken from A) Bangaru et al [116] B) Vergin et al [118] C) Yuen et al [117] 
 
Development of an adult oral population PBPK model 
Similarly to Workflow 1, 100 virtual individuals were created within an age range of 18-55 years. Once 
the population was created, a 400 mg oral dose was applied to the model, as well as six aspects of 
population variability as obtained from literature (Table 39). A hepatic CL CV of 30% was added to the 
population model, based on CMMG recovery reported in Soul-Lawton et al [119]. Once the population 
model had been generated, observed data from each of the three observed studies were superimposed onto 
the population model (Figure 46). Given that the majority of data points fell within one standard deviation 
of the mean population model, it was determined sufficient to progress to pediatric development. 
A B C 
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Table 39. Population variability incorporated into population model simulations for acyclovir 
Pathway Value Distribution 
Notes and 
reference 
GET  CV = 24% Log normal Table 6 
SITT CV = 22.5% Log normal Table 6 
Small intestinal surface area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had the 
same surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 13 
Hepatic CLspec CV = 30% Log normal Table 19 
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Figure 46. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 400 mg oral 
dose of acyclovir in adults. Observed data taken from Bangaru et al [116], Vergin et al [118], Yuen et al [117] 
 
Development of the pediatric population model for Workflow 1 and 2 
A pediatric study  investigating the pharmacokinetics of acyclovir  in infants and children, conducted by 
Sullender et al [120] was obtained from literature. In the study, a 600 mg/m
2
 dose of acyclovir was 
administered to 13 children, divided into two groups based on age. The first group consisted of 0.5-4 year 
olds with a mean body surface area (BSA) of 0.6 m
2
, whereas the second group consisted of 4-7 year olds 
with a mean BSA of 0.8 m
2
. As a result, the two groups of participants received an approximate mean 
dose of 1000 mg, and 750 mg respectively. This experimental study served as the comparative reference 
for the assessment of the utility of Workflow 1 in predicting the PK profile in pediatrics for acyclovir, as 
compared to the standard workflow. 1000 pediatric individuals were randomly selected from the reference 
population to reflect the age demographic of the observed studies. Variability with respect to Anatomy, 
physiology, physicochemical data, absorption, distribution and CL were incorporated within the model 
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(Table 40). The lack of ontogeny and variability information pertaining to the enzyme responsible for 
acyclovir metabolism may lead to inaccurate clearance predictions by the model.  
Table 40. Population variability parameters incorporated into the pediatric population model for Workflow 1 and 2 
Pathway Value Distribution Notes and reference 
GET  CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal 
surface area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had the 
same surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 61% Log normal Table 15 






















Workflow 1 of cimetidine 
 
Development of the Rat PBPK model following IV administration 
A rat PBPK model was created to simulate a 40 mg/kg IV bolus dose administration of cimetidine, based 
on the observed study conducted by Adedoyin et al [121]. All rat specific physiology parameters 
incorporated within PK-Sim were applied to the PBPK model. Various drug specific physicochemical 
properties required for initial input into the model were obtained from literature and applied to the model 
(Table 41). Once the PBPK rat model had been simulated, experimentally derived in vivo data was 
superimposed upon the simulated plasma concentration profile, as obtained from Adedoyin et al (Figure 
47) [121]. A numerical optimization of LogP determined 1.84 as the best value of input in order to 
achieve observed line shape.  
Table 41. Physicochemical parameters of cimetidine for initial input into Workflow 1 and 2 
Input Value Reference  Value in final model 
fuhuman 0.8 [121] 0.8 
furat 0.8 [121] 0.8 
Molecular weight 252.34 [39, 122] 252.34 
pKa 6.8 (base) [39, 122] 6.8 (base) 
Solubility 11.3 mg/ml @ pH 9.8 [39, 122] 11.3 mg/ml @ pH 9.8 
Dissolution profile 50% in 15 min [123] 50% in 15 min 
Dose administration IV 40  mg /kg [121] IV 40  mg /kg 
LogP (log units) 0.4 Optimized 1.84 
 
 
Figure 47. Simulated (line) and observed (symbols) plasma concentration data following a 40 mg/kg IV dose of cimetidine in 






Development of the cimetidine adult PBPK model following oral administration 
Using the rat IV model as a base, all species specific inputs were changed to reflect an average 30 year 
old European human male. This included anatomical and physiological inputs. All drug specific inputs 
were maintained as in the rat PBPK model with the addition of compound specific solubility and 
dissolution dat. Two adult oral PBPK models were simulated for the drug cimetidine, following a 200 mg 
oral dose of cimetidine, and were based on two experimental studies obtained from literature, in which a 
sample group of participants were administered oral doses of 200 and 400 mg cimetidine respectively 
[122, 124]. cimetidine has been observed to follow dose dependent kinetics when dosing within the 
therapeutic range, as a result, observed data from the study following a 400 mg oral dose of cimetidine 
was dose normalized  to 200 mg [122].   Observed derived data was superimposed upon the simulated 
profile to allow for goodness-of fit assessment. The simulated profile was optimized numerically for 
parameters of absorption (Pint), and renal and hepatic CL (Table 42, Figure 48a-b).  
 
CL pathway partitioning 
Once the adult oral PBPK model had been optimized, CL pathways were further refined. Experimentally, 
total renal CL was found to be greater than GFR, thereby indicating that a significant portion of 
cimetidine is eliminated via active TS by renal transporters. As a result, GFR and TS were added to the 
adult oral model in place of an overall renal CL as identified from the naïve adult oral model. Basic drugs 
are generally attributed to greater hepatic metabolism, however studies suggest the very low LogP of 
cimetidine may contribute to its unusually high level of renal CL [125]. Only, 10-20% of the administered 
oral dose was excreted in urine as sulfide metabolites due to various hepatic enzymes [122, 124]. As a 
result, the generic hepatic component applied initially was unchanged within the model. Due to a lack of 
knowledge regarding the exact enzyme responsible for cimetidine metabolism into sulfide metabolites, 
the specific ontogeny of said enzyme(s) was not incorporated into the model. This may affect the models 
ability to accurately quantify the variability of CL in adults and pediatrics as the model progresses.  CL 
parameters were optimized for each study and an arithmetic mean was obtained and applied to a final 


















Figure 48. Simulated (line) and observed (symbols) plasma concentration data following a 200 mg oral dose of cimetidine in 
adults. Observed data taken from A) Yamasaki et al [124] B) Jantratid et al [122] fe (dotted) included 
 
Table 42. Numerically optimized Pint, TS CLspec, and hepatic CL parameters based on observed data 
Study dose before dose 
normalization (mg)  Pint (cm/min) TS  CLspec (1/h) hepatic  CLspec (1/min) 
200 [124] 1.75 E-04 2.285 0.0827 
400 [122] 1.05 E-04 2.125 0.0922 
Mean 1.40 E-04 2.205 0.0875 
 
 
Development of an adult oral population PBPK  
For the population model of cimetidine, 100 virtual individuals were generated within an age range of 18-
55 years. A 200 mg oral dose was administered to each individual within the population to reflect dosing 
protocol from the observed studies [124] [122]. Six aspects of population variability were factored into 
the adult population model (Table 43) as obtained from literature. The lack of ontogeny and variability 
information pertaining to the enzyme(s) responsible for cimetidine metabolism may lead to inaccurate 
clearance predictions by the model. Physicochemical parameters were not further modified from the 
optimized adult PBPK model. Once the population model had been simulated, an arithmetic mean and 
standard deviation curve was generated to assess the characterization of inter-individual variability. 
Observed data was superimposed onto the model (Figure 49). Given that the majority of data points fell 
within one standard deviation of the mean population model, it was determined sufficient to progress to 








Table 43. Population variability incorporated into the adult population model simulation of cimetidine 
Pathway Value Distribution Notes and reference 
GET  CV = 24% Log normal Table 6 
SITT CV = 22.5% Log normal Table 6 
Small intestinal surface area  9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had 
the same surface enhancement factor 
applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 15 
Hepatic (specific) CV = 30% Log normal Table 19 
 
Time [h]




























Figure 49. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 200 mg oral 











Workflow 2 of cimetidine 
 
Development of the human PBPK model following IV administration 
An adult IV PBPK model was simulated for the drug cimetidine based on the dosing protocol from an 
adult IV study conducted by Jantratid et al, in which 300 mg of cimetidine was administered as an IV 
bolus [122]. Organism specific anatomy and physiology parameters incorporated into PK-Sim, pertaining 
to an average 30 year old European male were used. Physicochemical primary input parameters such as 
fu, LogP, pKa, and molecular weight were obtained from literature (Table 41). Once the PBPK adult IV 
base model had been simulated, experimentally derived in vivo data was superimposed upon the 
simulated plasma concentration profile [122]. LogP was numerically optimized to 0.2 log units. (Figure 
50, Table 44).  
Mass balance studies following IV administration of cimetidine, conducted by Jantratid et al and Somogyi 
et al, found that approximately 50-80% of intravenously administered cimetidine had been recovered in 
urine as unchanged drug, approximately 20-40% recovered as a sulfide metabolite, and the remainder 
recovered unchanged in feces [122, 125]. A hepatic CL component, TS renal component, and fixed GFR 
fraction of 1 were applied to the PBPK model. There was no biliary CL component included in the model, 
as multiple hepatic processes may lead to an over-prediction of CL within the PBPK model, thereby 
generating erroneous AUC estimates.  
  
Figure 50. Simulated (line) and observed (symbols) plasma concentration data following an IV dose of cimetidine in adults. 
Observed data was taken from Jantratid et [122]. 
 
Development of the adult PBPK model following oral administration  
An adult oral model was simulated to reflect demographic and dosing regimen of two observed obtained 
from literature [122, 124]. All physicochemical input parameters such as pKa, molecular weight, 
solubility, and optimized LogP remained consistent between the optimized adult IV model and each adult 
oral model. Once the adult oral PBPK model had been simulated following a 200 mg oral dose, 
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experimentally derived in vivo data was superimposed upon the simulated plasma concentration profiles 
[122, 124]; model parameters influencing absorption (Pint) were numerically optimized (Table 44, Figure 
51a-b). A mean Pint value was calculated from each of the optimized adult oral PBPK models, and was 
incorporated into a final mean adult simulation, which was further utilized in building an adult population 
model.  
Table 44. Numerically optimized parameters of LogP, Pint, TS, and hepatic CL spec 
Study dosing before dose 
normalization (mg)  
Pint (cm/min) TSspec Hepatic CLspec LogP (log units) 
300 mg IV bolus [121]  1.83 0.124 0.2  
200 [124] 2.75 E-06 
400 [122] 2.25 E-06 










Figure 51. Simulated (line) and observed (symbols) plasma concentration data following a 200 mg oral dose of cimetidine in 
adults. Observed data taken from A) Yamasaki et al [124]B) Jantratid et al [122] 
 
Development of an adult oral population PBPK model  
An adult population simulation was generated within PK-Sim to assess the inter-individual variability of 
cimetidine exposure in adults following a 200 mg oral dose administration to 100 adults. Since there were 
no additional CL compartments added to Workflow 2, identical aspects of population variability were 
factored into the Workflow 2 adult population model as in Workflow 1 (Table 43).Once the population 
model had been simulated to generate an arithmetic standard deviation curve, observed data obtained 
from each of the experimental observed studies was superimposed onto the model (Figure 52). Given that 
the majority of data points fell within one standard deviation of the mean population model, it was 

































Figure 52. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 200 mg oral 
dose of cimetidine in adults.  
 
Development of the pediatric population model for Workflow 1 and 2 of cimetidine 
A pediatric study investigating the pharmacokinetics of cimetidine in infants and children between the 
ages of 4-16 years was obtained from literature. In the study, patients received a 20 mg/kg dose, of oral 
cimetidine (n = 11) [126]. This experimental study served as the comparative reference for the assessment 
of the utility of Workflow 1 in predicting the PK profile in pediatrics for cimetidine, as compared to the 
standard workflow. 
Up to a maximum of 1000 individuals within the specified age range of the observed study were 
randomly selected from the reference pediatric population for cimetidine. All drug-specific parameters 
were equal to those of the final cimetidine simulation.  Similar to methods discussed previously, six 
aspects of population variability were factored into the pediatric population model, for workflows 1 and 2, 
as obtained from literature (Table 45). Once variability had been successfully incorporated into the 
pediatric population following a 20 mg/kg dose, PK parameters of AUC0-end, Cmax, and Tmax following 
the observed study protocol dosing regimen were obtained for comparison to corresponding observed 
values and further data analysis. 
Table 45. Population variability parameters incorporated into the pediatric model for Workflow 1 and 2 of cimetidine 
Pathway Value Distribution Notes and reference 
GET  CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had the 
same surface enhancement factor applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 61% Log normal Table 15 




Workflow 1 of azithromycin 
 
Development of the Rat PBPK model following IV administration  
A rat PBPK model simulation was created to simulate a 20 mg/kg intravenous bolus dose administration 
of azithromycin based on two observed studies obtained from literature [81, 127], [128]. Physicochemical 
properties were obtained from literature and incorporated into the rat PBPK simulation (Table 46). 
Studies by Shepard et al [128], as well as Tananika et al [127] suggest that azithromycin metabolism in 
the rat is due primarily to hepatic mechanisms. Although rat CL is not utilized within the workflow as a 
model predictor, hepatic CL was reflected in the rat PBPK model CL processes for model fitting 
purposes.  
Once rat PBPK model had been simulated, both experimentally derived in vivo data sets were 
superimposed upon the simulated plasma concentration profile. Model goodness of fit was achieved via 
numerical optimization of LogP (Figure 53). A numerical optimization of LogP determined 0.36 as the 
best value of input in order to achieve optimal line shape in the rat model.  
Table 46. Physicochemical initial parameter inputs for azithromycin in the Rat and adult model 
Parameter Value Reference Final value  
Molecular weight (g/mol) 748.98 [129] 748.98 
LogP (log units) 3  [129] 0.36 
Plasma protein Albumin [130] Albumin 
Fu rat 0.84 [128] 0.84 
Fu human 0.88 [130] 0.88 
pKa (acidic)  12.43 [129] 12.43 
pKa (base) 9.57 [129] 9.57 
Solubility in water (aqueous) 50 mg/mL @ pH 7 [131] 50 mg/mL @ pH 7 




Figure 53. Simulated (line) and observed (symbols) azithromycin Rat IV plasma concentration profile optimized for LogP, 
following 20 mg/kg IV bolus dose administration of azithromycin 
 
Development of the azithromycin adult PBPK model following oral administration 
Using the rat IV model as a base, all species specific inputs were changed to reflect an average 30 year 
old European human male. This included anatomical and physiological inputs. All drug specific inputs 
were maintained as in the rat PBPK model with the addition of compound specific solubility and 
dissolution data. Three adult oral PBPK models were simulated for the drug azithromycin based on 
dosing protocol of three existing observed studies, in which participants received a 500 mg oral dose 
[133-135]. CL of azithromycin was designated completely within generic hepatic and renal systems.  
Once each PBPK adult oral model had been simulated following a 500 mg, oral dose administration, 
experimentally derived in vivo data from three observed studies [133-135], were superimposed upon the 
simulated plasma concentration profile.  Model parameters influencing absorption (Pint) and CL were 
numerically optimized respective to each simulation (Table 47, Figure 54 a-c).  
 
CL pathway partitioning  
Pharmacokinetic studies following oral dose administration suggest azithromycin is a substrate of 
CYP3A4 and is primarily recovered in bile fluid unchanged and in feces as metabolites [136], whereas 
4.5% of the dose is excreted in urine unchanged (i.e. fe=0.045) [130]. In a pharmacokinetic study 
conducted by Fould et al [136], biliary CL was determined to be the primary route of elimination as 
concentration in bile fluids was greater than plasma concentrations [136]. Within the observed study, total 
renal CL was greater than GFR, thereby indicating that a portion of azithromycin is eliminated via active 
TS by renal transporters.  As a result, CL was modeled as 57.3% biliary CL, 38.2% CYP3A4 CL and 
4.5% as renal CL. Parameters pertaining to biliary CL, CYP3A4 CLspec, and TS were numerically 
optimized so that model CL could reflect dose exposure as closely to the observed studies as possible 
(Table 47). Due to limitations of bioavailability estimates within the Workflow 1, fe values within the 
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model did not truly reflect observed data. The mean value of the optimized TS and Pint parameters from of 
three adult oral simulations (Table 47, Figure 54a-c), were incorporated into a final mean adult model, 
which was utilized for the subsequent adult population model.  
Table 47. Optimized parameters of Pint, biliary CL, CYP 3A4 CL and TS within Workflow 1 of azithromycin 
Study Pint (cm/min) Biliary CLspec (1/min) 
CYP 3A4 CLspec 
(1/min) 
TS spec (1/min) 
Najib [135] 9.6 E-5 0.65 0.5 0.228   
Matzneller [133] 1.45 E-4  0.73 0.65 0.251   
Iqbal [134] 1.05 E-4 0.72 0.3 0.297   








Figure 54. Simulated (line) and observed (symbols) plasma concentration data following 500 mg of oral azithromycin. Observed 
data obtained from A) Najib et al [126] B) Matzneller et al [124] C) Iqbal et al[125]. Fe (dotted) included 
 
Building the mean adult population model  
Similar to methods discussed previously, an adult population of 100 adult individuals was generated, 
following a 500 mg oral dose of azithromycin. Seven aspects of population variability were factored into 
the adult population model (Table 48) as obtained from literature. CYP3A4 variability was obtained from 
Dorne et al [106] following a log normal distribution with CV of 46% in adults. Once the population 
model had been simulated to generate an arithmetic standard deviation curve, observed data obtained 
from each of the experimental study was superimposed onto the simulated population profile (Figure 55). 
Given that the majority of data points fell within one standard deviation of the mean population model, it 
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Table 48. Population variability incorporated into the adult population model simulations of azithromycin 
Pathway Value Distribution Notes and reference 
GET  CV = 24% Log normal Table 6 
SITT CV = 22.5% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform 
distribution (mean*3 – mean/3). 
Each individual had the same 
surface enhancement factor 
applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 30% Log normal Table 15 
CYP3A4 CV = 46% log normal 
Determined from Dorne et al [106] in 
which the inter-individual variability 
for various phase I, II and renal 
metabolic processes was assessed with 
various probe substrates.  
Biliary CV = 30% Log normal Table 27 
 
Time [h]































Figure 55. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 500 mg oral 








Workflow 2 of azithromycin 
 
Development of the human PBPK model following IV administration  
An adult PBPK model was simulated for the drug azithromycin based on the dosing protocol from an IV 
infusion study conducted in adults by Foulds et al, in which 500 mg of azithromycin was administered  
over 20 minutes to ten healthy male participants [130]. Organism specific input parameters pertaining to 
anatomy and physiology were incorporated within PK-Sim, reflecting an average 30 year old European 
male were applied to the model. Physicochemical primary input parameters such as fu, lipophilicity 
(LogP), pKa, molecular weight, and solubility at reference pH were obtained from literature (Table 46).  
Study findings by Foulds et [130] al suggest the fe of azithromycin was approximately 0.12. Biliary CL is 
an important route of elimination for azithromycin, as majority of the administered dose is found in bile 
fluids as unchanged compound [136].  Similar to Workflow 1, a biliary CL component, GFR, and TS 
pathways of CL were defined within the model. Once the PBPK adult IV base model had been simulated 
following a 500 mg IV infusion, experimentally derived in vivo data from Foulds et al., was superimposed 
upon the simulated plasma concentration profile (Figure 56). Given that the simulated data points did not 
reflect curve shape and exposure of the experimental data, model parameters influencing distribution (i.e. 
LogP) and CL were numerically optimized (Table 49); Log P was numerically optimized to 2.8 log units.  
 
Figure 56. Simulated (line) and observed (symbols) plasma concentration data, and fe (dotted), following a 500 mg IV infusion 
study. Workflow 2 adult iv model optimized for distribution and CL. Observed data taken from Foulds et al[130] 
 
Development of the azithromycin adult PBPK model following oral administration  
Similarly to methods discussed in Workflow 1, three adult oral models were simulated to reflect 
demographic and 500 mg oral dose described in three observed studies obtained from literature [133-
135]. All physicochemical input parameters such as pKa, molecular weight, optimized LogP and CL 
remained consistent between the optimized adult IV model and each adult oral model. Organism specific 
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anatomy and physiology input parameters incorporated into PK-Sim, for a mean European 30 year old 
male were applied to the model. Once all three PBPK adult oral models had been simulated following a 
500 mg oral dose, experimentally derived in vivo data was superimposed upon the simulated plasma 
concentration profiles [133-135]. Model parameters such as Pint were numerically optimized until a 
quantitative goodness of fit was achieved (Table 49, Figure 57a-c). The mean of the optimized Pint, Tsspec, 
and CYP3A4 CLspec values were incorporated into a final mean adult simulation, which was further 
utilized in building an adult population model.  











Foulds IV [130]  6.36 7.81 0.228 2.8  
Najib [135] 3.6 E-6 
Matzneller [133] 4.4 E-6 
85Iqbal [134] 3.73 E-6 








Figure 57. Simulated (line) and observed (symbols) plasma concentration data following 500 mg of oral azithromycin. Observed 
data obtained from A) Najib et al [126] B) Matzneller et al [124] C) Iqbal et al [125] 
 
Development of an adult oral population PBPK model  
Similar to Workflow 1, an adult population of 100 individuals was created within PK-Sim consisting of 
18-55 year old males to reflect the demographics of the reference observed study participants [126] [124] 
[125]. Population variability factors incorporated within the model were identical to Workflow 1 (Table 
43). Once the population model had been simulated to generate an arithmetic standard deviation curve, 
observed data obtained from each of the experimental observed studies was superimposed onto the model 
(Figure 58). Given that the majority of data points fell within one standard deviation of the mean 
population model, it was determined sufficient to progress to pediatric development. 































Figure 58. Simulated mean (central line) and standard deviation (dotted line) plasma concentration data in 100 individuals as 
compared to   observed (symbols) mean and standard deviation plasma concentration data following data following a 500 mg oral 
dose of azithromycin in adults. 
 
Development of the pediatric population model for Workflow 1 and 2 of azithromycin  
Two pediatric studies conducted by Nahata et al were obtained from literature [137, 138]. Both studies 
aimed to investigate the pharmacokinetics of azithromycin in infants and children between the ages of 
0.5-6 and 6-15 years of age. In the study, patients received a 5 mg/kg dose of oral azithromycin. Up to a 
maximum of 1000 individuals, reflecting the age range of each observed study patient population, were 
randomly selected from the reference pediatric population. Population variability for various parameters 
was factored into the pediatric population model, for workflows 1 and 2, as obtained from literature 
(Table 50). PK parameters of AUC0-end, Cmax, and Tmax following the observed study protocol dosing 
regimen were obtained for comparison to corresponding observed values and further data analysis. 
Table 50. Population variability parameters incorporated into the pediatric model for Workflow 2 of azithromycin 
Pathway Value Distribution Notes and reference 
GET  CV = 60% Log normal Table 6 
SITT  CV = 60% Log normal Table 6 
Small intestinal surface 
area  
9 fold variation in a uniform distribution 
(mean*3 – mean/3). Each individual had 
the same surface enhancement factor 
applied. 
Uniform Table 6 
GFR (specific) CV = 25% Normal Table 6 
TS (specific) CV = 60.7% Log normal Table 15 
CYP3A4 CV = 50% Log normal Table 78 
Biliary CV = 30% Log normal Table 27 
Hepatic CV = 30% Log normal Table 19 
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3.7 Comparison of model predictive performance  
3.7.1 Post-hoc ANOVA based tests (Aim 1 & 2) 
 
AUC, Cmax, and Tmax for each virtual pediatric population derived from Workflow 1 and Workflow 2 
were used to test the differences between parameters means from Workflow 1, Workflow 2 and observed 
data using analysis of variance (ANOVA) statistical methods (ie. F-test) in SAS 9.2. The F test was 
implemented to evaluate the null hypothesis that the three group means (Workflow 1, Workflow 2 and 
observed) were not statistically different. The level of siginificance for this study was chosen to be 5%, 
that is, differences between all three group means were considered significant if the corresponding p value 
was less than 0.05. The F-test was used for exploratory purposes, since the sample size of observed 
pediatric studies are limited, compared to a greater resolution achieved by the virtual population (i.e. 
1000+ individuals per population). Subsequently, a post-hoc multiple comparisons test (ie. Tukey-Kramer 
test) was conducted to assess differences between means. The multiple comparison test produced 
corresponding p values. A p>0.05 suggests group means are not significantly different from each other. 
Inversely, a p<0.05 suggests it is unlikely that differences in group means are due to random sampling, 
and therefore we must reject the null hypothesis and conclude the means are significantly different. 
Unbalanced sample sizes while comparing simulated vs. observed data may potentially compromise the 
validity of the underlying statistical assumptions of the F-test. While the employed post-hoc test adjusts 
for this limitation, results from largely unbalanced cases (1000+ vs 10+) should be taken cautiously and in 
an exploratory manner.  
The null hypotheses for aim 1 (H1), states that Workflow 1 and Workflow 2 derived predictions of 
pediatric PK data will not be significantly different from observed data at a significance level of 5%. 
Similarly, the null hypothesis for aim 2 (H2), states that PK predictions derived from Workflow 1  will 
not be statistically significant from Workflow 2.  The primary driver for acceptance of H1 and H2 was 
AUC as it serves as a quantitative measure of exposure in children. In the event that H1 is accepted for 
both workflows and H2 is also accepted, in that both workflow derived predictions were not different 
from observed and were not statistically different from one another, the conclusion is that IV data is not a 
necessary component of the workflow for model development and models were accurate. In the event that 
only H1 is accepted for both workflows, workflow derived means were not different from observed, and 
H2 is rejected, Workflow 1 means were not equal to those of Workflow 2,  we conclude that IV  data is 
not a necessary component of the workflow for model development, and models were accurate. Similarly, 
if we must reject H1 either workflow, but accept H2, we may still conclude that IV data is not a necessary 
component for pediatric PK model development. However, if we must reject H1 for Workflow 1 but 
accept H1 for Workflow 2; the conclusion is that IV data is a necessary component of the workflow for 
model development but models were not accurate. Lastly, in the event that H1, for either workflow, as 
well as H2 are rejected, then it is unknown if IV data is a necessary component of model development.  
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3.7.2 Assessing precision and bias of model derived predictions (Aim 3) 
 
An objective of this study was to assess the ability of pediatric PBPK models, developed under Workflow 
1 and Workflow 2, to predict observed PK parameters and to assess the implications to model accuracy 
when there is a lack of adult IV data. This was completed in addition to Aim 1 such that differences noted 
in Workflow 1 or Workflow 2 vs. observed using the above mentioned statistics may note statistical 
differences that are not necessarily relevant.  As a result, the model’s ability to effectively estimate mean 
AUC, Tmax and Cmax within the population, was subsequently evaluated using fold error (FE), absolute 
average fold error (AAFE) for a measure of model precision, and average fold error (AFE) for bias as in 















     (21) 
 
The measure of AAFE quantifies the overall magnitude of predictive deviation from observed data, 
irrespective of over- or under-prediction. Alternately, AFE indicates over prediction (AFE>1) or under 
prediction (AFE<1) of model derived predictions as compared to observed data; an AFE value closest to 
1 indicates greater predictive performance of a model. AUC will be the most significantly considered 
parameter over all others for inference of model predictive performance, as it is drives dosing estimates. 
Predictions from Workflow 1 and Workflow 2 will be considered reasonable if AAFE is less than 2 
meaning that the prediction is within two fold of the observed data.  Root mean square error (RMSE) was 
calculated as expressed in equation (22), to rank the overall precision of the model. A smaller RMSE 
value would indicate an overall better model predictive performance, as a result of smaller error in 
comparison to observed means: 
 𝑅𝑀𝑆𝐸 = √(
1
𝑛
∑(𝐿𝑂𝐺 𝑜𝑏𝑠𝑖 − 𝐿𝑂𝐺 𝑝𝑟𝑒𝑑𝑖)
2
    (22) 
A Chi square test was calculated to compare the overall predictive performance of each workflow based 
on the number of model derived estimates that were <2 fold AAFE, out of a possible 25 observed studies. 
The Chi square test would evaluate whether Workflow 1 performed differently than Workflow 2, and if 
either workflow performed with an overall greater predictive performance. A resulting p-value>0.05 





3.7.3 Assessing how BCS level influences pediatric model accuracy (Aim 4) 
 
A Chi square test was calculated to compare the workflow performance based on BCS classification. The 
number of pediatric PK parameters that were accurately predicted within 2 fold (i.e. AAFE<2) using 
Workflow 1, within each BCS class, out of a possible 25 observed study comparisons,  were compared to 
the corresponding number of model derived PK parameters within Workflow 2.  The Chi squared test 
allows for an inference to be made as to whether Workflow 1 or Workflow 2 has greater overall 
predictive performance within individual BCS classes, or if they perform similarly. If the p-value from 
each Chi square test is >0.05, we may infer that overall Workflow 1 did not perform differently than 

















4.1 Results for BCS class I compounds 
Acetaminophen 
 
Three clinical pediatric studies were compared to simulated data. In one study, conducted by Romsing et 
al, a sample group of 7-13 year old patients received a 22.5 mg/kg oral dose administration of 
acetaminophen [139]. In another study, conducted by Walson et al, a group of 2-11 year old children 
received a 10 mg/kg oral dose administration of aceaminophen [140]. Lastly, in a study conducted by 
Hopkins et al, pediatric patients ages 0.9-3.7 years of age received a 15 mg/kg oral dose administration of 
acetaminophen [141]. While 1000 individuals were simulated within the age range of each study, due to 
the narrow age range of 0.9-3.7 years as reported by Hopkins et al [141], only 874 individuals within the 
simulated population fell within this criteria. 
All F-tests resulted in statistically significant differences at a 5% level. Table 51 shows the corresponding 
p values. The subsequent post-hoc tests show that Workflow 1 and Workflow 2 AUC estimates were not 
significantly different from observed, in reference to the 2-11 and 0.9-3.7 yr studies, whereas all 
Workflow 1 means were significantly different from those derived from Workflow 2 (Table 52). There 
was a significant difference between all three means of Workflow 1, Workflow 2 and observed for the 7-
13 years study.  
As Table 53a shows, for AUC, Workflow 1 predicted less bias (AFE) and more precise (AAFE) estimates 
for the 7-13 yr study and Workflow 2 predicted AUC with better precision than Workflow 1 for the 0.9-
3.7 yr study. Statistically, as can be seen on Table 52, Cmax was different from observed in both 
Workflow 1 and Workflow 2 for the 7-13 and 0.9-3.7 yr studies. Predicted Tmax was not significant for 
0.9-3.7 year olds. For the exposure metrics of AUC and Cmax, Workflow 1 and Workflow 2 predictions 
were within the 2 fold criteria for accuracy as previously set (Table 53a). There was no clear trend with 
regards to bias of AUC and Cmax predictions (Table 53a). For Tmax,  precision was study specific 
however there was a bias towards underprediction in all studies for both workflows. Observed data is 






Table 51. ANOVA F-test summary comparing model derived vs. observed means of acetaminophen 





7-13 [139] 28.09 10, 1000 <0.0001 
2-11 [140] 6.96 7, 874 0.0010 
0.9-3.7 [141] 18.34 16, 1000 <.0001 
Cmax 
7-13 [139] 29.61 10, 1000 <.0001 
2-11 [140] 4.19 7, 874 0.0154 
0.9-3.7 [141] 12.67 16, 1000 <.0001 
Tmax 
7-13 [139] 33.51 10, 1000 <.0001 
2-11 [140] 103.00 7, 874 <.0001 
0.9-3.7 [141] 4.03 16, 1000 0.0180 
Differences not significant at a 5% level, shown in bold. 
 
Table 52. P-values from post-hoc multiple comparison tests, of model derived PK 
predictions of observed data for acetaminophen. 
Workflow 1 vs. Observed 
Study group age (yr.) AUC0-inf  Cmax Tmax 
7-13 [139] 0.0010 <.0001 <.0001 
2-11 [140] 0.0811 0.3056 <.0001 
0.9-3.7 [141] 0.9527 <.0001 0.1119 
Workflow 2 vs. Observed 
7-13 [139] <.0001 <.0001 <.0001 
2-11 [140] 0.167 0.1953 <.0001 
0.9-3.7 [141] 0.7169 <.0001 0.2395 
Workflow 1 vs Workflow 2 
7-13 [139] <.0001 0.0657 0.2938 
2-11 [140] 0.0045 0.0424 0.0251 
0.9-3.7 [141] <.0001 0.0534 0.0746 














Table 53a. Precision and bias measurements for Workflow 1 and Workflow 2 derived PK estimates 
based on observed studies of acetaminophen 
 acetaminophen Workflow 1, 7-13yr acetaminophen Workflow 2, 7-13yr 
 AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 62.6 18.8 0.83 69.9 19.1 0.84 
SD 24.5 2.72 0.22 27.2 2.62 0.22 
AFE 1.79 1.47 0.57 1.99 1.49 0.58 
AAFE 1.80 1.47 1.76 2.00 1.49 1.72 
RMSE 0.29 0.18 0.27 0.33 0.18 0.26 
 acetaminophen Workflow 1, 2-11yr acetaminophen Workflow 2, 2-11yr 
Mean 25.1 8.12 0.79 28.0 8.25 0.81 
SD 10.2 1.24 0.20 11.42 1.20 0.21 
AFE 0.91 1.18 0.85 1.02 1.20 0.87 
AAFE 1.32 1.21 1.27 1.30 1.23 1.26 
RMSE 0.15 0.10 0.12 0.15 0.10 0.12 
 acetaminophen Workflow 1, 0.9-3.7yr acetaminophen Workflow 2, 0.9-3.7yr 
Mean 32.1 11.3 0.75 35.8 11.5 0.77 
SD 23.5 2.02 0.18 26.3 1.94 0.17 
AFE 0.53 1.06 0.38 0.59 1.08 0.39 
AAFE 1.93 1.17 2.61 1.75 1.17 2.52 
RMSE 0.32 0.08 0.43 0.28 0.08 0.41 
 
Table 53b. Observed pediatric pharmacokinetic data for acetaminophen 
Study 
AUC0-inf ± SD 
(ug*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD (h) 
7-13 [139] 33.13 ± 10.14 12.7 ± 3.8 1.4  ± 0.5 
2-11 [140] 25.9 ± 6.34 6.8 ± 1.9 0.9 ± 0.4 














A pediatric pharmacokinetic study conducted by Chien et al [142] was selected for comparison of 
simulated pediatric PK results. Children and infants who participated in the study were subdivided into 
five groups based on age; 0-2, 2-5, 5-10, 10-12, 12-16 years [142]. All participants received an oral dose 
of 7 mg/kg of levofloxacin; up to a maximum dose of 500 mg. Up to a maximum of 1000 kids per age 
group were simulated to reflect the demographics of the study.  
F-tests for Cmax predictions in 2-5 and 5-10 year olds, and Tmax predictions for 5-10 year old children 
were not significant at a 5% level (Table 54) To  assess which workflow was a better predictor of 
observed PK data in children, Workflow 1 and Workflow 2 model derived estimates were compared 
(Table 55). Workflow 1 and Workflow 2 did not generate significantly different Cmax and Tmax 
estimates (Table 55). AUC was significantly different than observed for both Workflow 1 and Workflow 
2 for 2-5 year olds, and Cmax was different than observed for 0.5-2 yr and 10-12 year old subjects.  
With regards to the PK metrics, all predictions were within the 2 fold criteria for accuracy as previously 
designated (Table 56a). There was a bias towards over-prediction of AUC by both workflows; however 
there was no clear trend of bias for Cmax and Tmax predictions (Table 56a). For AUC estimates, 
Workflow 2 consistently predicted less bias and more precise estimates. Model derived Tmax estimates 
were predicted with similar precision between models (Table 56a), and not significantly different from 
observed. Observed data is shown in Table 56b.  
Table 54. ANOVA F-test summary between model derived vs. observed means of levofloxacin 





0.5-2 7.50 8, 297 0.0006 
2-5 29.95 8,911 <.0001 
5-10 26.67 8,1000 <.0001 
10-12 15.55 8, 581 <.0001 
12-16 20.22 8,1000 <.0001 
Cmax 
0.5-2 5.23 8, 297 0.0056 
2-5 0.82 8,911 0.4387 
5-10 0.15 8,1000 0.8628 
10-12 15.06 8, 581 <.0001 
12-16 2.00 8,1000 0.1361 
Tmax 
0.5-2 5.71 8, 297 0.0035 
2-5 19.41 8,911 <.0001 
5-10 2.53 8,1000 0.0803 
10-12 64.83 8, 581 <.0001 
12-16 20.55 8,1000 <.0001 





Table 55. P-values from post-hoc multiple comparison tests, of model derived PK 
predictions of observed data of levofloxacin 
Workflow 1 vs. Observed 
Study group age (yr.) AUC0-inf Cmax Tmax 
0.5-2 0.0219 0.0067 0.1057 
2-5 0.0021 0.4636 <.0001 
5-10 0.0051 1 0.6607 
10-12 0.0508 <.0001 <.0001 
12-16 0.0536 0.9878 <.0001 
Workflow 2 vs. Observed 
0.5-2 0.1108 0.004 0.0294 
2-5 0.0399 0.5101 <.0001 
5-10 0.0597 0.9977 0.5009 
10-12 0.3023 <.0001 <.0001 
12-16 0.2659 0.9942 <.0001 
Workflow 1 vs. Workflow 2 
0.5-2 0.0052 0.7677 0.041 
2-5 <.0001 0.8326 0.0729 
5-10 <.0001 0.8504 0.109 
10-12 <.0001 0.6493 0.358 
12-16 <.0001 0.1129 0.2993 


















Table 56a. Precision and bias measurements for Workflow 1 and Workflow 2 derived 
PK estimates based on observed studies for levofloxacin 
levofloxacin Workflow 1 – 0.5-2yr levofloxacin Workflow 2 – 0.5-2yr 
 
AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 40.1 4.80 1.33 35.9 4.83 1.31 
SD 16.0 0.49 0.14 13.3 0.50 0.15 
AFE 1.46 1.14 0.95 1.31 1.14 0.93 
AAFE 1.50 1.14 1.10 1.41 1.15 1.11 
RMSE 0.22 0.07 0.05 0.19 0.07 0.06 
levofloxacin Workflow 1 – 2-5yr levofloxacin Workflow 2 – 2-5yr 
Mean 43.7 4.73 1.31 38.7 4.71 1.30 
SD 15.9 0.40 0.16 13.6 0.42 0.15 
AFE 1.59 1.03 0.81 1.42 1.03 0.80 
AAFE 1.61 1.07 1.24 1.47 1.08 1.25 
RMSE 0.25 0.04 0.10 0.20 0.04 0.11 
levofloxacin Workflow 1 – 5-10yr levofloxacin Workflow 2 – 5-10yr 
Mean 46.9 4.64 1.29 42.0 4.65 1.28 
SD 17.4 0.37 0.14 14.8 0.39 0.14 
AFE 1.53 1.00 0.99 
 
1.37 1.00 0.98 
AAFE 1.56 1.07 1.08 1.44 1.07 1.08 
RMSE 0.23 0.03 0.04 0.20 0.04 0.05 
levofloxacin Workflow 1 – 10-12yr levofloxacin Workflow 2 – 10-12yr 
Mean 52.9 4.69 1.28 47.2 4.71 1.26 
SD 20.5 0.37 0.15 16.9 0.38 0.15 
AFE 1.33 1.17 0.67 1.20 1.18 0.66 
AAFE 1.41 1.17 1.50 1.33 1.18 1.52 
RMSE 0.19 0.08 0.18 0.16 0.08 0.19 
levofloxacin Workflow 1 – 12-16yr levofloxacin Workflow 2 – 12-16yr 
Mean 59.7 4.74 1.28 53.6 4.77 1.27 
SD 24.1 0.38 0.15 20.3 0.39 0.15 
AFE 1.36 0.99 0.79 1.23 1.00 0.79 
AAFE 1.43 1.06 1.27 1.34 1.07 1.28 
RMSE 0.20 0.03 0.11 0.17 0.04 0.12 
 
Table 56b. Observed pediatric pharmacokinetic data for levofloxacin 
Study 
AUC0-inf ± SD 
(ug*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD 
(h) 
0.5-2 25.80 ±  9.2 4.23 ± 1.5 1.44 ± 0.41 
2-5 25.93 ± 4.75 4.55 ± 0.84 1.64 ± 0.5 
5-10 28.97 ± 10.1 4.64 ± 0.4 1.33 ± 0.4 
10-12 37.29 ± 9.83 3.97 ± 0.87 1.95 ± 0.88 








Three clinical pediatric studies were compared to simulated data. In one study, conducted by McDermott 
et al, a sample group of infants ages 0.6-1 year received a mean 0.8 mg/kg IV dose administration of 
lorazepam [143]. In another study, conducted by Muchohi et al, a group of 2.7-7.6 year old children 
received a 0.1  mg/kg oral dose administration of lorazepam [144]. Lastly, in a study conducted by 
Chamberlain et al, pediatric patients ages 3-17 years of age received a 0.05 mg/kg oral dose 
administration of lorazepam [145]. While 1000 individuals were simulated within the age range of each 
study, due to the narrow age range of 0.6-1 years as reported by Mcdermott et al [143], only 100 
individuals within the simulated population fell within this criteria. 
All F-tests resulted in statistically significant differences at a 5% level. Table 57 shows the corresponding 
P values. Workflow 1 and Workflow 2 model derived estimates were compared to assess which workflow 
was a better predictor of observed PK data in children (Table 58). Workflow 1 and Workflow 2 did not 
generate significantly different AUC estimatesfrom observed, aside from the infant age group within 
Workflow 1. All Cmax estimates were significant at a level of 5%. Two of three age group predictions of 
T½ within Workflow 1 were not significant  from observed.  
With regards to the PK metrics, all AUC and Cmax predictions were within the 2 fold criteria for 
accuracy as previously determined (Table 59a). There was a noticable  bias towards over prediction of 
infant AUC estimates within both workflows, and underprediction of T½ estimates within all age groups. 
Observed data is shown in Table 59b. 
Table 57. ANOVA F-test summary between model derived vs. observed means of lorazepam 





0.6-1 [143] 8.39 10, 100 0.0003 
0.7-7.6 [144] 26.51 11, 1000 <.0001 
3-17 [145] 70.94 15, 1000 <.0001 
Cmax 
0.6-1 [143] 18.07 10, 100 <.0001 
0.7-7.6 [144] 853.15 11, 1000 <.0001 
3-17 [145] 23202.8 15, 1000 <.0001 
T½  
0.6-1 [143] 99.77 10, 100 <.0001 
0.7-7.6 [144] 122.84 11, 1000 <.0001 
3-17 [145] 278.02 15, 1000 <.0001 







Table 58. P-values from post-hoc multiple comparison tests, of model derived 
PK predictions of observed data for lorazepam 
Workflow 1 vs. Observed 
  AUC0-inf Cmax T½  
0.6-1 0.0093 <.0001 <.0001 
2.7-7.6 0.8307 <.0001 0.1434 
3-17 0.3647 <.0001 0.9973 
Workflow 2 vs. Observed 
0.6-1 0.2805 <.0001 <.0001 
2.7-7.6 0.2284 <.0001 <.0001 
3-17 0.7685 <.0001 0.0002 
Workflow 1 vs. Workflow 2 
0.6-1 0.0024 0.0139 <.0001 
2.7-7.6 <.0001 <.0001 0.0002 
3-17 <.0001 <.0001 <.0001 




Table 59b. Observed pediatric pharmacokinetic data for lorazepam 
Study 
AUC0-inf ± SD 
(ng*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD (h) 
0.6-1 6793.4 ± 3071.5 292.8 ± 260.8  40.2 ± 16.5 
2.7-7.6 2062.5 ± 792.7 130.2 ±  19.6 23.7 ± 6.95 
3-17 822.5 ± 706.1  56.1 ±  44.9 20.5 ± 10.2 
Table 59a. Precision and bias measurements for Workflow 1 and Workflow 2 derived PK estimates 
based on observed studies of lorazepam 
 
lorazepam Workflow 1 – 0.6-1 yr. lorazepam Workflow 2 – 0.6-1 yr. 
  AUC0-inf Cmax T½  AUC0-inf Cmax T½  
Mean 11903 206.47 14.93 9419 183.66 8.59 
SD 872.8 20.69 7.63 456.7 12.49 4.35 
AFE 1.61 0.70 0.4 1.28 0.63 0.72 
AAFE 1.67 1.43 2.95 1.4 1.6 5.01 
RMSE 0.27 0.16 0.49 0.2 0.2 0.72 
 
lorazepam Workflow 1 – 2.7-7.6 yr. lorazepam Workflow 2 – 2.7-7.6 yr. 
Mean 1870.4 241.80 17.32 1479.10 212.04 10.10 
SD 1405.1 21.36 13.2 995.86 15.37 7.80 
AFE 0.82 1.85 0.25 0.65 1.62 0.45 
AAFE 1.45 1.85 1.64 1.65 1.62 2.60 
RMSE 0.2 0.27 0.25 0.26 0.21 0.45 
 
lorazepam Workflow 1 – 3-17 yr. lorazepam Workflow 2 – 3-17 yr. 
Mean 972.94 112.57 20.79 775.11 94.76 12.31 
SD 409.47 11.85 9.84 323.92 12.58 5.73 
AFE 1.09 1.99 0.2 0.87 1.67 0.37 
AAFE 1.37 1.99 1.4 1.39 1.67 1.89 
RMSE 0.17 0.3 0.18 0.18 0.23 0.32 
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4.2 Results for BCS class II compounds 
Ciprofloxacin  
 
A pediatric pharmacokinetic study conducted by Peltola et al in children 5-14 weeks and 1-5 years, was 
selected for comparison of simulated pediatric PK results, with those obtained from literature [146].All 
participants received a single oral dose of 15 mg/kg of ciprofloxacin. Once pediatric populations 
following similar dosing regimen as in the study had been simulated, up to a maximum of 1000 kids per 
age group were isolated to reflect the demographics of the study. Due to limitations in age resolution 
within the standard 5000 simulated population of children between ages 0-17, only 58 infants between 
ages 5-14 weeks were created and incorporated into the comparative analysis of ciprofloxacin 
pharmacokinetics. 
All F-tests resulted in statistically significant differences at a 5% level (Table 60). Workflow 1 and 
Workflow 2 model derived estimates were compared to assess which workflow was a better predictor of 
observed PK data in children (Table 61).  AUC, Cmax and Tmax estimates were significant between 
Workflow 1 and Workflow 2 for both study groups. Model derived AUC and Cmax estimates were 
statistically significant from observed PK means for the study group consisting of 1-5 year old 
participants.   
Workflow 1 and Workflow 2 derived predictions of Cmax, and Tmax were within the designated 2 fold 
criteria of accuracy for both study groups, whereas AUC predictions for 1-5 year olds were not contained 
within 2 fold of accuracy. There was no clear trend towards bias of PK predictions (Table 62a). With 
regards to AUC and Cmax, Workflow 1 predictions were more precise and less bias in correspondence to 
the study of 5-14 week old participants, whereas Workflow 1 AUC estimates were less precise than those 
of Workflow 2 for the study of 1-5 year old participants. Precision of Tmax estimates was study specific. 
Observed data is shown in Table 62b. 
Table 60. ANOVA F-test summary between model derived vs. observed means for ciprofloxacin 





5-14 weeks 8.99 7,58 <.0001 
1-5 yrs.  46.43 10,1000 <.0001 
Cmax 
5-14 weeks 11.81 7,58 0.5042 
1-5 yrs. 33.93 10,1000 <.0001 
Tmax 
5-14 weeks 89.95 7,58 <.0001 
1-5 yrs. 133.69 10,1000 <.0001 





Table 61. P-values from post-hoc multiple comparison tests, of model 
derived PK predictions of observed data for ciprofloxacin 
Workflow 1 vs. Observed 
Study group AUC0-inf Cmax Tmax 
5-14 weeks 0.0906 0.9448 0.9737 
1-5 yr. <.0001 <.0001 0.4612 
Workflow 2 vs. Observed 
5-14 weeks 0.0016 0.8939 <.0001 
1-5 yr. <.0001 0.4378 <.0001 
Workflow 1 vs. Workflow 2 
5-14 weeks 0.0071 0.5112 <.0001 
1-5 yr. <.0001 <.0001 <.0001 
Differences not significant at a 5% level, shown in bold. 
 
Table 62a. Precision and bias measurements for Workflow 1 and Workflow 2 derived PK 
estimates based on observed studies of ciprofloxacin 
 
ciprofloxacin Workflow 1 – 5- 14 weeks ciprofloxacin Workflow 2 – 5-14 weeks 
  AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 11.45 3.15 1.20 30.51 3.10 2.26 
SD 4.18 0.52 0.06 12.54 1.16 0.36 
AFE 0.68 0.94 1.01 1.94 0.96 1.84 
AAFE 1.54 1.15 1.04 1.97 1.40 1.84 
RMSE 0.21 0.08 0.03 0.34 0.18 0.28 
 
ciprofloxacin Workflow 1 – 1-5 yr. ciprofloxacin Workflow 2 – 1-5 yr. 
Mean 8.71 2.77 0.89 13.95 2.18 2.07 
SD 2.37 0.48 0.17 6.17 0.99 0.22 
AFE 1.67 1.33 0.90 2.41 0.94 2.06 
AAFE 1.68 1.34 1.22 2.43 1.44 2.06 
RMSE 0.26 0.15 0.09 0.42 0.20 0.32 
 
Table 62b. Observed pediatric pharmacokinetic data for 
ciprofloxacin [146] 
Study 
AUC0-inf ± SD 
(mg*h/L) 
Cmax ± SD 
(mg/L) 
Tmax ± SD 
(h) 
5-14 weeks 16.14 ± 7.4 3.26 ± 1.35 1.18 ± 0.46 










A pediatric pharmacokinetic study conducted by Thee et al was selected for comparison of simulated 
pediatric PK results; study participants consisted of infants and children between the ages of 0.25-2, 2-6, 
and 6-8 years [147]. All participants received a single oral dose of 20 mg/kg of ofloxacin. Up to a 
maximum of 1000 kids per age group were simulated to reflect the demographics and dosing regimen of 
the study.   
The F-test comparing the AUC predictions of Workflow 1 vs Workflow 2 to observed data for 6-8 year 
olds was not significant at a 5% level (Table 64). To assess which workflow was better, Workflow 1 and 
Workflow 2 derived PK predictions were compared (Table 64). For Cmax, model derived estimates were 
statistically different between workflows and observed data. Model derived AUC was not statistically 
different for ages the study group consisting of 6-8 year olds. Tmax predictions were statistically different 
for all age groups, as compared to observed data. Model comparisons of Tmax were not significant 
corresponding to 0.25-2 year old study participants.  
All AUC and Cmax Workflow 1 and Workflow 2 model derived predictions were within 2 fold accuracy 
of observed data; there was a tendency for over-prediction bias within both workflows (Table 65a). Only 
Tmax estimates corresponding to 0.25-2 year olds was contained within the 2 fold accuracy benchmark. 
Workflow 2 produced less bias and slightly more precise AUC and Cmax estimates. There was a strong 
trend towards an under-prediction bias of Tmax estimates, which is likely due to the highly variable 
nature of this parameter (Table 65a). Observed data is shown in Table 65b. 
Table 63. ANOVA F-test summary between model derived vs. observed means of ofloxacin 





0.25-2 7.94 10, 508 0.0004 
2-6 9.11 10, 1000 0.0001 
6-8 2.27 5, 584 0.1041 
Cmax 
0.25-2 15.91 10, 508 <.0001 
2-6 78.87 10, 1000 <.0001 
6-8 53.53 5, 584 <.0001 
Tmax 
0.25-2 109.94 10, 508 <.0001 
2-6 196.02 10, 1000 <.0001 
6-8 271.21 5, 584 <.0001 








Table 64. P-values from post-hoc multiple comparison tests, of model 
derived PK predictions of observed data for ofloxacin 
Workflow 1 vs. observed 
Study group 
age (yr.) 
AUC0-inf Cmax Tmax 
0.25-2 0.0016 <.0001 <.0001 
2-6 0.0044 <.0001 <.0001 
6-8 0.137 <.0001 <.0001 
Workflow 2 vs. Observed 
0.25-2 0.0067 0.0003 <.0001 
2-6 0.0161 <.0001 <.0001 
6-8 0.1754 <.0001 <.0001 
Workflow 1 vs Workflow 2 
0.25-2 0.0603 0.0008 0.0547 
2-6 0.0063 <.0001 <.0001 
6-8 0.5416 <.0001 0.0021 
Differences not significant at a 5% level, shown in bold. 
 
Table 65a.   Precision  and accuracy measurements for  workflow  1 and  
workflow  2 derived PK estimates based on observed studies of ofloxacin 
 ofloxacin  Workflow 1 – 0.25-2yr ofloxacin  Workflow 2 – 0.25-2yr 
  AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 66.7 13.9 0.80 63.7 13.6 0.78 
SD 20.4 1.66 0.11 21.9 1.66 0.11 
AFE 1.37 1.27 0.65 1.30 1.24 0.64 
AAFE 1.42 1.27 1.54 1.40 1.24 1.57 
RMSE 0.19 0.12 0.20 0.18 0.11 0.20 
  ofloxacin Workflow 1 – 2-6yr ofloxacin  Workflow 2 – 2-6yr 
Mean 69.7 13.7 0.77 66.7 13.2 0.75 
SD 19.4 1.35 0.11 23.5 1.42 0.10 
AFE 1.51 1.56 0.49 1.42 1.49 0.47 
AAFE 1.53 1.56 2.05 1.49 1.49 2.11 
RMSE 0.22 0.20 0.32 0.21 0.18 0.33 
  ofloxacin  Workflow 1 – 6-8yr ofloxacin  Workflow 2 – 6-8yr 
Mean 71.0 13.7 0.75 69.6 13.2 0.73 
SD 19.3 1.19 0.11 24.1 1.25 0.10 
AFE 1.76 1.78 0.30 1.69 1.71 0.29 
AAFE 1.76 1.78 3.38 1.71 1.71 3.48 
RMSE 0.27 0.25 0.53 0.27 0.24 0.54 
Differences not significant at a 5% level, shown in bold. 
 
Table 65b. Observed pediatric pharmacokinetic data for ofloxacin 
Study 
AUC0-inf ± SD 
(ug*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD (h) 
0.25-2 42.079 ± 7.95 11.352 ± 2.85 1.35 ± 0.33 
2-6 46.821 ± 13.142 9.28 ± 2.65 1.48 ± 0.52 






A pediatric pharmacokinetic study conducted by Thee et al was selected for comparison of simulated 
pediatric PK results, with those obtained from literature [107]. Subjects in the study received an oral dose 
of 2 mg/kg of valsartan, with a maximum single dose of 80 mg was obtained from literature [107]. 
Subjects were stratified into four age groups; 1-4 years, 4-6 years, 6-12 years, and 12-16 year olds. Up to 
a maximum of 1000 kids per age group were isolated to reflect the demographics of the study.   
AUC and Cmax predictions for 6-12 year old children were not significant at a level of 5% (Table 66). 
Model derived AUC predictions from both workflows were not significant for the study groups 
corresponding to 6-12 and 12-16 year olds (Table 67). Workflow 1 derived Cmax estimates were not 
significant from observed data and Workflow 2 estimates within the latter two study groups. Workflow 1 
managed to generate AUC predictions that were not significantly different from Workflow 2 for three of 
four age groups. The final age group, 12-16, AUC estimates were not statistically significant in 
comparison to observed data, within each respective workflow. All Tmax predictions were statistically 
significant from observed data.  
To assess the question of which workflow is better, Workflow 1 and Workflow 2 were compared for 
prediction accuracy, bias, and precision (Table 68a). Aside from AAFE values corresponding to the 1-4 
year old age group, all AAFE values were ≤ 2 fold accuracy (Table 68a). Observed data is shown in Table 
68b.  
Table 66. ANOVA F-test summary between model derived vs. observed means for valsartan 





1-4 2451.58 7, 908 0.0004 
4-6 1991.52 7, 603 0.0014 
6-12 4071.30 8, 1000 0.3164 
12-16 4868.50 8, 1000 <.0001 
Cmax 
1-4 4876.08 7, 908 <.0001 
4-6 3916.81 7, 603 <.0001 
6-12 7459.51 8, 1000 0.0084 
12-16 5026.94 8, 1000 0.3989 
Tmax 
1-4 465.96 7, 908 <.0001 
4-6 513.61 7, 603 <.0001 
6-12 822.45 8, 1000 <.0001 
12-16 833.61 8, 1000 <.0001 







Table 67. P-values from post-hoc multiple comparison tests, of model derived 
PK predictions of observed data for valsartan 
Workflow 1 vs. Observed 
Study group age 
(yr.) 
AUC0-end Cmax Tmax 
1-4 0.0003 0.0052 <.0001 
4-6 0.007 0.0025 <.0001 
6-12 0.3722 0.1177 <.0001 
12-16 0.7529 0.8574 <.0001 
Workflow 2 vs. Observed 
1-4 0.0004 0.0006 <.0001 
4-6 0.0036 <.0001 <.0001 
6-12 0.5126 0.0296 <.0001 
12-16 0.3699 0.9243 <.0001 
Workflow 1 vs. Workflow 2 
1-4 0.7002 <.0001 <.0001 
4-6 0.1557 <.0001 <.0001 
6-12 0.5675 0.1602 <.0001 
12-16 <.0001 0.4079 <.0001 
Differences not significant at a 5% level, shown in bold. 
 
Table 68a. Precision and bias measurements for  workflow  1 and  workflow  2 derived PK estimates 
based on observed studies of valsartan 
 
valsartan Workflow 1 – 1-4yr valsartan  Workflow 2 – 1-4yr 
 
AUC0-end Cmax Tmax AUC0-end Cmax Tmax 
Mean 13878 2774 2.4 14137 2484 2.80 
SD 7413 1161 0.3 6928 1254 0.33 
AFE 0.47 0.59 1.2 0.5 0.52 1.40 
AAFE 2.17 1.76 1.21 2.08 1.9 1.40 
RMSE 0.40 0.3 0.1 0.37 0.36 0.16 
 
valsartan  Workflow 1 – 4-6yr valsartan  Workflow 2 – 4-6yr 
Mean 16653 3095 2.41 15984 2639 2.86 
SD 8829 1297 0.313 7267 1270 0.34 
AFE 0.54 
 
0.59 1.11 0.54 0.49 1.24 
AAFE 1.93 1.76 1.21 1.9 2.0 1.42 
RMSE 0.34 0.3 0.1 0.33 0.38 0.16 
 
valsartan  Workflow 1 – 6-12yr valsartan  Workflow 2 – 6-12yr 
Mean 17546 3259 2.39 18413 2994 2.82 
SD 5704 1045 0.73 8256 1403 0.34 
AFE 0.8 0.72 1.19 0.83 0.63 1.4 
AAFE 1.43 1.49 1.19 1.46 1.71 1.4 
RMSE 0.2 0.22 0.09 0.21 0.29 0.16 
 
valsartan  Workflow 1 – 12-16yr valsartan  Workflow 2 – 12-16yr 
Mean 18231 3163 2.45 20267 3088 2.84 
SD 7721 1194 0.28 9318 1411 0.32 
AFE 1.05 0.95 1.21 1.15 0.91 1.41 
AAFE 1.41 1.38 1.22 1.46 1.45 1.41 




Table 68b. Observed pediatric pharmacokinetic data for valsartan 
Study (yr.) 
AUC0-end ± SD 
(ng*h/mL) 
Cmax ± SD (ng/mL) Tmax ± SD (h) 
1-4 25823 ± 11103 4307 ± 1852 2 ± 0.52 
4-6 26800 ± 6968 4818 ± 1879 2 ± 0.19 
6-12 20214 ± 7277 4254 ± 1148 2 ± 0.37 





4.3 Results for BCS class III compounds 
Acyclovir  
 
A pediatric study  investigating the pharmacokinetics of acyclovir suspension in infants and children, 
conducted by Sullender et al was selected for comparison of model derived PK data [120]. In the study, a 
600 mg/m
2
 dose of acyclovir was administered to 13 children, divided into two groups based on age. The 
first group consisted of 0.5-4 year olds with a mean body surface area (BSA) of 0.6 m
2
, whereas the 
second group consisted of 4-7 year olds with a mean BSA of 0.8 m
2
. As a result, the two groups of 
participants received an approximate mean dose of 1000 mg, and 750 mg respectively.  
All F-tests resulted in statistically significant differences at a 5% level (Table 69). Workflow 1 and 
Workflow 2 derived AUC and Tmax estimates for statistically different for both study groups, whereas 
Cmax was different than observed data obtained from the younger study group (Table 70). Workflow 1 
and Workflow 2 derived AUC, Cmax and Tmax estimates were significant from observed means, with 
the exception of Workflow 1 derived Cmax and Workflow 2 derived Tmax corresponding to the 4-7 year 
old study group. For the assessment of each model’s comparative ability to effectively predict observed 
PK data, only Workflow 1 derived AUC and Workflow 2 derived Tmax predictions were contained 
within the designated 2 fold bias benchmark (Table 71a). There was a strong bias for over-prediction of 
AUC and Cmax within both workflows. Overall Workflow 2 produced comparatively less bias 
predictions of observed AUC, Cmax and Tmax estimates. Observed data is shown in Table 68. 
Table 69. ANOVA F-test summary between model derived vs. observed means of acyclovir 





0.5-4 11.05 8, 1000 <.0001 
4-7 122.39 7,904 <.0001 
Cmax 
0.5-4 226.10 8, 1000 <.0001 
4-7 9.73 7,904 <.0001 
Tmax 
0.5-4 4599.08 8, 1000 <.0001 
4-7 3575.76 7,904 <.0001 









Table 70. P-values from post-hoc multiple comparison tests, of model 
derived PK predictions of observed data for acyclovir 
Workflow 1 vs. Observed 
Obs. Study AUC0-inf Cmax Tmax 
0.5-4 yr. 0.0317 <.0001 <.0001 
4-7 yr. 0.5626 <.0001 <.0001 
Workflow 2 vs. Observed 
0.5-4 yr. 0.0085 0.0015 <.0001 
4-7 yr. 0.014 <.0001 0.2070 
Workflow 1 vs. Workflow 2 
0.5-4 yr. 0.0004 <.0001 <.0001 
4-7 yr. <.0001 0.9208 <.0001 
Differences significant at a 5% level, shown in bold 
 
Table 71a. Precision and bias measurements for Workflow 1 and Workflow 2 
derived PK estimates based on observed studies of acyclovir 
 
acyclovir Workflow 1: 0.5-4yr acyclovir Workflow 2 – 0.5-4yr 
  AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 11.7 3.87 0.66 12.5 2.65 2.44 
SD 4.71 1.13 0.15 7.13 1.28 0.57 
AFE 1.88 3.38 0.20 1.86 2.16 0.74 
AAFE 1.89 3.38 5.00 2.08 2.33 1.38 
RMSE 0.31 0.54 0.24 0.37 0.41 0.16 
 acyclovir Workflow 1 – 4-7yr acyclovir Workflow 2 – 4-7yr 
Mean 8.15 2.80 0.68 12.8 2.80 2.35 
SD 4.21 0.55 0.17 8.15 1.40 0.57 
AFE 1.40 3.07 0.25 1.99 2.72 0.87 
AAFE 1.46 3.07 3.98 2.21 2.82 1.25 
RMSE 0.21 0.49 0.61 0.40 0.50 0.11 
 
Table 71b. Observed pediatric pharmacokinetic data for acyclovir 
Study (yr.) 
AUC0-inf ± SD 
(ug*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD (h) 
0.5-4 5.68 ± 2.4 1.07 ± 0.44 3.21 ± 0.99 










A pediatric pharmacokinetic study conducted by Ziemniak et al was selected for comparison of simulated 
pediatric PK results, with those obtained from literature [126]. All participants received an oral dose of 20 
mg/kg of cimetidine. Once pediatric populations following similar dosing regimen as in the study had 
been simulated, up to a maximum of 1000 kids per age group were isolated to reflect the demographics of 
the study.  
All F-tests resulted in statistically significant differences at a 5% level (Table 72). To address the question 
of which workflow was a better predictor of pediatric PK data, both workflows were compared (Table 
73). In the event that they predicted significantly different results, identifying which workflow was better 
could be addressed by data presented in Table 74a. AUC estimates generated from Workflow 1 and 
Workflow 2 were not significant from observed data. Workflow 1 and Workflow 2 derived Tmax, and 
Workflow 2 derived Cmax were significantly different from observed data. Model comparisons suggest 
Workflow 1 PK estimates were statistically significant from Workflow 2.  
AUC and Cmax derived from Workflow 1 and AUC from Workflow 2 were within the designated 2 fold 
criteria for bias (Table 74a). Workflow 1 generated less bias and more precise AUC, Cmax and Tmax 
predictions of observed data. Observed data is shown in Table 74b. 
Table 72. ANOVA F-test summary between model derived vs. observed means 




AUC0-inf 9-16 19.61 8, 1000 <.0001 
Cmax 9-16 2759.19 8, 1000 <.0001 
Tmax 9-16 263.76 8, 1000  <.0001 
Differences not significant at a 5% level, shown in bold. 
 
Table 73. P-values from post-hoc multiple comparison tests, of 
model derived PK predictions of observed data for cimetidine 
Workflow 1 vs. Observed 
Study age 
group (yr.) 
AUC0-inf Cmax Tmax 
9-16  0.1949 0.4864 <.0001 
Workflow 2 vs. Observed 
9-16  0.0534 <.0001 <.0001 
Workflow 1 vs. Workflow 2 
9-16  <.0001 <.0001 <.0001 






Table 74a. Precision and bias measurements for Workflow 1 and Workflow 2 
derived PK estimates based on observed studies 
 cimetidine Workflow 1 - 9-16yr cimetidine Workflow 2 - 9-16yr 
  AUC0-inf Cmax Tmax AUC0-inf Cmax Tmax 
Mean 30.05 7.62 0.93 32.93 15.20 0.68 
SD 8.23 0.87 0.28 12.97 3.11 0.22 
AFE 1.22 1.13 0.44 1.31 2.22 0.33 
AAFE 1.31 1.15 2.28 1.40 2.22 3.06 




Table 74b. Observed pediatric pharmacokinetic data for cimetidine 
Study (yr.) 
AUC0-inf ± SD 
(ug*h/mL) 
Cmax ± SD (ug/mL) Tmax ± SD (h) 





















Two studies conducted by Nahata et al were selected for comparison of simulated pediatric PK results, 
with those obtained from literature [137, 138]. Once pediatric populations following similar dosing 
regimen as in the study had been simulated, up to a maximum of 1000 kids were isolated from each 
population to reflect the distribution from each of three observed studies. Therefore, 1000 kids’ ages 0.5-6 
years, and 6-12 years were isolated for PK analysis. 
All F-tests resulted in statistically significant differences at a 5% level (Table 75). With regards to 
determining which workflow was a better predictor of observed PK data in children, workflows 1 and 2 
were compared (Table 76). Both workflows predicted statistically different AUC and Cmax estimates. In 
this instance, determining which workflow is better could be addressed by data presented in Table 77a. 
Both Workflow 2 derived Tmax estimates and Workflow 1 derived Tmax for 6-15 year olds was not 
significant from observed Tmax data. With regards to the PK metrics, there was a bias towards under-
prediction of AUC and Cmax within both workflows; however there was not a clear trend for Tmax 
predictions. All AUC, Cmax, and Tmax predictions were within 2 fold bias for the study group consisting 
of 0.5-5 year old participants. Workflow 2 derived predictions corresponding to 6-15 year olds were less 
bias and more precise than those predicted by Workflow 1. Observed data is shown in Table 77b. 
Table 75.  ANOVA F-test summary between model derived vs. observed means 
of azithromycin 





0.5-5 73.88 13, 1000 <.0001 
6-15 703.54 15, 1000 <.0001 
Cmax 
0.5-5 198.65 13, 1000 <.0001 
6-15 419.91 15, 1000 <.0001 
Tmax 
0.5-5 294.87 13, 1000 <.0001 
6-15 189.50 15, 1000 <.0001 
Differences not significant at a 5% level, shown in bold. 
 
Table 76. P-values from post-hoc multiple comparison tests, of 
model derived PK predictions of observed data 
Workflow 1 vs. Observed 
Study group 
age (yr.) 
AUCt-end Cmax Tmax 
0.5-5 <.0001 <.0001 <.0001 
6-15 <.0001 <.0001 0.1267 
Workflow 2 vs. Observed 
0.5-5 <.0001 0.0392 0.2273 
6-15 <.0001 <.0001 0.4008 
Workflow 1 vs. Workflow 2 
0.5-5 0.0003 <.0001 <.0001 
6-15 <.0001 <.0001 <.0001 
Differences significant at a 5% level, shown in bold 
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Table 77a. Precision and bias measurements for Workflow 1 and Workflow 2 derived PK 
estimates based on observed studies of azithromycin 
azithromycin Workflow 1 - 0.5-5yr azithromycin Workflow 2 - 0.5-5yr 
  AUCt-end Cmax Tmax AUCt-end Cmax Tmax 
Mean 1116.0 130.81 2.86 1077.5 182.9 2.09 
SD 124.5 32.9 0.83 282.5 76.9 0.57 
AFE 0.60 0.56 1.53 0.57 0.73 1.13 
AAFE 1.66 1.78 1.53 1.76 1.53 1.20 
RMSE 0.23 0.28 0.21 0.26 0.27 0.11 
azithromycin Workflow 1 - 6-15yr azithromycin Workflow 2 - 6-15yr 
Mean 1128.75 136.81 2.76 1444.06 238.14 2.21 
SD 115.7 34.6 0.72 331.59 110.11 0.53 
AFE 0.36 0.34 1.12 0.45 0.54 0.90 
AAFE 2.77 2.90 1.19 2.21 1.89 1.23 
RMSE 0.44 0.48 0.11 0.36 0.36 0.11 
 
Table 77b. Observed pediatric pharmacokinetic data for azithromycin 
Study 
AUCt-end ± SD 
(ug*h/mL) 
Cmax ± SD 
(ug/mL) 
Tmax ± SD (h) 
0.5-5 1840.92 ± 651.25 236.83 ± 115.58 1.83 ± 0.39 

















4.4 Summary of aim 1 and aim 2 
 
To assess aim 1 and aim 2, an ANOVA test with Tukey-Kramer pairwise comparisons was conducted in 
order to determine the requirement of IV data based on statistical significance. Acceptance and rejection 
of the null hypotheses respective to aim 1 and aim 2 were based on the criteria established above. 
Looking at aim 1, which postulates the possibility that IV data may not be required for the derivation of 
pediatric PK estimates (Table 78), 9/25 (36%) of Workflow 1 derived AUC estimates were not different 
from observed data. Looking at aim 2, which postulates that that IV data would not be required (Table 
78), 6/25 (24%) comparisons of Workflow 1 derived AUC estimates were not different from Workflow 2. 
Only 3/25 (12%) of AUC comparisons were comparable exclusively between Workflow 2 and observed 
data, and 7/25 (28%) did not fulfil any of the criteria, and were therefore subject to assessment by aim 3.  
Overall, 15/25 (60%) of AUC comparisons within Workflow 1 were comparable to either observed data 
or Workflow 2. There were 13/25 (52%) of Cmax and Tmax estimates from Workflow 1 that were 
comparable to either observed data or Workflow 2 (Table 78).   
Table 78. Summary of aim 1 and aim 3 ANOVA and pairwise comparison 
PK parameter 
May not require IV 
data  
(Workflow 1 = 
Observed) 
Do not require IV 
data  
(Workflow 1 = 
Workflow 2) 
Inconclusive 
May require IV data 
(only Workflow 2 = 
observed) 
AUC 9 (36%) 6 (24%) 7 (28%) 3 (12%) 
Cmax 3 (12%) 10 (40%) 11 (44%) 1 (4%) 
Tmax 5 (20%) 8 (32%) 10 (40%) 2 (8%) 
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4.5 Summary of Chi squared statistic of BCS class comparison (Aim 3 & 4)  
 
To assess aim 3, a Chi square test was conducted to assess the overall comparative predictive 
performance of each workflow to predict pediatric parameters within 2 fold AAFE. The objective of the 
Chi-square test for aim 3 was to evaluate if Workflow 1 performed differently than Workflow 2, and 
whether one workflow performed with an overall greater predictive performance than the other. Table 79 
compares the total number of pediatric PK parameters, out of a possible 25 studies, that were predicted 
within, or greater than, 2 fold AAFE between workflows. Overall, 23/25 (92%) AUC estimates within 
Workflow 1 were within <2 fold AAFE compared to 20/25 (80%) within Workflow 2. A total of 22/25 
(88%) Cmax estimates within both workflows were <2 fold AAFE. Lastly, 18/25 (72%) and 19/25 (76%) 
Tmax estimates were <2 fold AAFE respectively.  Given that each p-value produced by the Chi squared 
test was >0.05, we may infer that there is no statistical significance in the predictive performance of 
Workflow 1, in comparison to Workflow 2 (Table 79).  
Table 79. Chi squared statistic comparing overall predictive performance of each 
workflow to predict pediatric parameters within 2 fold AAFE 
Parameter 2 < AAFE < 2 
Workflow 1  
(# of studies /25) 
Workflow 2  
(# of studies / 25) 
p-value 
AUC 
AAFE<2 23 20 
1.00 
AAFE>2 2 5 
Cmax 
AAFE<2 22 22 
1.00 
AAFE>2 3 3 
Tmax 
AAFE<2 18 19 
1.00 
AAFE>2 7 6 
 
To assess aim 4, a Chi square test was conducted to evaluate if there was a difference in the predictive 
performance of Workflow 1, based on BCS class stratification, in comparison to corresponding PK value 
predictions derived from Workflow 2 (Table 80). Within the BCS Class 1 stratification, 11/11 (100%) 
AUC and Cmax estimates were <2 fold AAFE within both workflows; 9/11 (82%) and 8/22 (73%) Tmax 
values within Workflow 1 and Workflow 2, respectively, were predicted within 2 fold AAFE. The Chi 
square test for evaluating a difference between Workflow 1 and Workflow 2 produced a p-value >0.05 for 
all respective PK parameters; from this we may infer that BCS Classification did not limit the ability of 
Workflow 1 to predict observed PK parameters as compared to Workflow 2 (Table 80). Within the BCS 
Class 2 stratification, 8/9 (89%) and 7/9 (78%) of AUC estimates were predicted within 2 fold AAFE 
within Workflow 1 and Workflow 2 respectively, 9/9 (100%) Cmax estimates and 7/9 (78%) Tmax 
estimates were predicted within 2 fold AAFE within both workflows. The Chi Square test for evaluating a 
difference between workflows based on BCS Class II stratification  produced a p-value >0.05 for all 
respective PK parameters; from this, we may infer that limitations of solubility within BCS class II did 
not limit the predictive performance of Workflow 1 (Table 80). Lastly, Within the BCS Class 3 
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stratification, 4/5 (80%) and 2/5 (40%) of AUC estimates within Workflow 1 and Workflow 2 
respectively, were predicted within 2 fold AAFE. Similarly, 2/5 (40%) Cmax estimates within both 
workflows, and 2/5 (40%) and 4/5 (80%) of Tmax estimates within Workflow 1 and Workflow 2 
respectively, were predicted within 2 fold AAFE. The Chi square test for evaluating a difference between 
workflows based on BCS Class III stratification produced a p-value>0.05 for all respective PK 
parameters; from this we may infer that limitations of permeability and solubility within BCS Class 3 
stratification did not limit the predictive performance of Workflow 1 (Table 80).  




2 < AAFE < 
2 
Workflow 1 
(# of studies /25) 
Workflow 2 




AAFE<2 11 11 
1.00 
AAFE>2 0 0 
Cmax 
AAFE<2 11 11 
1.00 
AAFE>2 0 0 
Tmax 
AAFE<2 9 8 
1.00 
AAFE>2 2 3 
BCS 2 
AUC 
AAFE<2 8 7 
0.2941 
AAFE>2 1 2 
Cmax 
AAFE<2 9 9 
1.00 
AAFE>2 0 0 
Tmax 
AAFE<2 7 7 
1.00 
AAFE>2 2 2 
BCS 3 
AUC 
AAFE<2 4 2 
0.5238 
AAFE>2 1 3 
Cmax 
AAFE<2 2 2 
1.00 
AAFE>2 3 3 
Tmax 
AAFE<2 2 4 
0.5238 











5. Discussion  
 
This study proposed an alternate workflow method for pediatric PBPK modeling which yielded 
comparable pediatric pharmacokinetic predictions as the standard workflow of practice. Nine compounds 
were selected for this study based on current approval for administration in infants and children, 
availability of compound specific physicochemical data, organism specific plasma concentration profiles, 
as well as all relevant clearance processes data. Compounds were selected based on their respective BCS 
classification; three compounds from each of BCS I, II and III. The purpose of stratifying drug selection 
by BCS class was to assess whether uncertainties presented by the compound relative to solubility, and 
permeability would impede model performance. It was imperative that all in vivo and in vitro data were 
available for each drug included in the study.  
The main objective of this study was to assess an alternate PBPK workflow which would serve as an 
acceptable replacement for the standard workflow as described by Maharaj and Edginton [22]. The 
proposed alternate workflow would ideally predict pediatric PK parameters (i.e. AUC, Cmax, and Tmax) 
that would statistically compare to observed data, when adult IV data is not available for a given 
compound. The null hypothesis for aim 1 of this study (H1) postulated that Workflow 1 and Workflow 2 
derived predictions of pediatric PK data will not be significantly different from observed data at a 
significance level of 5%. Additionally the null hypothesis for aim 2 (H2), postulated that PK predictions 
derived from Workflow 1 would not be statistically significant from Workflow 2. The null hypothesis for 
aim 3 of this study (H3) postulated that the prediction accuracy of pediatric PK observed data using 
Workflow 1 will be comparable to Workflow 2 and within a 2 fold AAFE from observed data. 
There were 11 age group stratifications within BCS I compounds where 6/11 predicted mean AUCs were 
not significantly different from observed within Workflow 1, whereas Workflow 2 had 9/11 mean AUCs 
that were not significantly different from observed. This would indicate that Workflow 2 was a more 
accurate model, as bolstered by comparison of AAFE outcomes discussed below. This was expected, 
given the availability of human IV data.  All AUC predictions were statistically similar between 
Workflow 1 and Workflow 2 indicating that the starting point for model development does not alter the 
final product, which, in this case, were pediatric PK predictions. Based on model performance of AUC 
predictions, we fail to reject H1 for Workflow 1 derived estimates of BCS class 1 compounds, with 
moderate confidence and conclude that adult IV data is not required for BCS class I compounds when 
making pediatric PK predictions. Similarly, we fail to reject H1 for Workflow 2 derived AUC predictions 
with greater confidence than that of Workflow 1. The third aim of this study was to compare pediatric PK 
prediction accuracy within each workflow. Of the 11 age stratifications within BCS class 1, 11/11 AUC 
predictions were within a 2 fold of observed data for both workflows. As a result, H3 is accepted. In 
summary, for AUC, Workflow 2 was more accurate than Workflow 1 although for all predictions, 
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regardless of workflow, the predictions were within 2 fold of the observed data. While AUC was the most 
important metric to consider as it drives dosing, Cmax and Tmax may also be of importance and are 
considered here. Only 4/11 Cmax and 5/11 Tmax predictions within Workflow 1 were not significant 
from observed; however, >60% Cmax and >50% Tmax values were not different between Workflow 1 
and Workflow 2. The majority of Cmax and Tmax predictions within Workflow 1 were comparable to 
observed or Workflow 2 derived means.  We therefore fail to reject H1 for Workflow 1 and H2, and must 
conclude that IV data is not required for Cmax and Tmax estimates. Within Workflow 2, the majority of 
Cmax and Tmax predicted values were not different from observed or Workflow 1; as a result, we fail to 
reject H1 for Workflow 2 with respect to Cmax, and Tmax. All Cmax estimates, and most Tmax 
predictions were within a 2 fold AAFE of observed data within both workflows, we therefore fail to reject 
H3, and may conclude that both models were equally precise. 
There were 9 age group stratifications within BCS class II compounds, where 4/9 mean AUC predictions 
within Workflow 1 were not significant from observed, compared to 3 of 9 within Workflow 2. This 
would indicate that both workflows were equally poor in model performance. There were 5/9 AUC 
predictions that were not statistically different between Workflow 1 and Workflow 2, thereby allowing us 
to accept H2 with moderate confidence. In total, 7/9 AUC predictions within Workflow 1 were either not 
significant from observed and/or not significant from Workflow 2, compared to 6 of 9 for Workflow 2. 
Although we fail to accept H1 for the majority of AUC predictions within both workflows, we fail to 
reject H2, from which we must conclude that that IV data is not a necessary component of pediatric 
model development for BCS class II compounds. Of the three compounds within BCS class II, ofloxacin, 
and valsartan undergo considerable biliary elimination which may very likely be the cause of such poor 
model performance. Biliary secretion creates great uncertainty towards model CL and mean residence 
time of the compound within an organism; it may also lead to enterohepatic recirculation which increases 
the possibility for first pass metabolism of the parent compound. With regards to the third aim of this 
study, 8/9 AUC predictions generated from Workflow 1 and 7/9 from Workflow 2 were within 2 fold 
AAFE of observed data. We fail to reject H3 with sufficient confidence, and must conclude that the 
accuracy of Workflow 1 was comparable to that of Workflow 2. In summary, neither workflow was able 
to generate accurate AUC estimates similar to observed data; however both workflows were equally 
precise in generating AUCs within a 2 fold AAFE of observed data. Only 3/9 predicted Cmax values 
within Workflow 1 and Workflow 1 independently, were not significant from observed; similarly only 3/9 
Cmax values derived from Workflow 1 were not significant from Workflow 2. From this, we fail to 
accept H2 and H1 for both workflows, with respect to the prediction of Cmax. Similarly, only 2/9, and 
1/9 Tmax predictions within Workflow 1 and Workflow 2, respectively, were not different from 
observed; there weren’t any similar predictions between workflows. We therefore fail to accept H2 and 
H1 for both workflows. In summary, we are unable to conclude if IV data is a necessary component in 
pediatric model development in deriving Cmax and Tmax estimates. Looking at model prediction 
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accuracy, all 9 Cmax predictions, and 7/9 Tmax predictions, were within 2 fold AAFE. We therefore fail 
to reject H3 and must conclude that Workflow 1 was comparable to Workflow 2 in model precision, 
despite a lack of IV data.  
Lastly, there were 5 age group stratifications within BCS class 3 compounds, of which only 2/5 predicted 
mean AUCs within Workflow 1 were not different from observed, compared to only 1/5 within Workflow 
2. There were not any AUC predictions that were similar between Workflow 1 and Workflow 2. Based on 
model performance of AUC predictions, we fail to accept H2 and H1 for both workflows; therefore, we 
must conclude that it is unknown as to whether or not IV data is needed for sufficient model development. 
In assessing the third aim of this study for model precision, 4/5 Workflow 1 derived AUC estimates, and 
2/5 within Workflow 2, were <2 fold AAFE. Although it would seem the majority of Workflow 2 derived 
AUC estimates fall outside of the acceptance range for the precision metric, a Chi-squared test suggests 
this result is of similar statistical power to the Workflow 1. Therefore, we fail to reject H3, and must 
conclude that Workflow 1 and Workflow 2 were not significant in model performance, despite a lack of 
adult IV data. For the comparison of PK prediction accuracy of Cmax and Tmax within each workflow, 
only 1/5 Cmax within Workflow 1 was not significant from observed, compared to 2/5 for Workflow 2; 
only 1/5 Cmax estimates were not different between both workflows. We therefore fail to reject H2, and 
H1 for both Workflow 1 and Workflow 2.Tmax was also poorly predicted by Workflow 1, as there were 
not any predictions within BCS class III that were similar to observed data. There were 3/5 predictions 
within Workflow 2 that were not different from observed, and only 1/5 which was similar between 
workflows. In summary, we fail to accept H2 and H1 for both workflows and must conclude that there is 
insufficient evidence to determine whether or not IV data is a necessary component of model 
development for the prediction of Cmax and Tmax. Although only 2/3 Cmax and Tmax predictions fell 
within a 2 fold AAFE for both workflows, according to the Chi-square test, we are able accept H3, and 
conclude, that although the models were not accurate, Workflow 1 model performance was not different 
from Workflow 2.  
The final aim was to assess if the biopharmaceutical classification system holds significance over model 
predictive performance. The number of pediatric PK parameters, within each BCS class, that were 
accurately predicted within 2 fold AAFE using Workflow 1, were compared to the number of PK 
parameters that were accurately predicted within 2  fold AAFE using Workflow 2. A difference between 
workflow performances, stratified by BCS class, would indicate that compound permeability and 
solubility impede model prediction; this would therefore contribute to limitations in overall model 
performance.  Workflow 1 did not perform differently than Workflow 2 overall, or within individual BCS 
classifications. As a result, BCS class does not significantly impact model predictive performance. This 
suggests that the absorption model that was used along with the optimization of CL and Pint led to 
accurate predictions of bioavailability regardless of BCS class and this filtered down to the pediatric 
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models.  One limitation of this study was that there were few compounds chosen from each BCS class for 
modeling. This limits our confidence in factoring the effect of BCS classification on model performance. 
Although the results of this study, with respect to testing by BCS class, unanimously concluded that BCS 
class does not matter, an n = 3 within each class provides minimal confidence in the final conclusion. 
There were no BCS class 4 compounds selected for this study due to a scarcity of experimental data. For 
future research, it would be of value to examine the effects of BCS class stratification on compounds 
regulated by a diverse array of reaction mechanisms, as well as an overall larger sample size of 
compounds within each class.  
 
In the final assessment of whether human IV data provides a significant advantage over pre-clinical rat IV 
data in the prediction of pediatric PK data, it would appear predictive performance of both workflows was 
comparable. Aim 1 and aim 2 of this study were established to examine model performance based 
explicitly on the statistical significance between model derived PK prediction and observed data. Based 
on conclusions drawn by a systematic assessment of the null hypotheses H1 and H2 (see Objectives 
section), for 15 of the 25 pediatric studies (60%), there was no advantage to having human IV data to 
predict observed data; of the remaining 10 studies, 3 required human IV data for accurate prediction 
(12%), while for 7 studies (28%) it was inconclusive whether the presence of human IV data was 
advantageous. In contrast to the initial two aims of this study, Aim 3 was established for an assessment of 
model performance within clinical relevance, rather than a strict assessment of statistical significance 
which suffered slightly from unbalanced comparisons. If the predicted mean of the PK parameter was 
within 2 fold (AAFE) of the observed mean, the model derived PK parameter was considered clinically 
similar. For example, this suggests that a predicted AUC value that is double or half of the observed value 
will derive a reasonable dose in children. Although there is currently no standard metric for deriving 
clinical relevance in this scenario, a 2 fold comparison is the most frequently applied metric within 
literature[148-150]. While this may be acceptable for drugs with wide therapeutic indices, this would not 
be ideal for compounds that exhibit a narrow therapeutic index in pediatrics, as an inadvertent doubling of 
dose may lead to concentrations that exceed toxicity threshold values and could potentially lead to various 
adverse events. On the other hand, under-dosing may lead to sub therapeutic concentrations that do not 
ameliorate the indication for which the drug is given.  
 
Successful dose calculation relies on the accurate quantification of CL and F, as both these values will 
have a direct effect on the derivation of exposure (e.g. AUC). Given the purpose of this study, it would be 
beneficial to assess the ability of Workflow 1 to accurately predict total plasma CL. Total plasma CL is 
usually derived following IV administration where the systemic dose is known and CL can be precisely 
calculated. In the case of Workflow 1, CL was optimized based solely on the terminal slope of human oral 
data. The terminal slope is a function of the volume of distribution and CL. Volume of distribution is 
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dependent upon both the organism (e.g. Kp) and the drug’s physico-chemistry where, in Workflow 1, drug 
physico-chemistry was optimized within the rat model. A comparison of Workflow 1 derived total CL 
values in adults to those obtained from adult IV data in Workflow 2 will help to assess the validity of the 
Workflow 1 derived CL. The total plasma CL values for 6 compounds (acetaminophen, levofloxacin, 
lorazepam, ofloxacin, acyclovir, and cimetidine) within Workflow 1 were within 25% of Workflow 2 
total plasma CL values. Of the remaining 3 compounds (ciprofloxacin, valsartan, and azithromycin), total 
plasma CL was over predicted by 1.4, 3.6, and 1.8 fold error respectively. Much like CL, the precise 
derivation of F relies on complete systemic dose absorption which can only occur following IV dose 
administration. F is calculated as the ratio of AUC values from oral and IV dose administrations. 
Workflow 1 derived F values were within 20% of Workflow 2 value for the same 6 compounds for which 
CL was within 25% of Workflow 2. Of the remaining 3 compounds (ciprofloxacin, valsartan, and 
azithromycin), F values were over predicted by 1.6, 3.4, and 1.7 fold error, respectively. The over 
prediction of F values was proportional to the over prediction of CL values within the same compounds. 
This means that CL and F compensate for each other in the optimization procedure. It should be noted 
that this was the case for only some BCS II and III compounds and not for any BCS I compounds where 
bioavailability is predicted to be high. This CL and F over prediction did not appear to hinder prediction 
accuracy in children as it was determined that BCS class was irrelevant. This may become more 
problematic if human oral data is used to derive CL values as in Workflow 1 but is used to predict 
exposure following IV administration in children where F can no longer compensate for the over or under 
prediction of CL. In this case, it is expected that pediatric prediction would be less accurate than 
prediction of exposure following oral administration. Overall a large majority of total plasma CL and F 
values predicted from rat IV + human oral data were within 25% of those derived using human IV data. 
As discussed, care should be taken if exposure prediction following IV administration is completed for 













In summary, this study has found that the proposed alternate workflow method for pediatric PBPK 
modeling (Workflow 1) may serve as a viable alternative to the standard workflow of practice (Workflow 
2). Based on AUC predictions, approximately 60% of Workflow 1 derived pediatric AUC predictions 
were not statistically significant from either Workflow 2, and/or observed data; thereby suggesting that 
human IV data does not necessarily provide an advantage towards the prediction of pediatric AUC. The 
viability of Workflow 1 was further bolstered by the fact that approximately 92% of Workflow 1 derived 
pediatric AUC means were predicted within 2 fold of observed data. This lends itself to substantial 
clinical relevance, suggesting that predicted pediatric exposures can be reasonably scaled from adults 
using Workflow 1. The alternative workflow did not hinder prediction accuracy in children as a 
consequence of inaccurate CL and F prediction, given that the added limitations of the biopharmaceutical 
classification system were not relevant. In conclusion Workflow 1 has demonstrated that the substitution 
of rat IV data in the absence of human IV data, within the constructs of PBPK modeling, does not impede 
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